[
   {
      "id":3996,
      "name":"DAXI  (RT002)",
      "craft_entry_id":2545,
      "indication":"Moderate to severe glabellar (frown) lines",
      "advisory_committee_date":false,
      "catalyst_date":"2020-11-25",
      "fda_calendar":1,
      "press_link":"https://www.businesswire.com/news/home/20210805005976/en/",
      "catalyst_date_text":"Decision deferred by FDA",
      "note":"PDUFA date November 25, 2020. Decision has been deferred by the the FDA as it was unable to conduct a required inspection of a manufacturing facility due to travel restrictions associated with the COVID-19 pandemic. Inspection initiated June 2021. Decision expected 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-05 17:19:10",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":270,
         "ticker":"RVNC",
         "name":"Revance Therapeutics Inc.",
         "exchange":null,
         "price":26.969999999999999,
         "change":1.0600000000000001,
         "percent_change":4.0899999999999999,
         "number_of_shares":71829718,
         "market_cap":1937247494,
         "short_ratio":null,
         "volume":387470,
         "average_daily_volume":444799,
         "relative_volume":0.87,
         "price_to_book":10.41,
         "open":25.780000000000001,
         "previous_close":25.91,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Glabellar lines"
      ],
      "cashflow":{
         "id":212,
         "ticker":"RVNC",
         "earnings":{
            "id":"5f2bc343713ee300019e0087",
            "eps":"-1.070",
            "date":"2021-08-05",
            "name":"Revance Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"RVNC",
            "eps_est":"-1.050",
            "revenue":"18804000.000",
            "updated":1628199645,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.120",
            "importance":0,
            "period_year":2021,
            "revenue_est":"15480000.000",
            "eps_surprise":"-0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"299000.000",
            "date_confirmed":1,
            "revenue_surprise":"3324000.0000",
            "eps_surprise_percent":"-0.0190",
            "revenue_surprise_percent":"0.2147"
         },
         "prev_quarter_earnings":{
            "id":"5eb3b243885f2800019b36f2",
            "eps":"-1.080",
            "date":"2021-05-10",
            "name":"Revance Therapeutics",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"RVNC",
            "eps_est":"-1.090",
            "revenue":"13299000.000",
            "updated":1620679338,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.150",
            "importance":0,
            "period_year":2021,
            "revenue_est":"10980000.000",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"58000.000",
            "date_confirmed":1,
            "revenue_surprise":"2319000.0000",
            "eps_surprise_percent":"0.0092",
            "revenue_surprise_percent":"0.2112"
         },
         "cash_equivalents_and_short_term_investments":336296000,
         "operating_cash_flow":-49005000,
         "monthly_cash_burn":-16335000,
         "est_live_cash":307437500,
         "est_months_cash":18.820783593510868,
         "total_liabilities":454640000,
         "net_cash":-147202500,
         "enterpriseValue":1927876494,
         "total_debt_to_equity":1.76,
         "float":69053708,
         "insiderholdingspct":2.5
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":6469,
      "name":"MYL-1402O",
      "craft_entry_id":43162,
      "indication":"Avastin (bevacizumab) biosimilar",
      "advisory_committee_date":false,
      "catalyst_date":"2020-12-27",
      "fda_calendar":0,
      "press_link":"https://www.biocon.com/biocon-biologics-statement-on-the-status-of-bevacizumab-fda-action-date-in-dec-2020/",
      "catalyst_date_text":"Decision deferred by FDA",
      "note":"BsUFA date has been deferred by the the FDA as it was unable to conduct a required inspection of a manufacturing facility due to travel restrictions associated with the COVID-19 pandemic.",
      "estimated_primary_completion_date":"",
      "updated_at":"2020-12-31 05:14:14",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":851,
         "ticker":"VTRS",
         "name":"Viatris Inc.",
         "exchange":null,
         "price":14.69,
         "change":-0.040000000000000036,
         "percent_change":-0.27000000000000002,
         "number_of_shares":1209290460,
         "market_cap":17764476857,
         "short_ratio":null,
         "volume":7277624,
         "average_daily_volume":6706061,
         "relative_volume":1.0900000000000001,
         "price_to_book":0.83999999999999997,
         "open":14.609999999999999,
         "previous_close":14.73,
         "created_at":"2020-11-19T21:22:44.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Biosimilar"
      ],
      "cashflow":{
         "id":714,
         "ticker":"VTRS",
         "earnings":{
            "id":"5fca31c1bb3cbc00019f6a79",
            "eps":"0.980",
            "date":"2021-08-09",
            "name":"Viatris",
            "time":"06:59:00",
            "notes":"",
            "period":"Q2",
            "ticker":"VTRS",
            "eps_est":"0.870",
            "revenue":"4578000000.000",
            "updated":1628508617,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"4400000000.000",
            "eps_surprise":"0.1100",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"178000000.0000",
            "eps_surprise_percent":"0.1264",
            "revenue_surprise_percent":"0.0405"
         },
         "prev_quarter_earnings":{
            "id":"5fca31c1bb3cbc00019f6a7b",
            "eps":"0.920",
            "date":"2021-05-10",
            "name":"Viatris",
            "time":"07:55:29",
            "notes":"",
            "period":"Q1",
            "ticker":"VTRS",
            "eps_est":"0.800",
            "revenue":"4400000000.000",
            "updated":1620645000,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"4180000000.000",
            "eps_surprise":"0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"220000000.0000",
            "eps_surprise_percent":"0.1500",
            "revenue_surprise_percent":"0.0526"
         },
         "cash_equivalents_and_short_term_investments":852300000,
         "operating_cash_flow":559400000,
         "monthly_cash_burn":186466666,
         "est_live_cash":1181724443,
         "est_months_cash":6.3374568138629135,
         "total_liabilities":36777200000,
         "net_cash":-35595475557,
         "enterpriseValue":41612176857,
         "total_debt_to_equity":1.1599999999999999,
         "float":1077478657,
         "insiderholdingspct":0.29999999999999999
      },
      "updated_at_formatted":"31/12/2020"
   },
   {
      "id":4618,
      "name":"VERED (Epsolay)",
      "craft_entry_id":15300,
      "indication":"Papulopustular rosacea",
      "advisory_committee_date":false,
      "catalyst_date":"2021-04-26",
      "fda_calendar":0,
      "press_link":"https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-technologies-provides-update-fda-review-epsolayr",
      "catalyst_date_text":"Decision deferred by FDA",
      "note":"PDUFA date April 26, 2021. Decision has been deferred as the FDA has not been able to conduct a pre-approval inspection of the production site due to COVID-19.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-04-27 16:06:14",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":528,
         "ticker":"SLGL",
         "name":"Sol-Gel Technologies Ltd.",
         "exchange":null,
         "price":9.3699999999999992,
         "change":-0.089999999999999969,
         "percent_change":-0.94999999999999996,
         "number_of_shares":23029951,
         "market_cap":215790641,
         "short_ratio":null,
         "volume":4042,
         "average_daily_volume":40985,
         "relative_volume":0.10000000000000001,
         "price_to_book":5.5099999999999998,
         "open":9.4100000000000001,
         "previous_close":9.4600000000000009,
         "created_at":"2018-04-05T05:52:53.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Papulopustular Rosacea"
      ],
      "cashflow":{
         "id":408,
         "ticker":"SLGL",
         "earnings":{
            "id":"5f2bc446713ee300019e00af",
            "eps":"-0.350",
            "date":"2021-08-04",
            "name":"Sol-Gel Technologies",
            "time":"07:05:00",
            "notes":"",
            "period":"Q2",
            "ticker":"SLGL",
            "eps_est":"-0.210",
            "revenue":"928000.000",
            "updated":1628084055,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.310",
            "importance":0,
            "period_year":2021,
            "revenue_est":"2890000.000",
            "eps_surprise":"-0.1400",
            "revenue_type":"GAAP",
            "revenue_prior":"1133000.000",
            "date_confirmed":1,
            "revenue_surprise":"-1962000.0000",
            "eps_surprise_percent":"-0.6667",
            "revenue_surprise_percent":"-0.6789"
         },
         "prev_quarter_earnings":{
            "id":"5ebcecc84b88bb0001fc2fee",
            "eps":"-0.180",
            "date":"2021-05-13",
            "name":"Sol-Gel Technologies",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"SLGL",
            "eps_est":"-0.470",
            "revenue":"701000.000",
            "updated":1620981503,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.330",
            "importance":0,
            "period_year":2021,
            "revenue_est":"3370000.000",
            "eps_surprise":"0.2900",
            "revenue_type":"GAAP",
            "revenue_prior":"3465000.000",
            "date_confirmed":1,
            "revenue_surprise":"-2669000.0000",
            "eps_surprise_percent":"0.6170",
            "revenue_surprise_percent":"-0.7920"
         },
         "cash_equivalents_and_short_term_investments":38882000,
         "operating_cash_flow":null,
         "monthly_cash_burn":null,
         "est_live_cash":38882000,
         "est_months_cash":null,
         "total_liabilities":7158000,
         "net_cash":31724000,
         "enterpriseValue":178515640,
         "total_debt_to_equity":0.040000000000000001,
         "float":5349816,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"27/04/2021"
   },
   {
      "id":7113,
      "name":"TAK-721",
      "craft_entry_id":71983,
      "indication":"Eosinophilic esophagitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-06-15",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20201215005640/en/",
      "catalyst_date_text":"PDUFA date has passed",
      "note":"PDUFA date has passed. Company rep notes that discussions continue with the FDA regarding the submission and any approval is subject to the outcome of those discussions.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-06-22 08:05:29",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":751,
         "ticker":"TAK",
         "name":"Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)",
         "exchange":null,
         "price":16.68,
         "change":0.089999999999999997,
         "percent_change":0.54000000000000004,
         "number_of_shares":3145059016,
         "market_cap":52459584387,
         "short_ratio":null,
         "volume":966440,
         "average_daily_volume":1875590,
         "relative_volume":0.52000000000000002,
         "price_to_book":1.1000000000000001,
         "open":16.609999999999999,
         "previous_close":16.59,
         "created_at":"2020-05-04T06:35:24.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Eosinophilic esophagitis"
      ],
      "cashflow":{
         "id":616,
         "ticker":"TAK",
         "earnings":{
            "id":"5f23c4c0bcf9e90001c5d047",
            "eps":"1.030",
            "date":"2021-07-30",
            "name":"Takeda Pharmaceutical",
            "time":"15:00:00",
            "notes":"FXC",
            "period":"Q1",
            "ticker":"TAK",
            "eps_est":"",
            "revenue":"8641000000.000",
            "updated":1628087142,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"1.140",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"7458000000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ec4d5cd88a06b0001f81c6d",
            "eps":"0.820",
            "date":"2021-05-11",
            "name":"Takeda Pharmaceutical",
            "time":"15:00:00",
            "notes":"FXC",
            "period":"Q4",
            "ticker":"TAK",
            "eps_est":"",
            "revenue":"7241000000.000",
            "updated":1622023626,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"0.010",
            "importance":3,
            "period_year":2020,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"7079000000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":684850000000,
         "operating_cash_flow":166858000000,
         "monthly_cash_burn":55619333333,
         "est_live_cash":783110822221,
         "est_months_cash":14.079831153897805,
         "total_liabilities":7418591000000,
         "net_cash":-6635480177779,
         "enterpriseValue":86297643852,
         "total_debt_to_equity":0.82999999999999996,
         "float":3145059016,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"22/06/2021"
   },
   {
      "id":6991,
      "name":"RINVOQ (upadacitinib)",
      "craft_entry_id":62382,
      "indication":"Active Ankylosing Spondylitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-06-25",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/abbvie-provides-update-regarding-rinvoq-upadacitinib-in-psoriatic-arthritis-and-ankylosing-spondylitis-in-the-us-301319940.html",
      "catalyst_date_text":"PDUFA date has passed",
      "note":"PDUFA estimate June 25, 2021 will not be met - noted June 25, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-06-25 17:38:11",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":369,
         "ticker":"ABBV",
         "name":"AbbVie Inc.",
         "exchange":null,
         "price":118.81999999999999,
         "change":0.89000000000000001,
         "percent_change":0.75,
         "number_of_shares":1767175532,
         "market_cap":209975796712,
         "short_ratio":null,
         "volume":4111104,
         "average_daily_volume":5727260,
         "relative_volume":0.71999999999999997,
         "price_to_book":16.710000000000001,
         "open":118.09999999999999,
         "previous_close":117.93000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Ankylosing spondylitis"
      ],
      "cashflow":{
         "id":294,
         "ticker":"ABBV",
         "earnings":{
            "id":"5f23c177bcf9e90001c5cf49",
            "eps":"3.110",
            "date":"2021-07-30",
            "name":"AbbVie",
            "time":"07:44:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ABBV",
            "eps_est":"3.090",
            "revenue":"13959000000.000",
            "updated":1627645810,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"2.340",
            "importance":4,
            "period_year":2021,
            "revenue_est":"13630000000.000",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"10425000000.000",
            "date_confirmed":1,
            "revenue_surprise":"329000000.0000",
            "eps_surprise_percent":"0.0065",
            "revenue_surprise_percent":"0.0241"
         },
         "prev_quarter_earnings":{
            "id":"5eabc8fb7951770001128a03",
            "eps":"2.950",
            "date":"2021-04-30",
            "name":"AbbVie",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ABBV",
            "eps_est":"2.830",
            "revenue":"13010000000.000",
            "updated":1619783445,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"2.420",
            "importance":4,
            "period_year":2021,
            "revenue_est":"12760000000.000",
            "eps_surprise":"0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"8619000000.000",
            "date_confirmed":1,
            "revenue_surprise":"250000000.0000",
            "eps_surprise_percent":"0.0424",
            "revenue_surprise_percent":"0.0196"
         },
         "cash_equivalents_and_short_term_investments":8600000000,
         "operating_cash_flow":4890000000,
         "monthly_cash_burn":1630000000,
         "est_live_cash":11479666666,
         "est_months_cash":7.0427402858895709,
         "total_liabilities":135378000000,
         "net_cash":-123898333334,
         "enterpriseValue":283513796712,
         "total_debt_to_equity":6.5300000000000002,
         "float":1765652810,
         "insiderholdingspct":0.10000000000000001
      },
      "updated_at_formatted":"25/06/2021"
   },
   {
      "id":6386,
      "name":"RINVOQ (Upadacitinib)",
      "craft_entry_id":40440,
      "indication":"Psoriatic arthritis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-06-29",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/abbvie-provides-update-regarding-rinvoq-upadacitinib-in-psoriatic-arthritis-and-ankylosing-spondylitis-in-the-us-301319940.html",
      "catalyst_date_text":"PDUFA date has passed",
      "note":"PDUFA estimate June 25, 2021 will not be met - noted June 25, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-06-29 18:38:01",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":369,
         "ticker":"ABBV",
         "name":"AbbVie Inc.",
         "exchange":null,
         "price":118.81999999999999,
         "change":0.89000000000000001,
         "percent_change":0.75,
         "number_of_shares":1767175532,
         "market_cap":209975796712,
         "short_ratio":null,
         "volume":4111104,
         "average_daily_volume":5727260,
         "relative_volume":0.71999999999999997,
         "price_to_book":16.710000000000001,
         "open":118.09999999999999,
         "previous_close":117.93000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Psoriatic arthritis"
      ],
      "cashflow":{
         "id":294,
         "ticker":"ABBV",
         "earnings":{
            "id":"5f23c177bcf9e90001c5cf49",
            "eps":"3.110",
            "date":"2021-07-30",
            "name":"AbbVie",
            "time":"07:44:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ABBV",
            "eps_est":"3.090",
            "revenue":"13959000000.000",
            "updated":1627645810,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"2.340",
            "importance":4,
            "period_year":2021,
            "revenue_est":"13630000000.000",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"10425000000.000",
            "date_confirmed":1,
            "revenue_surprise":"329000000.0000",
            "eps_surprise_percent":"0.0065",
            "revenue_surprise_percent":"0.0241"
         },
         "prev_quarter_earnings":{
            "id":"5eabc8fb7951770001128a03",
            "eps":"2.950",
            "date":"2021-04-30",
            "name":"AbbVie",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ABBV",
            "eps_est":"2.830",
            "revenue":"13010000000.000",
            "updated":1619783445,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"2.420",
            "importance":4,
            "period_year":2021,
            "revenue_est":"12760000000.000",
            "eps_surprise":"0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"8619000000.000",
            "date_confirmed":1,
            "revenue_surprise":"250000000.0000",
            "eps_surprise_percent":"0.0424",
            "revenue_surprise_percent":"0.0196"
         },
         "cash_equivalents_and_short_term_investments":8600000000,
         "operating_cash_flow":4890000000,
         "monthly_cash_burn":1630000000,
         "est_live_cash":11479666666,
         "est_months_cash":7.0427402858895709,
         "total_liabilities":135378000000,
         "net_cash":-123898333334,
         "enterpriseValue":283513796712,
         "total_debt_to_equity":6.5300000000000002,
         "float":1765652810,
         "insiderholdingspct":0.10000000000000001
      },
      "updated_at_formatted":"29/06/2021"
   },
   {
      "id":3030,
      "name":"RINVOQ (Upadacitinib)",
      "craft_entry_id":3696,
      "indication":"Atopic Dermatitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-07-02",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/abbvie-provides-update-regarding-rinvoq-upadacitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-the-us-301335375.html",
      "catalyst_date_text":"PDUFA date has passed",
      "note":"PDUFA date early 3Q 2021 not met. The FDA cited its ongoing review of Pfizer's post-marketing study, ORAL Surveillance, evaluating tofacitinib in patients with rheumatoid arthritis for the delay.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-07-16 08:39:52",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":369,
         "ticker":"ABBV",
         "name":"AbbVie Inc.",
         "exchange":null,
         "price":118.81999999999999,
         "change":0.89000000000000001,
         "percent_change":0.75,
         "number_of_shares":1767175532,
         "market_cap":209975796712,
         "short_ratio":null,
         "volume":4111104,
         "average_daily_volume":5727260,
         "relative_volume":0.71999999999999997,
         "price_to_book":16.710000000000001,
         "open":118.09999999999999,
         "previous_close":117.93000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Atopic dermatitis"
      ],
      "cashflow":{
         "id":294,
         "ticker":"ABBV",
         "earnings":{
            "id":"5f23c177bcf9e90001c5cf49",
            "eps":"3.110",
            "date":"2021-07-30",
            "name":"AbbVie",
            "time":"07:44:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ABBV",
            "eps_est":"3.090",
            "revenue":"13959000000.000",
            "updated":1627645810,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"2.340",
            "importance":4,
            "period_year":2021,
            "revenue_est":"13630000000.000",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"10425000000.000",
            "date_confirmed":1,
            "revenue_surprise":"329000000.0000",
            "eps_surprise_percent":"0.0065",
            "revenue_surprise_percent":"0.0241"
         },
         "prev_quarter_earnings":{
            "id":"5eabc8fb7951770001128a03",
            "eps":"2.950",
            "date":"2021-04-30",
            "name":"AbbVie",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ABBV",
            "eps_est":"2.830",
            "revenue":"13010000000.000",
            "updated":1619783445,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"2.420",
            "importance":4,
            "period_year":2021,
            "revenue_est":"12760000000.000",
            "eps_surprise":"0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"8619000000.000",
            "date_confirmed":1,
            "revenue_surprise":"250000000.0000",
            "eps_surprise_percent":"0.0424",
            "revenue_surprise_percent":"0.0196"
         },
         "cash_equivalents_and_short_term_investments":8600000000,
         "operating_cash_flow":4890000000,
         "monthly_cash_burn":1630000000,
         "est_live_cash":11479666666,
         "est_months_cash":7.0427402858895709,
         "total_liabilities":135378000000,
         "net_cash":-123898333334,
         "enterpriseValue":283513796712,
         "total_debt_to_equity":6.5300000000000002,
         "float":1765652810,
         "insiderholdingspct":0.10000000000000001
      },
      "updated_at_formatted":"16/07/2021"
   },
   {
      "id":2306,
      "name":"OLUMIANT (baricitinib)",
      "craft_entry_id":10912,
      "indication":"Atopic dermatitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-07-06",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/lilly-and-incyte-provide-update-on-supplemental-new-drug-application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-301335605.html",
      "catalyst_date_text":"PDUFA date not met",
      "note":"Noted FDA will not meet assigned July 2021 PDUFA date - July 16, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-07-16 10:23:45",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":167,
         "ticker":"INCY",
         "name":"Incyte Corporation",
         "exchange":null,
         "price":74.900000000000006,
         "change":0.39000000000000001,
         "percent_change":0.52000000000000002,
         "number_of_shares":220835269,
         "market_cap":16540561648,
         "short_ratio":null,
         "volume":772335,
         "average_daily_volume":1289837,
         "relative_volume":0.59999999999999998,
         "price_to_book":5.6399999999999997,
         "open":74.469999999999999,
         "previous_close":74.510000000000005,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Atopic dermatitis"
      ],
      "cashflow":{
         "id":138,
         "ticker":"INCY",
         "earnings":{
            "id":"5f2908e12902dd0001f85620",
            "eps":"0.800",
            "date":"2021-08-03",
            "name":"Incyte",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"INCY",
            "eps_est":"0.750",
            "revenue":"705709000.000",
            "updated":1627990115,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"1.240",
            "importance":3,
            "period_year":2021,
            "revenue_est":"686980000.000",
            "eps_surprise":"0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"688043000.000",
            "date_confirmed":1,
            "revenue_surprise":"18729000.0000",
            "eps_surprise_percent":"0.0667",
            "revenue_surprise_percent":"0.0273"
         },
         "prev_quarter_earnings":{
            "id":"5eb10f2a13dffb0001540c23",
            "eps":"0.670",
            "date":"2021-05-04",
            "name":"Incyte",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"INCY",
            "eps_est":"0.640",
            "revenue":"604718000.000",
            "updated":1620127319,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-2.860",
            "importance":0,
            "period_year":2021,
            "revenue_est":"659240000.000",
            "eps_surprise":"0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"568507000",
            "date_confirmed":1,
            "revenue_surprise":"-54522000.0000",
            "eps_surprise_percent":"0.0469",
            "revenue_surprise_percent":"-0.0827"
         },
         "cash_equivalents_and_short_term_investments":2080967000,
         "operating_cash_flow":172944000,
         "monthly_cash_burn":57648000,
         "est_live_cash":2182811800,
         "est_months_cash":37.864484457396614,
         "total_liabilities":968762000,
         "net_cash":1214049800,
         "enterpriseValue":14504835648,
         "total_debt_to_equity":0.02,
         "float":155219007,
         "insiderholdingspct":1.5
      },
      "updated_at_formatted":"16/07/2021"
   },
   {
      "id":2306,
      "name":"OLUMIANT (baricitinib)",
      "craft_entry_id":10912,
      "indication":"Atopic dermatitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-07-06",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/lilly-and-incyte-provide-update-on-supplemental-new-drug-application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-301335605.html",
      "catalyst_date_text":"PDUFA date not met",
      "note":"Noted FDA will not meet assigned July 2021 PDUFA date - July 16, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-07-16 10:23:45",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":382,
         "ticker":"LLY",
         "name":"Eli Lilly and Company",
         "exchange":null,
         "price":270.91000000000003,
         "change":0.51000000000000001,
         "percent_change":0.19,
         "number_of_shares":956580893,
         "market_cap":259147329723,
         "short_ratio":null,
         "volume":1536811,
         "average_daily_volume":2804717,
         "relative_volume":0.55000000000000004,
         "price_to_book":40.189999999999998,
         "open":269.38,
         "previous_close":270.39999999999998,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Atopic dermatitis"
      ],
      "cashflow":{
         "id":306,
         "ticker":"LLY",
         "earnings":{
            "id":"5f2270ce44c96f00014e775f",
            "eps":"1.870",
            "date":"2021-08-03",
            "name":"Eli Lilly",
            "time":"06:25:00",
            "notes":"",
            "period":"Q2",
            "ticker":"LLY",
            "eps_est":"1.920",
            "revenue":"6740000000.000",
            "updated":1627986765,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"1.890",
            "importance":4,
            "period_year":2021,
            "revenue_est":"6650000000.000",
            "eps_surprise":"-0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"5499000000.000",
            "date_confirmed":1,
            "revenue_surprise":"90000000.0000",
            "eps_surprise_percent":"-0.0260",
            "revenue_surprise_percent":"0.0135"
         },
         "prev_quarter_earnings":{
            "id":"5ea13d2c5afd4900017c67b5",
            "eps":"1.870",
            "date":"2021-04-27",
            "name":"Eli Lilly",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"LLY",
            "eps_est":"2.140",
            "revenue":"6805600000.000",
            "updated":1619519639,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"1.750",
            "importance":4,
            "period_year":2021,
            "revenue_est":"7020000000.000",
            "eps_surprise":"-0.2700",
            "revenue_type":"GAAP",
            "revenue_prior":"5860000000.000",
            "date_confirmed":1,
            "revenue_surprise":"-214400000.0000",
            "eps_surprise_percent":"-0.1262",
            "revenue_surprise_percent":"-0.0305"
         },
         "cash_equivalents_and_short_term_investments":3271200000,
         "operating_cash_flow":1775500000,
         "monthly_cash_burn":591833333,
         "est_live_cash":4316772221,
         "est_months_cash":7.2938984344094049,
         "total_liabilities":41145500000,
         "net_cash":-36828727779,
         "enterpriseValue":272391229722,
         "total_debt_to_equity":2.5600000000000001,
         "float":792287037,
         "insiderholdingspct":0.5
      },
      "updated_at_formatted":"16/07/2021"
   },
   {
      "id":6345,
      "name":"XELJANZ (tofacitinib)",
      "craft_entry_id":39850,
      "indication":"Ankylosing spondylitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-07-15",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210721005857/en/",
      "catalyst_date_text":"PDUFA date not met. ",
      "note":"PDUFA of 3Q 2021 will not be met, no date has been provided. ",
      "estimated_primary_completion_date":"December 19, 2019",
      "updated_at":"2021-07-21 16:50:42",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":387,
         "ticker":"PFE",
         "name":"Pfizer Inc.",
         "exchange":null,
         "price":48.719999999999999,
         "change":-0.07999999999999996,
         "percent_change":-0.16000000000000003,
         "number_of_shares":5606688356,
         "market_cap":273157856704,
         "short_ratio":null,
         "volume":35001260,
         "average_daily_volume":30140765,
         "relative_volume":1.1599999999999999,
         "price_to_book":3.8999999999999999,
         "open":48.979999999999997,
         "previous_close":48.799999999999997,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Ankylosing spondylitis"
      ],
      "cashflow":{
         "id":311,
         "ticker":"PFE",
         "earnings":{
            "id":"5f1fce010132700001765441",
            "eps":"1.070",
            "date":"2021-07-28",
            "name":"Pfizer",
            "time":"06:45:00",
            "notes":"",
            "period":"Q2",
            "ticker":"PFE",
            "eps_est":"0.960",
            "revenue":"18977000000.000",
            "updated":1627469540,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"0.780",
            "importance":5,
            "period_year":2021,
            "revenue_est":"18450000000.000",
            "eps_surprise":"0.1100",
            "revenue_type":"GAAP",
            "revenue_prior":"11801000000.000",
            "date_confirmed":1,
            "revenue_surprise":"527000000.0000",
            "eps_surprise_percent":"0.1146",
            "revenue_surprise_percent":"0.0286"
         },
         "prev_quarter_earnings":{
            "id":"5ea7d4be1b319c000108ca16",
            "eps":"0.930",
            "date":"2021-05-04",
            "name":"Pfizer",
            "time":"06:45:00",
            "notes":"",
            "period":"Q1",
            "ticker":"PFE",
            "eps_est":"0.780",
            "revenue":"14582000000.000",
            "updated":1620125211,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"0.800",
            "importance":5,
            "period_year":2021,
            "revenue_est":"13600000000.000",
            "eps_surprise":"0.1500",
            "revenue_type":"GAAP",
            "revenue_prior":"12028000000.000",
            "date_confirmed":1,
            "revenue_surprise":"982000000.0000",
            "eps_surprise_percent":"0.1923",
            "revenue_surprise_percent":"0.0722"
         },
         "cash_equivalents_and_short_term_investments":21700000000,
         "operating_cash_flow":11299000000,
         "monthly_cash_burn":3766333333,
         "est_live_cash":28353855554,
         "est_months_cash":7.528238487435015,
         "total_liabilities":99605000000,
         "net_cash":-71251144446,
         "enterpriseValue":289192856704,
         "total_debt_to_equity":0.54000000000000004,
         "float":5605213314,
         "insiderholdingspct":0.29999999999999999
      },
      "updated_at_formatted":"21/07/2021"
   },
   {
      "id":6096,
      "name":"Abrocitinib",
      "craft_entry_id":32321,
      "indication":"Atopic Dermatitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-07-21",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210721005857/en/",
      "catalyst_date_text":"PDUFA date not met",
      "note":"PDUFA date of 3Q 2021 will not be met, no date provided. ",
      "estimated_primary_completion_date":"August 13, 2019",
      "updated_at":"2021-07-21 16:48:22",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":387,
         "ticker":"PFE",
         "name":"Pfizer Inc.",
         "exchange":null,
         "price":48.719999999999999,
         "change":-0.07999999999999996,
         "percent_change":-0.16000000000000003,
         "number_of_shares":5606688356,
         "market_cap":273157856704,
         "short_ratio":null,
         "volume":35001260,
         "average_daily_volume":30140765,
         "relative_volume":1.1599999999999999,
         "price_to_book":3.8999999999999999,
         "open":48.979999999999997,
         "previous_close":48.799999999999997,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Atopic dermatitis"
      ],
      "cashflow":{
         "id":311,
         "ticker":"PFE",
         "earnings":{
            "id":"5f1fce010132700001765441",
            "eps":"1.070",
            "date":"2021-07-28",
            "name":"Pfizer",
            "time":"06:45:00",
            "notes":"",
            "period":"Q2",
            "ticker":"PFE",
            "eps_est":"0.960",
            "revenue":"18977000000.000",
            "updated":1627469540,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"0.780",
            "importance":5,
            "period_year":2021,
            "revenue_est":"18450000000.000",
            "eps_surprise":"0.1100",
            "revenue_type":"GAAP",
            "revenue_prior":"11801000000.000",
            "date_confirmed":1,
            "revenue_surprise":"527000000.0000",
            "eps_surprise_percent":"0.1146",
            "revenue_surprise_percent":"0.0286"
         },
         "prev_quarter_earnings":{
            "id":"5ea7d4be1b319c000108ca16",
            "eps":"0.930",
            "date":"2021-05-04",
            "name":"Pfizer",
            "time":"06:45:00",
            "notes":"",
            "period":"Q1",
            "ticker":"PFE",
            "eps_est":"0.780",
            "revenue":"14582000000.000",
            "updated":1620125211,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"0.800",
            "importance":5,
            "period_year":2021,
            "revenue_est":"13600000000.000",
            "eps_surprise":"0.1500",
            "revenue_type":"GAAP",
            "revenue_prior":"12028000000.000",
            "date_confirmed":1,
            "revenue_surprise":"982000000.0000",
            "eps_surprise_percent":"0.1923",
            "revenue_surprise_percent":"0.0722"
         },
         "cash_equivalents_and_short_term_investments":21700000000,
         "operating_cash_flow":11299000000,
         "monthly_cash_burn":3766333333,
         "est_live_cash":28353855554,
         "est_months_cash":7.528238487435015,
         "total_liabilities":99605000000,
         "net_cash":-71251144446,
         "enterpriseValue":289192856704,
         "total_debt_to_equity":0.54000000000000004,
         "float":5605213314,
         "insiderholdingspct":0.29999999999999999
      },
      "updated_at_formatted":"21/07/2021"
   },
   {
      "id":4870,
      "name":"Dextromethorphan-bupropion (AXS-05)",
      "craft_entry_id":17325,
      "indication":"Major Depressive Disorder",
      "advisory_committee_date":false,
      "catalyst_date":"2021-08-22",
      "fda_calendar":1,
      "press_link":"https://www.globenewswire.com/news-release/2021/08/09/2276982/0/en/Axsome-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Business-Update.html",
      "catalyst_date_text":"",
      "note":"PDUFA date under priority review August 22, 2021. Noted August 9, 2021 that the FDA that it has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-09 07:55:09",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":61,
         "ticker":"AXSM",
         "name":"Axsome Therapeutics Inc.",
         "exchange":null,
         "price":21.559999999999999,
         "change":1.6499999999999999,
         "percent_change":8.2899999999999991,
         "number_of_shares":37681948,
         "market_cap":812422799,
         "short_ratio":null,
         "volume":1628163,
         "average_daily_volume":827734,
         "relative_volume":1.97,
         "price_to_book":11.35,
         "open":19.890000000000001,
         "previous_close":19.91,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Depression"
      ],
      "cashflow":{
         "id":47,
         "ticker":"AXSM",
         "earnings":{
            "id":"5f30f081a7bff3000162b1f7",
            "eps":"-0.860",
            "date":"2021-08-09",
            "name":"Axsome Therapeutics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"AXSM",
            "eps_est":"-0.970",
            "revenue":"0.000",
            "updated":1628508701,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.490",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.1100",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.1134",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eb50383f857860001768c12",
            "eps":"-0.780",
            "date":"2021-05-10",
            "name":"Axsome Therapeutics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"AXSM",
            "eps_est":"-0.870",
            "revenue":"0.000",
            "updated":1620647564,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.880",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.1034",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":141219090,
         "operating_cash_flow":-25393553,
         "monthly_cash_burn":-8464517,
         "est_live_cash":126265109,
         "est_months_cash":14.91698923872443,
         "total_liabilities":71828130,
         "net_cash":54436979,
         "enterpriseValue":721257011,
         "total_debt_to_equity":0.69999999999999996,
         "float":22349124,
         "insiderholdingspct":0.5
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":4590,
      "name":"KORSUVA (CR845/difelikefalin) injection",
      "craft_entry_id":15266,
      "indication":"Chronic kidney disease (CKD) on hemodialysis (HD) with Moderate-to Severe Pruritus",
      "advisory_committee_date":false,
      "catalyst_date":"2021-08-23",
      "fda_calendar":1,
      "press_link":"https://www.businesswire.com/news/home/20210307005039/en/",
      "catalyst_date_text":"",
      "note":"PDUFA date under priority review August 23, 2021.",
      "estimated_primary_completion_date":"March 30, 2020",
      "updated_at":"2021-03-08 01:14:13",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":77,
         "ticker":"CARA",
         "name":"Cara Therapeutics Inc.",
         "exchange":null,
         "price":13.699999999999999,
         "change":1.29,
         "percent_change":10.390000000000001,
         "number_of_shares":50089936,
         "market_cap":686232123,
         "short_ratio":null,
         "volume":1887953,
         "average_daily_volume":570517,
         "relative_volume":3.3100000000000001,
         "price_to_book":3.3700000000000001,
         "open":12.449999999999999,
         "previous_close":12.41,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Pruritus",
         "Chronic Kidney Disease-Associated Pruritus"
      ],
      "cashflow":{
         "id":62,
         "ticker":"CARA",
         "earnings":{
            "id":"5f30f086a7bff3000162b20d",
            "eps":"-0.610",
            "date":"2021-08-09",
            "name":"Cara Therapeutics",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CARA",
            "eps_est":"-0.530",
            "revenue":"0.000",
            "updated":1628541220,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.540",
            "importance":2,
            "period_year":2021,
            "revenue_est":"2360000.000",
            "eps_surprise":"-0.0800",
            "revenue_type":"GAAP",
            "revenue_prior":"5634000.000",
            "date_confirmed":1,
            "revenue_surprise":"-2360000.0000",
            "eps_surprise_percent":"-0.1509",
            "revenue_surprise_percent":"-1.0000"
         },
         "prev_quarter_earnings":{
            "id":"5eb8f807470dcc00012d9dcd",
            "eps":"-0.470",
            "date":"2021-05-10",
            "name":"Cara Therapeutics",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"CARA",
            "eps_est":"-0.590",
            "revenue":"1935000.000",
            "updated":1620679028,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.620",
            "importance":2,
            "period_year":2021,
            "revenue_est":"2360000.000",
            "eps_surprise":"0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"8093000.000",
            "date_confirmed":1,
            "revenue_surprise":"-425000.0000",
            "eps_surprise_percent":"0.2034",
            "revenue_surprise_percent":"-0.1801"
         },
         "cash_equivalents_and_short_term_investments":155176000,
         "operating_cash_flow":-21005000,
         "monthly_cash_burn":-7001666,
         "est_live_cash":142806390,
         "est_months_cash":20.3960585951972,
         "total_liabilities":17988000,
         "net_cash":124818390,
         "enterpriseValue":535551123,
         "total_debt_to_equity":0.02,
         "float":49119725,
         "insiderholdingspct":3.3999999999999999
      },
      "updated_at_formatted":"08/03/2021"
   },
   {
      "id":5647,
      "name":"ALRN-6924",
      "craft_entry_id":25441,
      "indication":"Small Cell Lung Cancer (SCLC)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-08-25",
      "fda_calendar":0,
      "press_link":"https://www.benzinga.com/pressreleases/21/08/g22453987/aileron-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business-update",
      "catalyst_date_text":"",
      "note":"Phase 1b/2 final data to be presented at ISEH Virtual Scientific Meeting, August 25-28, 2021.",
      "estimated_primary_completion_date":"June 2022",
      "updated_at":"2021-08-11 18:42:20",
      "stage":{
         "id":3,
         "label":"Phase 1b",
         "value":"phase1b"
      },
      "companies":{
         "id":425,
         "ticker":"ALRN",
         "name":"Aileron Therapeutics Inc.",
         "exchange":null,
         "price":1.02,
         "change":0.01,
         "percent_change":0.98999999999999999,
         "number_of_shares":90553806,
         "market_cap":92364882,
         "short_ratio":null,
         "volume":381867,
         "average_daily_volume":422887,
         "relative_volume":0.90000000000000002,
         "price_to_book":1.6400000000000001,
         "open":1.02,
         "previous_close":1.01,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Small cell lung cancer (SCLC)"
      ],
      "cashflow":{
         "id":344,
         "ticker":"ALRN",
         "earnings":{
            "id":"5f2babe0713ee300019dfd3b",
            "eps":"-0.060",
            "date":"2021-08-11",
            "name":"Aileron Therapeutics",
            "time":"16:20:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ALRN",
            "eps_est":"-0.070",
            "revenue":"0.000",
            "updated":1628722278,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.140",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.1429",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ebcec7f4b88bb0001fc2ecc",
            "eps":"-0.080",
            "date":"2021-05-11",
            "name":"Aileron Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ALRN",
            "eps_est":"-0.070",
            "revenue":"0.000",
            "updated":1620805166,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.240",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.1429",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":59479000,
         "operating_cash_flow":-3763000,
         "monthly_cash_burn":-1254333,
         "est_live_cash":57263011,
         "est_months_cash":45.652160152048936,
         "total_liabilities":4401000,
         "net_cash":52862011,
         "enterpriseValue":33106882,
         "total_debt_to_equity":0,
         "float":71295333,
         "insiderholdingspct":1.3999999999999999
      },
      "updated_at_formatted":"11/08/2021"
   },
   {
      "id":5219,
      "name":"LPCN 1144",
      "craft_entry_id":20612,
      "indication":"Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-08-31",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-second-quarter-ended-june-30-2021-301348161.html",
      "catalyst_date_text":"August 2021",
      "note":"Phase 2 top-line change in liver fat data met primary endpoint January 12, 2021. 36-week biopsy data are expected August 2021.",
      "estimated_primary_completion_date":"January 2021",
      "updated_at":"2021-08-05 09:13:41",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":189,
         "ticker":"LPCN",
         "name":"Lipocine Inc.",
         "exchange":null,
         "price":1.3900000000000001,
         "change":0,
         "percent_change":null,
         "number_of_shares":88290650,
         "market_cap":122724003,
         "short_ratio":null,
         "volume":802107,
         "average_daily_volume":918275,
         "relative_volume":0.87,
         "price_to_book":3.48,
         "open":1.3700000000000001,
         "previous_close":1.3900000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Nonalcoholic steatohepatitis (NASH)",
         "Nonalcoholic fatty liver disease (NAFLD)"
      ],
      "cashflow":{
         "id":152,
         "ticker":"LPCN",
         "earnings":{
            "id":"5f2cfc29a3eee500019e8ef9",
            "eps":"-0.030",
            "date":"2021-08-05",
            "name":"Lipocine",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"LPCN",
            "eps_est":"-0.050",
            "revenue":"0.000",
            "updated":1628172684,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.130",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.4000",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eb503b1f857860001768cb6",
            "eps":"-0.040",
            "date":"2021-05-06",
            "name":"Lipocine",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"LPCN",
            "eps_est":"-0.050",
            "revenue":"0.000",
            "updated":1620370554,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.140",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.2000",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":46639772,
         "operating_cash_flow":-2363282,
         "monthly_cash_burn":-787760,
         "est_live_cash":45248062,
         "est_months_cash":57.438892556108456,
         "total_liabilities":11433720,
         "net_cash":33814342,
         "enterpriseValue":80041858,
         "total_debt_to_equity":0.11,
         "float":86149561,
         "insiderholdingspct":3.5
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":5518,
      "name":"Elamipretide",
      "craft_entry_id":23669,
      "indication":"Barth",
      "advisory_committee_date":false,
      "catalyst_date":"2021-08-31",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/stealth-biotherapeutics-reports-second-quarter-2021-financial-results-and-recent-business-highlights-301348928.html",
      "catalyst_date_text":"August 2021",
      "note":"Phase 2/3 trial did not meet primary endpoint December 2018. NDA filing due August 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-05 09:46:47",
      "stage":{
         "id":10,
         "label":"NDA Filing",
         "value":"ndaFiling"
      },
      "companies":{
         "id":633,
         "ticker":"MITO",
         "name":"Stealth BioTherapeutics Corp.",
         "exchange":null,
         "price":1.1699999999999999,
         "change":-0.010000000000000009,
         "percent_change":-0.84999999999999998,
         "number_of_shares":57582815,
         "market_cap":67371894,
         "short_ratio":null,
         "volume":189272,
         "average_daily_volume":442284,
         "relative_volume":0.42999999999999999,
         "price_to_book":-2.54,
         "open":1.1899999999999999,
         "previous_close":1.1799999999999999,
         "created_at":"2019-02-15T22:57:49.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Barth"
      ],
      "cashflow":{
         "id":506,
         "ticker":"MITO",
         "earnings":{
            "id":"5f2bbd93713ee300019dff99",
            "eps":"-0.030",
            "date":"2021-08-05",
            "name":"Stealth BioTherapeutics",
            "time":"07:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"MITO",
            "eps_est":"-0.020",
            "revenue":"0.000",
            "updated":1628165424,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.020",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.5000",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5e858dad38d1030001c22093",
            "eps":"-0.030",
            "date":"2021-04-06",
            "name":"Stealth BioTherapeutics",
            "time":"08:00:00",
            "notes":"",
            "period":"Q4",
            "ticker":"MITO",
            "eps_est":"0.010",
            "revenue":"0.000",
            "updated":1617710725,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"0.020",
            "importance":0,
            "period_year":2020,
            "revenue_est":"17500000.000",
            "eps_surprise":"-0.0400",
            "revenue_type":"GAAP",
            "revenue_prior":"21087000.000",
            "date_confirmed":1,
            "revenue_surprise":"-17500000.0000",
            "eps_surprise_percent":"-4.0000",
            "revenue_surprise_percent":"-1.0000"
         },
         "cash_equivalents_and_short_term_investments":30766000,
         "operating_cash_flow":null,
         "monthly_cash_burn":null,
         "est_live_cash":30766000,
         "est_months_cash":null,
         "total_liabilities":58573000,
         "net_cash":-27807000,
         "enterpriseValue":42057894,
         "total_debt_to_equity":3.9500000000000002,
         "float":57582815,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":6908,
      "name":"Quellor",
      "craft_entry_id":58798,
      "indication":"Immune mediated complications from COVID-19",
      "advisory_committee_date":false,
      "catalyst_date":"2021-08-31",
      "fda_calendar":0,
      "press_link":"https://www.inmunebio.com/index.php/en/news-2/2021/465-muneioncnnounceseconduarter2021esultsand20210804",
      "catalyst_date_text":"August 2021",
      "note":"Phase 2 DSMB analysis due August 2021.",
      "estimated_primary_completion_date":"February 2021",
      "updated_at":"2021-08-04 19:41:52",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":690,
         "ticker":"INMB",
         "name":"INmune Bio Inc.",
         "exchange":null,
         "price":16.530000000000001,
         "change":0.66000000000000003,
         "percent_change":4.1600000000000001,
         "number_of_shares":17703692,
         "market_cap":292642029,
         "short_ratio":null,
         "volume":171271,
         "average_daily_volume":496894,
         "relative_volume":0.34000000000000002,
         "price_to_book":6.7800000000000002,
         "open":15.630000000000001,
         "previous_close":15.869999999999999,
         "created_at":"2019-08-06T00:27:21.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Coronavirus",
         "COVID-19"
      ],
      "cashflow":{
         "id":558,
         "ticker":"INMB",
         "earnings":{
            "id":"5f2bb9c8713ee300019dff27",
            "eps":"-0.440",
            "date":"2021-08-04",
            "name":"INmune Bio",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"INMB",
            "eps_est":"-0.340",
            "revenue":"0.000",
            "updated":1628115489,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.200",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.1000",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.2941",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ebceca64b88bb0001fc2f6a",
            "eps":"-0.320",
            "date":"2021-05-05",
            "name":"INmune Bio",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"INMB",
            "eps_est":"-0.270",
            "revenue":"4000.000",
            "updated":1620253959,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.190",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.1852",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":39520000,
         "operating_cash_flow":-5709000,
         "monthly_cash_burn":-1903000,
         "est_live_cash":76158033,
         "est_months_cash":40.019985811875983,
         "total_liabilities":17467000,
         "net_cash":58691033,
         "enterpriseValue":267612028,
         "total_debt_to_equity":0.34000000000000002,
         "float":11663924,
         "insiderholdingspct":28.100000000000001
      },
      "updated_at_formatted":"04/08/2021"
   },
   {
      "id":4783,
      "name":"AFP (ADP-A2AFP)",
      "craft_entry_id":16698,
      "indication":"Hepatocellular carcinoma",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-02",
      "fda_calendar":1,
      "press_link":"https://www.adaptimmune.com/investors-and-media/news-events/press-releases/detail/188/adaptimmune-reports-fourth-quarter-full-year-2020",
      "catalyst_date_text":"",
      "note":"Phase 1 update at International Liver Cancer Association (ILCA) conference September 2-5, 2021.",
      "estimated_primary_completion_date":"September 2023",
      "updated_at":"2021-02-25 09:09:27",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":12,
         "ticker":"ADAP",
         "name":"Adaptimmune Therapeutics plc",
         "exchange":null,
         "price":3.7999999999999998,
         "change":0.040000000000000001,
         "percent_change":1.0600000000000001,
         "number_of_shares":156088449,
         "market_cap":593136106,
         "short_ratio":null,
         "volume":376423,
         "average_daily_volume":731820,
         "relative_volume":0.51000000000000001,
         "price_to_book":2.1299999999999999,
         "open":3.75,
         "previous_close":3.7599999999999998,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Oncology",
         "Hepatocellular carcinoma (HCC)"
      ],
      "cashflow":{
         "id":10,
         "ticker":"ADAP",
         "earnings":{
            "id":"5f2baa93713ee300019dfd13",
            "eps":"-0.040",
            "date":"2021-08-09",
            "name":"Adaptimmune Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ADAP",
            "eps_est":"-0.240",
            "revenue":"3095000.000",
            "updated":1628590560,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.040",
            "importance":0,
            "period_year":2021,
            "revenue_est":"1360000.000",
            "eps_surprise":"0.2000",
            "revenue_type":"GAAP",
            "revenue_prior":"502000.000",
            "date_confirmed":1,
            "revenue_surprise":"1735000.0000",
            "eps_surprise_percent":"0.8333",
            "revenue_surprise_percent":"1.2757"
         },
         "prev_quarter_earnings":{
            "id":"5ebcec7c4b88bb0001fc2ebc",
            "eps":"-0.040",
            "date":"2021-05-06",
            "name":"Adaptimmune Therapeutics",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ADAP",
            "eps_est":"-0.250",
            "revenue":"434000.000",
            "updated":1620303526,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.040",
            "importance":0,
            "period_year":2021,
            "revenue_est":"1830000.000",
            "eps_surprise":"0.2100",
            "revenue_type":"GAAP",
            "revenue_prior":"761000.000",
            "date_confirmed":1,
            "revenue_surprise":"-1396000.0000",
            "eps_surprise_percent":"0.8400",
            "revenue_surprise_percent":"-0.7628"
         },
         "cash_equivalents_and_short_term_investments":285370000,
         "operating_cash_flow":-31459000,
         "monthly_cash_burn":-10486333,
         "est_live_cash":266844145,
         "est_months_cash":25.446850200160533,
         "total_liabilities":111854000,
         "net_cash":154990145,
         "enterpriseValue":330411106,
         "total_debt_to_equity":0.080000000000000002,
         "float":124957108,
         "insiderholdingspct":3.2999999999999998
      },
      "updated_at_formatted":"25/02/2021"
   },
   {
      "id":8129,
      "name":"KEYTRUDA (pembrolizumab)and LENVIMA (lenvatinib)",
      "craft_entry_id":125938,
      "indication":"Endometrial carcinoma",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-03",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210506005287/en/",
      "catalyst_date_text":"",
      "note":"PDUFA date under priority review September 3, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-11 18:37:19",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":383,
         "ticker":"MRK",
         "name":"Merck & Company Inc.",
         "exchange":null,
         "price":78.680000000000007,
         "change":0.22,
         "percent_change":0.28000000000000003,
         "number_of_shares":2531374696,
         "market_cap":199168561081,
         "short_ratio":null,
         "volume":6283536,
         "average_daily_volume":10295142,
         "relative_volume":0.60999999999999999,
         "price_to_book":5.9800000000000004,
         "open":78.530000000000001,
         "previous_close":78.459999999999994,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Endometrial cancer"
      ],
      "cashflow":{
         "id":307,
         "ticker":"MRK",
         "earnings":{
            "id":"5f23c3a5bcf9e90001c5cfeb",
            "eps":"1.310",
            "date":"2021-07-29",
            "name":"Merck & Co",
            "time":"06:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"MRK",
            "eps_est":"1.440",
            "revenue":"11402000000.000",
            "updated":1627555401,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"1.370",
            "importance":5,
            "period_year":2021,
            "revenue_est":"11540000000.000",
            "eps_surprise":"-0.1300",
            "revenue_type":"GAAP",
            "revenue_prior":"10872000000.000",
            "date_confirmed":1,
            "revenue_surprise":"-138000000.0000",
            "eps_surprise_percent":"-0.0903",
            "revenue_surprise_percent":"-0.0120"
         },
         "prev_quarter_earnings":{
            "id":"5ea7d4b41b319c000108c9f2",
            "eps":"1.400",
            "date":"2021-04-29",
            "name":"Merck & Co",
            "time":"06:45:00",
            "notes":"",
            "period":"Q1",
            "ticker":"MRK",
            "eps_est":"1.630",
            "revenue":"12080000000.000",
            "updated":1619693207,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"1.500",
            "importance":5,
            "period_year":2021,
            "revenue_est":"12660000000.000",
            "eps_surprise":"-0.2300",
            "revenue_type":"GAAP",
            "revenue_prior":"12057000000.000",
            "date_confirmed":1,
            "revenue_surprise":"-580000000.0000",
            "eps_surprise_percent":"-0.1411",
            "revenue_surprise_percent":"-0.0458"
         },
         "cash_equivalents_and_short_term_investments":8575000000,
         "operating_cash_flow":2490000000,
         "monthly_cash_burn":830000000,
         "est_live_cash":10041333333,
         "est_months_cash":12.097991967469879,
         "total_liabilities":57300000000,
         "net_cash":-47258666667,
         "enterpriseValue":217114561081,
         "total_debt_to_equity":0.80000000000000004,
         "float":2529800503,
         "insiderholdingspct":0.10000000000000001
      },
      "updated_at_formatted":"11/08/2021"
   },
   {
      "id":7717,
      "name":"TRUDHESA (Dihydroergotamine)",
      "craft_entry_id":105398,
      "indication":"Migraine",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-06",
      "fda_calendar":0,
      "press_link":"https://impelnp.com/treatments/",
      "catalyst_date_text":"",
      "note":"PDUFA date September 6, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-18 16:58:30",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":928,
         "ticker":"IMPL",
         "name":"Impel NeuroPharma Inc.",
         "exchange":null,
         "price":12.800000000000001,
         "change":-0.42000000000000004,
         "percent_change":-3.1800000000000002,
         "number_of_shares":19509619,
         "market_cap":249723123,
         "short_ratio":null,
         "volume":809460,
         "average_daily_volume":93272,
         "relative_volume":8.6799999999999997,
         "price_to_book":4.8700000000000001,
         "open":14.300000000000001,
         "previous_close":13.220000000000001,
         "created_at":"2021-04-22T21:29:33.000000Z",
         "updated_at":"2021-08-20T23:55:05.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Migraine"
      ],
      "cashflow":{
         "id":790,
         "ticker":"IMPL",
         "earnings":{
            "id":"608c11eeeb87ad000158ecc5",
            "eps":"-0.790",
            "date":"2021-08-16",
            "name":"Impel NeuroPharma",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"IMPL",
            "eps_est":"-0.600",
            "revenue":"0.000",
            "updated":1629116611,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.1900",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.3167",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"608c11eeeb87ad000158eccc",
            "eps":"-0.540",
            "date":"2021-06-07",
            "name":"Impel NeuroPharma",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"IMPL",
            "eps_est":"",
            "revenue":"0.000",
            "updated":1623067925,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":60948000,
         "operating_cash_flow":-16034000,
         "monthly_cash_burn":-5344666,
         "est_live_cash":71505756,
         "est_months_cash":13.37890075825131,
         "total_liabilities":17864000,
         "net_cash":53641756,
         "enterpriseValue":197632123,
         "total_debt_to_equity":0.17000000000000001,
         "float":7107968,
         "insiderholdingspct":0.59999999999999998
      },
      "updated_at_formatted":"18/08/2021"
   },
   {
      "id":7636,
      "name":"FB-401",
      "craft_entry_id":99705,
      "indication":"Atopic Dermatitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-07",
      "fda_calendar":0,
      "press_link":"https://www.fortebiorx.com/investor-relations/news/news-details/2021/Forte-Biosciences-Inc.-to-Review-the-Second-Quarter-2021-Results-and-Expects-to-Announce-Topline-Data-From-Phase-2-Clinical-Trial-of-FB-401-for-the-Treatment-of-Atopic-Dermatitis-on-Sept.-7/default.aspx",
      "catalyst_date_text":"",
      "note":"Phase 2 top-line data due September 7, 2021.",
      "estimated_primary_completion_date":"July 2021",
      "updated_at":"2021-08-16 16:24:14",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":915,
         "ticker":"FBRX",
         "name":"Forte Biosciences Inc.",
         "exchange":null,
         "price":27.030000000000001,
         "change":1.1400000000000001,
         "percent_change":4.4000000000000004,
         "number_of_shares":14079057,
         "market_cap":380556911,
         "short_ratio":null,
         "volume":329725,
         "average_daily_volume":250473,
         "relative_volume":1.3200000000000001,
         "price_to_book":7.6399999999999997,
         "open":26.600000000000001,
         "previous_close":25.890000000000001,
         "created_at":"2021-03-24T12:05:56.000000Z",
         "updated_at":"2021-08-20T23:55:05.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Atopic dermatitis"
      ],
      "cashflow":{
         "id":777,
         "ticker":"FBRX",
         "earnings":{
            "id":"5f30f096a7bff3000162b259",
            "eps":"-0.430",
            "date":"2021-08-16",
            "name":"Forte Biosciences, Inc. - Common Stock",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"FBRX",
            "eps_est":"-0.430",
            "revenue":"0.000",
            "updated":1629154072,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-9.520",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0000",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0000",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ee8a43257aa6100018961d2",
            "eps":"-0.360",
            "date":"2021-05-10",
            "name":"Forte Biosciences, Inc. - Common Stock",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"FBRX",
            "eps_est":"-0.520",
            "revenue":"0.000",
            "updated":1620680745,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.1600",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.3077",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":50795000,
         "operating_cash_flow":-3938000,
         "monthly_cash_burn":-1312666,
         "est_live_cash":48475956,
         "est_months_cash":36.929391025592189,
         "total_liabilities":2978000,
         "net_cash":45497956,
         "enterpriseValue":329761910,
         "total_debt_to_equity":"",
         "float":10279073,
         "insiderholdingspct":17.199999999999999
      },
      "updated_at_formatted":"16/08/2021"
   },
   {
      "id":5921,
      "name":"Onvansertib, FOLFIRI and AVASTIN (bevacizumab)",
      "craft_entry_id":29247,
      "indication":"KRAS-Mutated Colorectal Cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-08",
      "fda_calendar":0,
      "press_link":"https://cardiffoncology.investorroom.com/2021-08-05-Cardiff-Oncology-Reports-Second-Quarter-2021-Results-and-Provides-Business-Updates",
      "catalyst_date_text":"",
      "note":"Phase 1b/2 updated data to be presented September 8, 2021.",
      "estimated_primary_completion_date":"May 2022",
      "updated_at":"2021-08-06 01:32:58",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":754,
         "ticker":"CRDF",
         "name":"Cardiff Oncology Inc.",
         "exchange":null,
         "price":5.4900000000000002,
         "change":0.080000000000000002,
         "percent_change":1.48,
         "number_of_shares":39552129,
         "market_cap":217141188,
         "short_ratio":null,
         "volume":338431,
         "average_daily_volume":699866,
         "relative_volume":0.47999999999999998,
         "price_to_book":1.5600000000000001,
         "open":5.5,
         "previous_close":5.4100000000000001,
         "created_at":"2020-05-07T23:35:17.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Colorectal cancer"
      ],
      "cashflow":{
         "id":619,
         "ticker":"CRDF",
         "earnings":{
            "id":"5f33938ab7c159000133e74d",
            "eps":"-0.170",
            "date":"2021-08-05",
            "name":"Cardiff Oncology",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CRDF",
            "eps_est":"-0.150",
            "revenue":"68000.000",
            "updated":1628212243,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.510",
            "importance":0,
            "period_year":2021,
            "revenue_est":"150000.000",
            "eps_surprise":"-0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"43000.000",
            "date_confirmed":1,
            "revenue_surprise":"-82000.0000",
            "eps_surprise_percent":"-0.1333",
            "revenue_surprise_percent":"-0.5467"
         },
         "prev_quarter_earnings":{
            "id":"5eb503daf857860001768d50",
            "eps":"-0.140",
            "date":"2021-05-06",
            "name":"Cardiff Oncology",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"CRDF",
            "eps_est":"-0.160",
            "revenue":"72000.000",
            "updated":1620371140,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.410",
            "importance":0,
            "period_year":2021,
            "revenue_est":"160000.000",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"68000.000",
            "date_confirmed":1,
            "revenue_surprise":"-88000.0000",
            "eps_surprise_percent":"0.1250",
            "revenue_surprise_percent":"-0.5500"
         },
         "cash_equivalents_and_short_term_investments":140051000,
         "operating_cash_flow":-4301000,
         "monthly_cash_burn":-1433666,
         "est_live_cash":137518190,
         "est_months_cash":95.920660739670183,
         "total_liabilities":4816000,
         "net_cash":132702190,
         "enterpriseValue":77499188,
         "total_debt_to_equity":0,
         "float":38902247,
         "insiderholdingspct":4.9000000000000004
      },
      "updated_at_formatted":"06/08/2021"
   },
   {
      "id":7795,
      "name":"Toripalimab (CHOICE-01)",
      "craft_entry_id":108306,
      "indication":"Non-small cell lung cancer (NSCLC)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-13",
      "fda_calendar":0,
      "press_link":"https://investors.coherus.com/news-releases/news-release-details/coherus-and-junshi-biosciences-announce-positive-interim-results",
      "catalyst_date_text":"",
      "note":"Phase 3 PFS primary endpoint reached at interim analysis. Data to be presented at World Conference on Lung Cancer September 13, 2021.",
      "estimated_primary_completion_date":"April 14, 2021",
      "updated_at":"2021-08-18 18:48:33",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":89,
         "ticker":"CHRS",
         "name":"Coherus BioSciences Inc.",
         "exchange":null,
         "price":15,
         "change":0.46999999999999997,
         "percent_change":3.23,
         "number_of_shares":76480152,
         "market_cap":1147202280,
         "short_ratio":null,
         "volume":810240,
         "average_daily_volume":627775,
         "relative_volume":1.29,
         "price_to_book":7.3499999999999996,
         "open":14.23,
         "previous_close":14.529999999999999,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Non-small cell lung cancer (NSCLC)",
         "Lung cancer"
      ],
      "cashflow":{
         "id":73,
         "ticker":"CHRS",
         "earnings":{
            "id":"5f2cfc0ba3eee500019e8e7f",
            "eps":"-0.360",
            "date":"2021-08-05",
            "name":"Coherus BioSciences",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CHRS",
            "eps_est":"-0.170",
            "revenue":"87643000.000",
            "updated":1628206345,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"0.810",
            "importance":2,
            "period_year":2021,
            "revenue_est":"89810000.000",
            "eps_surprise":"-0.1900",
            "revenue_type":"GAAP",
            "revenue_prior":"135674000.000",
            "date_confirmed":1,
            "revenue_surprise":"-2167000.0000",
            "eps_surprise_percent":"-1.1176",
            "revenue_surprise_percent":"-0.0241"
         },
         "prev_quarter_earnings":{
            "id":"5eb3b208885f2800019b3434",
            "eps":"0.010",
            "date":"2021-05-06",
            "name":"Coherus BioSciences",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"CHRS",
            "eps_est":"0.060",
            "revenue":"83034000.000",
            "updated":1620335628,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"0.480",
            "importance":2,
            "period_year":2021,
            "revenue_est":"96000000.000",
            "eps_surprise":"-0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"116180000.000",
            "date_confirmed":1,
            "revenue_surprise":"-12966000.0000",
            "eps_surprise_percent":"-0.8333",
            "revenue_surprise_percent":"-0.1351"
         },
         "cash_equivalents_and_short_term_investments":454421000,
         "operating_cash_flow":-188000,
         "monthly_cash_burn":-62666,
         "est_live_cash":454310290,
         "est_months_cash":7249.7094118022533,
         "total_liabilities":583322000,
         "net_cash":-129011710,
         "enterpriseValue":1110723280,
         "total_debt_to_equity":2.6800000000000002,
         "float":54173405,
         "insiderholdingspct":1.3999999999999999
      },
      "updated_at_formatted":"18/08/2021"
   },
   {
      "id":6702,
      "name":"Nefecon (NefIgArd)",
      "craft_entry_id":49760,
      "indication":"IgA nephropathy",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-15",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/fda-grants-priority-review-for-nefecon-for-patients-with-iga-nephropathy-301278761.html",
      "catalyst_date_text":"",
      "note":"PDUFA date under priority review September 15, 2021.",
      "estimated_primary_completion_date":"February 2023",
      "updated_at":"2021-04-28 04:26:25",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":768,
         "ticker":"CALT",
         "name":"Calliditas Therapeutics AB",
         "exchange":null,
         "price":21.030000000000001,
         "change":-0.88,
         "percent_change":-4.0199999999999996,
         "number_of_shares":26170792,
         "market_cap":550371756,
         "short_ratio":null,
         "volume":59207,
         "average_daily_volume":20895,
         "relative_volume":2.8300000000000001,
         "price_to_book":4.4100000000000001,
         "open":21.34,
         "previous_close":21.91,
         "created_at":"2020-06-05T07:08:26.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "IgA nephropathy"
      ],
      "cashflow":{
         "id":633,
         "ticker":"CALT",
         "earnings":{
            "id":"5f34e5071ef0a0000183c26a",
            "eps":"-0.760",
            "date":"2021-08-19",
            "name":"Calliditas Therapeutics",
            "time":"01:00:00",
            "notes":"fxc",
            "period":"Q2",
            "ticker":"CALT",
            "eps_est":"-0.480",
            "revenue":"0.000",
            "updated":1629381996,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.150",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.2800",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.5833",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ee351dd57aa61000188d681",
            "eps":"-0.300",
            "date":"2021-05-18",
            "name":"Calliditas Therapeutics",
            "time":"01:00:00",
            "notes":"fxc",
            "period":"Q1",
            "ticker":"CALT",
            "eps_est":"-0.430",
            "revenue":"0.000",
            "updated":1621340358,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"10000.000",
            "eps_surprise":"0.1300",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"-10000.0000",
            "eps_surprise_percent":"0.3023",
            "revenue_surprise_percent":"-1.0000"
         },
         "cash_equivalents_and_short_term_investments":867346000,
         "operating_cash_flow":-134179000,
         "monthly_cash_burn":-44726333,
         "est_live_cash":689659601,
         "est_months_cash":15.419542688643846,
         "total_liabilities":254551000,
         "net_cash":435108601,
         "enterpriseValue":466094428,
         "total_debt_to_equity":"",
         "float":26170792,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"28/04/2021"
   },
   {
      "id":3677,
      "name":"Fexapotide Triflutate (NX-1207)",
      "craft_entry_id":2384,
      "indication":"BPH",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-15",
      "fda_calendar":0,
      "press_link":"https://www.globenewswire.com/news-release/2021/05/06/2224875/10918/en/Nymox-Announces-Date-for-Fexapotide-Filing.html#:~:text=HASBROUCK%20HEIGHTS%2C%20N.J.%2C%20May%2006,or%20before%2015%20September%202021.",
      "catalyst_date_text":"",
      "note":"NDA filing planned by September 15, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-06-17 18:06:10",
      "stage":{
         "id":10,
         "label":"NDA Filing",
         "value":"ndaFiling"
      },
      "companies":{
         "id":219,
         "ticker":"NYMX",
         "name":"Nymox Pharmaceutical Corporation",
         "exchange":null,
         "price":1.9399999999999999,
         "change":0.14999999999999999,
         "percent_change":8.3800000000000008,
         "number_of_shares":83731000,
         "market_cap":162438140,
         "short_ratio":null,
         "volume":240918,
         "average_daily_volume":399141,
         "relative_volume":0.59999999999999998,
         "price_to_book":32.329999999999998,
         "open":1.76,
         "previous_close":1.79,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Prostate cancer"
      ],
      "cashflow":{
         "id":178,
         "ticker":"NYMX",
         "earnings":{
            "id":"5fbf52a495505d0001cd1ed0",
            "eps":"-0.050",
            "date":"2021-08-13",
            "name":"Nymox Pharmaceutical",
            "time":"13:32:00",
            "notes":"",
            "period":"Q2",
            "ticker":"NYMX",
            "eps_est":"",
            "revenue":"0.000",
            "updated":1628889081,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.040",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ee08539ff6db400010562e0",
            "eps":"-0.030",
            "date":"2021-05-14",
            "name":"Nymox Pharmaceutical",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"NYMX",
            "eps_est":"",
            "revenue":"0.000",
            "updated":1621951432,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.040",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"5350.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":6201000,
         "operating_cash_flow":-1902000,
         "monthly_cash_burn":-634000,
         "est_live_cash":5080933,
         "est_months_cash":8.0140899053627752,
         "total_liabilities":1963000,
         "net_cash":3117933,
         "enterpriseValue":156553140,
         "total_debt_to_equity":0.070000000000000007,
         "float":48376644,
         "insiderholdingspct":34.399999999999999
      },
      "updated_at_formatted":"17/06/2021"
   },
   {
      "id":5134,
      "name":"GRANITE-001 (GO-004)",
      "craft_entry_id":19537,
      "indication":"Colorectal Cancer / Gastric Cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-reports-first-quarter-2021-financial-results-and",
      "catalyst_date_text":"",
      "note":"Phase 1 and 2 data to be presented at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"July 2022",
      "updated_at":"2021-08-13 08:07:18",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":592,
         "ticker":"GRTS",
         "name":"Gritstone bio Inc.",
         "exchange":null,
         "price":7.5300000000000002,
         "change":0.11,
         "percent_change":1.48,
         "number_of_shares":49447693,
         "market_cap":372341128,
         "short_ratio":null,
         "volume":770589,
         "average_daily_volume":653651,
         "relative_volume":1.1799999999999999,
         "price_to_book":2.0800000000000001,
         "open":7.5700000000000003,
         "previous_close":7.4199999999999999,
         "created_at":"2018-10-02T03:31:09.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Gastric cancer",
         "Colorectal cancer"
      ],
      "cashflow":{
         "id":467,
         "ticker":"GRTS",
         "earnings":{
            "id":"5f2bb7ca713ee300019dfed9",
            "eps":"-0.330",
            "date":"2021-08-05",
            "name":"Gritstone Oncology",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"GRTS",
            "eps_est":"-0.580",
            "revenue":"2843000.000",
            "updated":1628208653,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.690",
            "importance":0,
            "period_year":2021,
            "revenue_est":"2240000.000",
            "eps_surprise":"0.2500",
            "revenue_type":"GAAP",
            "revenue_prior":"488000.000",
            "date_confirmed":1,
            "revenue_surprise":"603000.0000",
            "eps_surprise_percent":"0.4310",
            "revenue_surprise_percent":"0.2692"
         },
         "prev_quarter_earnings":{
            "id":"5eb503a2f857860001768c7c",
            "eps":"0.100",
            "date":"2021-05-06",
            "name":"Gritstone Bio",
            "time":"09:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"GRTS",
            "eps_est":"-0.580",
            "revenue":"39693000.000",
            "updated":1620370199,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.710",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.6800",
            "revenue_type":"GAAP",
            "revenue_prior":"1262000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"1.1724",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":171182000,
         "operating_cash_flow":-22682000,
         "monthly_cash_burn":-7560666,
         "est_live_cash":157824823,
         "est_months_cash":20.874460398065462,
         "total_liabilities":45399000,
         "net_cash":112425823,
         "enterpriseValue":223506128,
         "total_debt_to_equity":0.12,
         "float":40257957,
         "insiderholdingspct":1.5
      },
      "updated_at_formatted":"13/08/2021"
   },
   {
      "id":6158,
      "name":"MARGENZA (margetuximab) and MGA012 (MAHOGANY)",
      "craft_entry_id":33434,
      "indication":"Gastric cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-5",
      "catalyst_date_text":"",
      "note":"Phase 2/3 safety and efficacy data due at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"May 2024",
      "updated_at":"2021-07-29 16:54:04",
      "stage":{
         "id":8,
         "label":"Phase 2/3",
         "value":"phase23"
      },
      "companies":{
         "id":197,
         "ticker":"MGNX",
         "name":"MacroGenics Inc.",
         "exchange":null,
         "price":21.98,
         "change":0.29999999999999999,
         "percent_change":1.3799999999999999,
         "number_of_shares":61107288,
         "market_cap":1343138190,
         "short_ratio":null,
         "volume":468799,
         "average_daily_volume":644591,
         "relative_volume":0.72999999999999998,
         "price_to_book":4.21,
         "open":21.510000000000002,
         "previous_close":21.68,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Gastric cancer"
      ],
      "cashflow":{
         "id":160,
         "ticker":"MGNX",
         "earnings":{
            "id":"5f2270dc44c96f00014e7787",
            "eps":"-0.660",
            "date":"2021-07-29",
            "name":"Macrogenics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"MGNX",
            "eps_est":"-0.460",
            "revenue":"30757000.000",
            "updated":1627590316,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.940",
            "importance":0,
            "period_year":2021,
            "revenue_est":"30030000.000",
            "eps_surprise":"-0.2000",
            "revenue_type":"GAAP",
            "revenue_prior":"20257000.000",
            "date_confirmed":1,
            "revenue_surprise":"727000.0000",
            "eps_surprise_percent":"-0.4348",
            "revenue_surprise_percent":"0.0242"
         },
         "prev_quarter_earnings":{
            "id":"5eb10f3613dffb0001540c81",
            "eps":"-0.900",
            "date":"2021-04-29",
            "name":"Macrogenics",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"MGNX",
            "eps_est":"-0.610",
            "revenue":"16881000.000",
            "updated":1619729300,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.910",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.2900",
            "revenue_type":"GAAP",
            "revenue_prior":"13682000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.4754",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":297316000,
         "operating_cash_flow":-45690000,
         "monthly_cash_burn":-15230000,
         "est_live_cash":270409666,
         "est_months_cash":17.75506671043992,
         "total_liabilities":106866000,
         "net_cash":163543666,
         "enterpriseValue":1073397190,
         "total_debt_to_equity":0.089999999999999997,
         "float":59522546,
         "insiderholdingspct":2.3999999999999999
      },
      "updated_at_formatted":"29/07/2021"
   },
   {
      "id":7724,
      "name":"Toripalimab (JUPITER-06)",
      "craft_entry_id":105512,
      "indication":"Esophageal Squamous Cell Carcinoma",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://investors.coherus.com/news-releases/news-release-details/coherus-biosciences-reports-second-quarter-2021-financial",
      "catalyst_date_text":"",
      "note":"Phase 3 trial met primary endpoints of Progression Free Survival and Overall Survival - April 23, 2021. Data to be presented at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"January 31, 2021",
      "updated_at":"2021-08-05 20:26:11",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":89,
         "ticker":"CHRS",
         "name":"Coherus BioSciences Inc.",
         "exchange":null,
         "price":15,
         "change":0.46999999999999997,
         "percent_change":3.23,
         "number_of_shares":76480152,
         "market_cap":1147202280,
         "short_ratio":null,
         "volume":810240,
         "average_daily_volume":627775,
         "relative_volume":1.29,
         "price_to_book":7.3499999999999996,
         "open":14.23,
         "previous_close":14.529999999999999,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Esophageal cancer"
      ],
      "cashflow":{
         "id":73,
         "ticker":"CHRS",
         "earnings":{
            "id":"5f2cfc0ba3eee500019e8e7f",
            "eps":"-0.360",
            "date":"2021-08-05",
            "name":"Coherus BioSciences",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CHRS",
            "eps_est":"-0.170",
            "revenue":"87643000.000",
            "updated":1628206345,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"0.810",
            "importance":2,
            "period_year":2021,
            "revenue_est":"89810000.000",
            "eps_surprise":"-0.1900",
            "revenue_type":"GAAP",
            "revenue_prior":"135674000.000",
            "date_confirmed":1,
            "revenue_surprise":"-2167000.0000",
            "eps_surprise_percent":"-1.1176",
            "revenue_surprise_percent":"-0.0241"
         },
         "prev_quarter_earnings":{
            "id":"5eb3b208885f2800019b3434",
            "eps":"0.010",
            "date":"2021-05-06",
            "name":"Coherus BioSciences",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"CHRS",
            "eps_est":"0.060",
            "revenue":"83034000.000",
            "updated":1620335628,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"0.480",
            "importance":2,
            "period_year":2021,
            "revenue_est":"96000000.000",
            "eps_surprise":"-0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"116180000.000",
            "date_confirmed":1,
            "revenue_surprise":"-12966000.0000",
            "eps_surprise_percent":"-0.8333",
            "revenue_surprise_percent":"-0.1351"
         },
         "cash_equivalents_and_short_term_investments":454421000,
         "operating_cash_flow":-188000,
         "monthly_cash_burn":-62666,
         "est_live_cash":454310290,
         "est_months_cash":7249.7094118022533,
         "total_liabilities":583322000,
         "net_cash":-129011710,
         "enterpriseValue":1110723280,
         "total_debt_to_equity":2.6800000000000002,
         "float":54173405,
         "insiderholdingspct":1.3999999999999999
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":5166,
      "name":"Rebastinib and paclitaxel",
      "craft_entry_id":20248,
      "indication":"Solid tumors",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210803005981/en/",
      "catalyst_date_text":"",
      "note":"Phase 1b/2 updated data in the endometrial cancer cohort due at ASCO June 4-8, 2021 noted Progression Free Survival of 6.2 months. Platinum-resistant ovarian cancer cohort data due at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"October 1, 2022",
      "updated_at":"2021-08-03 16:25:51",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":472,
         "ticker":"DCPH",
         "name":"Deciphera Pharmaceuticals Inc.",
         "exchange":null,
         "price":26.629999999999999,
         "change":0.17000000000000001,
         "percent_change":0.64000000000000001,
         "number_of_shares":58041410,
         "market_cap":1545642748,
         "short_ratio":null,
         "volume":692148,
         "average_daily_volume":346973,
         "relative_volume":1.99,
         "price_to_book":3.46,
         "open":26.199999999999999,
         "previous_close":26.460000000000001,
         "created_at":"2018-01-24T06:32:57.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology"
      ],
      "cashflow":{
         "id":381,
         "ticker":"DCPH",
         "earnings":{
            "id":"5f2908282902dd0001f85594",
            "eps":"-1.210",
            "date":"2021-08-03",
            "name":"Deciphera Pharmaceuticals",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"DCPH",
            "eps_est":"-1.150",
            "revenue":"23573000.000",
            "updated":1628021891,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.200",
            "importance":0,
            "period_year":2021,
            "revenue_est":"22000000.000",
            "eps_surprise":"-0.0600",
            "revenue_type":"GAAP",
            "revenue_prior":"7090000.000",
            "date_confirmed":1,
            "revenue_surprise":"1573000.0000",
            "eps_surprise_percent":"-0.0522",
            "revenue_surprise_percent":"0.0715"
         },
         "prev_quarter_earnings":{
            "id":"5eb10f1413dffb0001540bb5",
            "eps":"-1.060",
            "date":"2021-05-04",
            "name":"Deciphera Pharmaceuticals",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"DCPH",
            "eps_est":"-1.070",
            "revenue":"25156000.000",
            "updated":1620161018,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.360",
            "importance":0,
            "period_year":2021,
            "revenue_est":"22410000.000",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"62000.000",
            "date_confirmed":1,
            "revenue_surprise":"2746000.0000",
            "eps_surprise_percent":"0.0093",
            "revenue_surprise_percent":"0.1225"
         },
         "cash_equivalents_and_short_term_investments":395352000,
         "operating_cash_flow":-51967000,
         "monthly_cash_burn":-17322333,
         "est_live_cash":364749211,
         "est_months_cash":21.056586950499103,
         "total_liabilities":93910000,
         "net_cash":270839211,
         "enterpriseValue":1180750748,
         "total_debt_to_equity":0.070000000000000007,
         "float":41090493,
         "insiderholdingspct":0.29999999999999999
      },
      "updated_at_formatted":"03/08/2021"
   },
   {
      "id":6710,
      "name":"AL101 (ACCURACY)",
      "craft_entry_id":50288,
      "indication":"Adenoid cystic carcinoma",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://ir.ayalapharma.com/news-releases/news-release-details/ayala-pharmaceuticals-reports-second-quarter-2021-financial",
      "catalyst_date_text":"",
      "note":"Phase 2 update at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"October 2021",
      "updated_at":"2021-08-13 08:13:11",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":771,
         "ticker":"AYLA",
         "name":"Ayala Pharmaceuticals Inc.",
         "exchange":null,
         "price":12.460000000000001,
         "change":0.54000000000000004,
         "percent_change":4.5300000000000002,
         "number_of_shares":13242834,
         "market_cap":165005712,
         "short_ratio":null,
         "volume":85633,
         "average_daily_volume":33420,
         "relative_volume":2.5600000000000001,
         "price_to_book":3.8599999999999999,
         "open":12.66,
         "previous_close":11.92,
         "created_at":"2020-06-08T22:38:14.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Adenoid cystic carcinoma"
      ],
      "cashflow":{
         "id":635,
         "ticker":"AYLA",
         "earnings":{
            "id":"5f3b7c806d76a20001793a5d",
            "eps":"-0.750",
            "date":"2021-08-13",
            "name":"Ayala Pharmaceuticals",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"AYLA",
            "eps_est":"-0.630",
            "revenue":"761000.000",
            "updated":1628858733,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.740",
            "importance":0,
            "period_year":2021,
            "revenue_est":"1020000.000",
            "eps_surprise":"-0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"1045000.000",
            "date_confirmed":1,
            "revenue_surprise":"-259000.0000",
            "eps_surprise_percent":"-0.1905",
            "revenue_surprise_percent":"-0.2539"
         },
         "prev_quarter_earnings":{
            "id":"5ebe4acc4a1e1000013214ff",
            "eps":"-0.740",
            "date":"2021-05-14",
            "name":"Ayala Pharmaceuticals",
            "time":"08:15:00",
            "notes":"",
            "period":"Q1",
            "ticker":"AYLA",
            "eps_est":"-0.720",
            "revenue":"974000.000",
            "updated":1621237406,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.320",
            "importance":0,
            "period_year":2021,
            "revenue_est":"1350000.000",
            "eps_surprise":"-0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"1001000.000",
            "date_confirmed":1,
            "revenue_surprise":"-376000.0000",
            "eps_surprise_percent":"-0.0278",
            "revenue_surprise_percent":"-0.2785"
         },
         "cash_equivalents_and_short_term_investments":44412000,
         "operating_cash_flow":-11548000,
         "monthly_cash_burn":-3849333,
         "est_live_cash":37611511,
         "est_months_cash":9.7709164159089372,
         "total_liabilities":5712000,
         "net_cash":31899511,
         "enterpriseValue":121095711,
         "total_debt_to_equity":0.01,
         "float":4598420,
         "insiderholdingspct":1.3
      },
      "updated_at_formatted":"13/08/2021"
   },
   {
      "id":7259,
      "name":"FS120",
      "craft_entry_id":76594,
      "indication":"Advanced Cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://investors.f-star.com/news-releases/news-release-details/f-star-therapeutics-reports-second-quarter-2021-financial",
      "catalyst_date_text":"",
      "note":"Phase 1 trial in progress update at ESMO September 16-21, 2021",
      "estimated_primary_completion_date":"November 2023",
      "updated_at":"2021-08-12 09:28:39",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":855,
         "ticker":"FSTX",
         "name":"F-star Therapeutics Inc.",
         "exchange":null,
         "price":5.9399999999999995,
         "change":0.52000000000000002,
         "percent_change":9.5899999999999999,
         "number_of_shares":20620021,
         "market_cap":122482925,
         "short_ratio":null,
         "volume":166256,
         "average_daily_volume":158696,
         "relative_volume":1.05,
         "price_to_book":1.24,
         "open":5.4000000000000004,
         "previous_close":5.4199999999999999,
         "created_at":"2020-11-26T00:08:03.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology"
      ],
      "cashflow":{
         "id":718,
         "ticker":"FSTX",
         "earnings":{
            "id":"5fc61711bb3cbc00019ee0b3",
            "eps":"-0.920",
            "date":"2021-08-12",
            "name":"F-star Therapeutics",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"FSTX",
            "eps_est":"-0.740",
            "revenue":"0.000",
            "updated":1628770509,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"750000.000",
            "eps_surprise":"-0.1800",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"-750000.0000",
            "eps_surprise_percent":"-0.2432",
            "revenue_surprise_percent":"-1.0000"
         },
         "prev_quarter_earnings":{
            "id":"5fc61712bb3cbc00019ee0b5",
            "eps":"-1.080",
            "date":"2021-05-17",
            "name":"F-star Therapeutics",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"FSTX",
            "eps_est":"-1.160",
            "revenue":"2917000.000",
            "updated":1621253462,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"1200000.000",
            "eps_surprise":"0.0800",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"1717000.0000",
            "eps_surprise_percent":"0.0690",
            "revenue_surprise_percent":"1.4308"
         },
         "cash_equivalents_and_short_term_investments":81648000,
         "operating_cash_flow":-8955000,
         "monthly_cash_burn":-2985000,
         "est_live_cash":88374500,
         "est_months_cash":29.606197654941372,
         "total_liabilities":25981000,
         "net_cash":62393500,
         "enterpriseValue":54409924,
         "total_debt_to_equity":0.14000000000000001,
         "float":20549167,
         "insiderholdingspct":3.2000000000000002
      },
      "updated_at_formatted":"12/08/2021"
   },
   {
      "id":7266,
      "name":"SBT6050",
      "craft_entry_id":76819,
      "indication":"HER2 Positive Solid Tumors",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210812005212/en/",
      "catalyst_date_text":"",
      "note":"Phase 1 presentation at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"August 2023",
      "updated_at":"2021-08-12 17:43:44",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":861,
         "ticker":"SBTX",
         "name":"Silverback Therapeutics Inc.",
         "exchange":null,
         "price":27.710000000000001,
         "change":-1.1200000000000001,
         "percent_change":-3.8799999999999999,
         "number_of_shares":35036477,
         "market_cap":970860778,
         "short_ratio":null,
         "volume":165850,
         "average_daily_volume":121360,
         "relative_volume":1.3700000000000001,
         "price_to_book":2.7800000000000002,
         "open":28.600000000000001,
         "previous_close":28.829999999999998,
         "created_at":"2020-12-04T19:35:25.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology"
      ],
      "cashflow":{
         "id":724,
         "ticker":"SBTX",
         "earnings":{
            "id":"5fcde585accf7400015819e1",
            "eps":"-0.700",
            "date":"2021-08-12",
            "name":"Silverback Therapeutics",
            "time":"03:19:17",
            "notes":"",
            "period":"Q2",
            "ticker":"SBTX",
            "eps_est":"-0.530",
            "revenue":"0.000",
            "updated":1628811336,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-9.650",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.1700",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.3208",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5fcde586accf7400015819e3",
            "eps":"-0.540",
            "date":"2021-05-13",
            "name":"Silverback Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"SBTX",
            "eps_est":"-0.390",
            "revenue":"0.000",
            "updated":1620984090,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-7.890",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.1500",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.3846",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":359689000,
         "operating_cash_flow":-14135000,
         "monthly_cash_burn":-4711666,
         "est_live_cash":351365056,
         "est_months_cash":74.573421800271916,
         "total_liabilities":17326000,
         "net_cash":334039056,
         "enterpriseValue":613907777,
         "total_debt_to_equity":0.01,
         "float":17656237,
         "insiderholdingspct":0.80000000000000004
      },
      "updated_at_formatted":"12/08/2021"
   },
   {
      "id":7779,
      "name":"TAZVERIK (Tazemetostat) and XTANDI (Enzalutamide) - EZH-1101",
      "craft_entry_id":108167,
      "indication":"Prostate Cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210809005168/en/",
      "catalyst_date_text":"",
      "note":"Phase 2 part of trial has been initiated. Phase 1b update due at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"March 1, 2022",
      "updated_at":"2021-08-09 07:39:31",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":132,
         "ticker":"EPZM",
         "name":"Epizyme Inc.",
         "exchange":null,
         "price":4.8600000000000003,
         "change":0.040000000000000001,
         "percent_change":0.82999999999999996,
         "number_of_shares":102249517,
         "market_cap":496932653,
         "short_ratio":null,
         "volume":837173,
         "average_daily_volume":1185428,
         "relative_volume":0.70999999999999996,
         "price_to_book":15.68,
         "open":4.8399999999999999,
         "previous_close":4.8200000000000003,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Prostate cancer"
      ],
      "cashflow":{
         "id":106,
         "ticker":"EPZM",
         "earnings":{
            "id":"5f2908432902dd0001f855b6",
            "eps":"-0.630",
            "date":"2021-08-09",
            "name":"Epizyme",
            "time":"06:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"EPZM",
            "eps_est":"-0.620",
            "revenue":"13010000.000",
            "updated":1628509232,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.580",
            "importance":0,
            "period_year":2021,
            "revenue_est":"8720000.000",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"2467000.000",
            "date_confirmed":1,
            "revenue_surprise":"4290000.0000",
            "eps_surprise_percent":"-0.0161",
            "revenue_surprise_percent":"0.4920"
         },
         "prev_quarter_earnings":{
            "id":"5eafc39439af700001db269e",
            "eps":"-0.690",
            "date":"2021-05-06",
            "name":"Epizyme",
            "time":"06:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"EPZM",
            "eps_est":"-0.580",
            "revenue":"7631000.000",
            "updated":1620304065,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.510",
            "importance":0,
            "period_year":2021,
            "revenue_est":"6560000.000",
            "eps_surprise":"-0.1100",
            "revenue_type":"GAAP",
            "revenue_prior":"1354000.000",
            "date_confirmed":1,
            "revenue_surprise":"1071000.0000",
            "eps_surprise_percent":"-0.1897",
            "revenue_surprise_percent":"0.1633"
         },
         "cash_equivalents_and_short_term_investments":244006000,
         "operating_cash_flow":-56671000,
         "monthly_cash_burn":-18890333,
         "est_live_cash":235633078,
         "est_months_cash":12.473738710693983,
         "total_liabilities":284920000,
         "net_cash":-49286922,
         "enterpriseValue":522866652,
         "total_debt_to_equity":7.4199999999999999,
         "float":64859831,
         "insiderholdingspct":1.1000000000000001
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":7020,
      "name":"DKN-01 and Tislelizumab ( DisTinGuish)",
      "craft_entry_id":66549,
      "indication":"Gastric / Gastroesophageal Junction Cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-the-esmo-2021-virtual-congress-301340715.html",
      "catalyst_date_text":"",
      "note":"Phase 2a initial data to be presented at ESMO September 16, 2021.",
      "estimated_primary_completion_date":"December 2021",
      "updated_at":"2021-07-26 07:10:28",
      "stage":{
         "id":5,
         "label":"Phase 2a",
         "value":"phase2a"
      },
      "companies":{
         "id":340,
         "ticker":"BGNE",
         "name":"BeiGene Ltd.",
         "exchange":null,
         "price":249.59999999999999,
         "change":-25.84,
         "percent_change":-9.3800000000000008,
         "number_of_shares":93159001,
         "market_cap":23252486650,
         "short_ratio":null,
         "volume":1445694,
         "average_daily_volume":315067,
         "relative_volume":4.5899999999999999,
         "price_to_book":6.4500000000000002,
         "open":274.30000000000001,
         "previous_close":275.44,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Gastric cancer"
      ],
      "cashflow":{
         "id":270,
         "ticker":"BGNE",
         "earnings":{
            "id":"5f2cfc06a3eee500019e8e6b",
            "eps":"-5.230",
            "date":"2021-08-05",
            "name":"BeiGene",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"BGNE",
            "eps_est":"-4.140",
            "revenue":"149992000.000",
            "updated":1628208251,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-4.310",
            "importance":1,
            "period_year":2021,
            "revenue_est":"215430000.000",
            "eps_surprise":"-1.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"65635000.000",
            "date_confirmed":1,
            "revenue_surprise":"-65438000.0000",
            "eps_surprise_percent":"-0.2633",
            "revenue_surprise_percent":"-0.3038"
         },
         "prev_quarter_earnings":{
            "id":"5eba4981a2467b00013633ef",
            "eps":"0.690",
            "date":"2021-05-06",
            "name":"BeiGene",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"BGNE",
            "eps_est":"-4.810",
            "revenue":"605872000.000",
            "updated":1620367871,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-4.700",
            "importance":1,
            "period_year":2021,
            "revenue_est":"91820000.000",
            "eps_surprise":"5.5000",
            "revenue_type":"GAAP",
            "revenue_prior":"52059000.000",
            "date_confirmed":1,
            "revenue_surprise":"514052000.0000",
            "eps_surprise_percent":"1.1435",
            "revenue_surprise_percent":"5.5985"
         },
         "cash_equivalents_and_short_term_investments":4381900000,
         "operating_cash_flow":-420266000,
         "monthly_cash_burn":-140088666,
         "est_live_cash":4134410023,
         "est_months_cash":29.512808859212065,
         "total_liabilities":1917341000,
         "net_cash":2217069023,
         "enterpriseValue":21094720121,
         "total_debt_to_equity":0.19,
         "float":89530472,
         "insiderholdingspct":0.29999999999999999
      },
      "updated_at_formatted":"26/07/2021"
   },
   {
      "id":7020,
      "name":"DKN-01 and Tislelizumab ( DisTinGuish)",
      "craft_entry_id":66549,
      "indication":"Gastric / Gastroesophageal Junction Cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-the-esmo-2021-virtual-congress-301340715.html",
      "catalyst_date_text":"",
      "note":"Phase 2a initial data to be presented at ESMO September 16, 2021.",
      "estimated_primary_completion_date":"December 2021",
      "updated_at":"2021-07-26 07:10:28",
      "stage":{
         "id":5,
         "label":"Phase 2a",
         "value":"phase2a"
      },
      "companies":{
         "id":398,
         "ticker":"LPTX",
         "name":"Leap Therapeutics Inc.",
         "exchange":null,
         "price":1.6800000000000002,
         "change":-0.020000000000000018,
         "percent_change":-1.1800000000000002,
         "number_of_shares":59672014,
         "market_cap":100248984,
         "short_ratio":null,
         "volume":592545,
         "average_daily_volume":375915,
         "relative_volume":1.5800000000000001,
         "price_to_book":3.3599999999999999,
         "open":1.72,
         "previous_close":1.7,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Gastric cancer"
      ],
      "cashflow":{
         "id":322,
         "ticker":"LPTX",
         "earnings":{
            "id":"5f3636ac63170b0001c878ad",
            "eps":"-0.120",
            "date":"2021-08-13",
            "name":"Leap Therapeutics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"LPTX",
            "eps_est":"-0.120",
            "revenue":"375000.000",
            "updated":1628858551,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.120",
            "importance":0,
            "period_year":2021,
            "revenue_est":"280000.000",
            "eps_surprise":"0.0000",
            "revenue_type":"GAAP",
            "revenue_prior":"375000.000",
            "date_confirmed":1,
            "revenue_surprise":"95000.0000",
            "eps_surprise_percent":"0.0000",
            "revenue_surprise_percent":"0.3393"
         },
         "prev_quarter_earnings":{
            "id":"5ebe3e2854da7600011d02bf",
            "eps":"-0.120",
            "date":"2021-05-14",
            "name":"Leap Therapeutics",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"LPTX",
            "eps_est":"-0.120",
            "revenue":"375000.000",
            "updated":1621237239,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.550",
            "importance":0,
            "period_year":2021,
            "revenue_est":"190000",
            "eps_surprise":"0.0000",
            "revenue_type":"GAAP",
            "revenue_prior":"375000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0000",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":35734000,
         "operating_cash_flow":-7752000,
         "monthly_cash_burn":-2584000,
         "est_live_cash":31168933,
         "est_months_cash":12.062280572755418,
         "total_liabilities":8056000,
         "net_cash":23112933,
         "enterpriseValue":64868983,
         "total_debt_to_equity":0.01,
         "float":34644794,
         "insiderholdingspct":0
      },
      "updated_at_formatted":"26/07/2021"
   },
   {
      "id":5748,
      "name":"ADP-A2M4CD8 (SURPASS)",
      "craft_entry_id":26681,
      "indication":"Solid tumors",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://www.adaptimmune.com/investors-and-media/news-events/press-releases/detail/188/adaptimmune-reports-fourth-quarter-full-year-2020",
      "catalyst_date_text":"",
      "note":"Phase 1 update due at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"April 30, 2022",
      "updated_at":"2021-08-13 08:07:35",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":12,
         "ticker":"ADAP",
         "name":"Adaptimmune Therapeutics plc",
         "exchange":null,
         "price":3.7999999999999998,
         "change":0.040000000000000001,
         "percent_change":1.0600000000000001,
         "number_of_shares":156088449,
         "market_cap":593136106,
         "short_ratio":null,
         "volume":376423,
         "average_daily_volume":731820,
         "relative_volume":0.51000000000000001,
         "price_to_book":2.1299999999999999,
         "open":3.75,
         "previous_close":3.7599999999999998,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology"
      ],
      "cashflow":{
         "id":10,
         "ticker":"ADAP",
         "earnings":{
            "id":"5f2baa93713ee300019dfd13",
            "eps":"-0.040",
            "date":"2021-08-09",
            "name":"Adaptimmune Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ADAP",
            "eps_est":"-0.240",
            "revenue":"3095000.000",
            "updated":1628590560,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.040",
            "importance":0,
            "period_year":2021,
            "revenue_est":"1360000.000",
            "eps_surprise":"0.2000",
            "revenue_type":"GAAP",
            "revenue_prior":"502000.000",
            "date_confirmed":1,
            "revenue_surprise":"1735000.0000",
            "eps_surprise_percent":"0.8333",
            "revenue_surprise_percent":"1.2757"
         },
         "prev_quarter_earnings":{
            "id":"5ebcec7c4b88bb0001fc2ebc",
            "eps":"-0.040",
            "date":"2021-05-06",
            "name":"Adaptimmune Therapeutics",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ADAP",
            "eps_est":"-0.250",
            "revenue":"434000.000",
            "updated":1620303526,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.040",
            "importance":0,
            "period_year":2021,
            "revenue_est":"1830000.000",
            "eps_surprise":"0.2100",
            "revenue_type":"GAAP",
            "revenue_prior":"761000.000",
            "date_confirmed":1,
            "revenue_surprise":"-1396000.0000",
            "eps_surprise_percent":"0.8400",
            "revenue_surprise_percent":"-0.7628"
         },
         "cash_equivalents_and_short_term_investments":285370000,
         "operating_cash_flow":-31459000,
         "monthly_cash_burn":-10486333,
         "est_live_cash":266844145,
         "est_months_cash":25.446850200160533,
         "total_liabilities":111854000,
         "net_cash":154990145,
         "enterpriseValue":330411106,
         "total_debt_to_equity":0.080000000000000002,
         "float":124957108,
         "insiderholdingspct":3.2999999999999998
      },
      "updated_at_formatted":"13/08/2021"
   },
   {
      "id":7541,
      "name":"MGC018",
      "craft_entry_id":92790,
      "indication":"Solid tumors",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-5",
      "catalyst_date_text":"",
      "note":"Phase 1 trial data due at ESMO Sept 16-21 2021. ",
      "estimated_primary_completion_date":"March 2022",
      "updated_at":"2021-07-29 16:53:11",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":197,
         "ticker":"MGNX",
         "name":"MacroGenics Inc.",
         "exchange":null,
         "price":21.98,
         "change":0.29999999999999999,
         "percent_change":1.3799999999999999,
         "number_of_shares":61107288,
         "market_cap":1343138190,
         "short_ratio":null,
         "volume":468799,
         "average_daily_volume":644591,
         "relative_volume":0.72999999999999998,
         "price_to_book":4.21,
         "open":21.510000000000002,
         "previous_close":21.68,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology"
      ],
      "cashflow":{
         "id":160,
         "ticker":"MGNX",
         "earnings":{
            "id":"5f2270dc44c96f00014e7787",
            "eps":"-0.660",
            "date":"2021-07-29",
            "name":"Macrogenics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"MGNX",
            "eps_est":"-0.460",
            "revenue":"30757000.000",
            "updated":1627590316,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.940",
            "importance":0,
            "period_year":2021,
            "revenue_est":"30030000.000",
            "eps_surprise":"-0.2000",
            "revenue_type":"GAAP",
            "revenue_prior":"20257000.000",
            "date_confirmed":1,
            "revenue_surprise":"727000.0000",
            "eps_surprise_percent":"-0.4348",
            "revenue_surprise_percent":"0.0242"
         },
         "prev_quarter_earnings":{
            "id":"5eb10f3613dffb0001540c81",
            "eps":"-0.900",
            "date":"2021-04-29",
            "name":"Macrogenics",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"MGNX",
            "eps_est":"-0.610",
            "revenue":"16881000.000",
            "updated":1619729300,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.910",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.2900",
            "revenue_type":"GAAP",
            "revenue_prior":"13682000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.4754",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":297316000,
         "operating_cash_flow":-45690000,
         "monthly_cash_burn":-15230000,
         "est_live_cash":270409666,
         "est_months_cash":17.75506671043992,
         "total_liabilities":106866000,
         "net_cash":163543666,
         "enterpriseValue":1073397190,
         "total_debt_to_equity":0.089999999999999997,
         "float":59522546,
         "insiderholdingspct":2.3999999999999999
      },
      "updated_at_formatted":"29/07/2021"
   },
   {
      "id":1918,
      "name":"Vimseltinib (DCC-3014)",
      "craft_entry_id":14052,
      "indication":"Tenosynovial Giant Cell tumor",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":1,
      "press_link":"https://www.businesswire.com/news/home/20210803005981/en/",
      "catalyst_date_text":"",
      "note":"Phase 1 updated data due at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"July 2022",
      "updated_at":"2021-08-03 16:25:07",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":472,
         "ticker":"DCPH",
         "name":"Deciphera Pharmaceuticals Inc.",
         "exchange":null,
         "price":26.629999999999999,
         "change":0.17000000000000001,
         "percent_change":0.64000000000000001,
         "number_of_shares":58041410,
         "market_cap":1545642748,
         "short_ratio":null,
         "volume":692148,
         "average_daily_volume":346973,
         "relative_volume":1.99,
         "price_to_book":3.46,
         "open":26.199999999999999,
         "previous_close":26.460000000000001,
         "created_at":"2018-01-24T06:32:57.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Solid tumors",
         "Oncology"
      ],
      "cashflow":{
         "id":381,
         "ticker":"DCPH",
         "earnings":{
            "id":"5f2908282902dd0001f85594",
            "eps":"-1.210",
            "date":"2021-08-03",
            "name":"Deciphera Pharmaceuticals",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"DCPH",
            "eps_est":"-1.150",
            "revenue":"23573000.000",
            "updated":1628021891,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.200",
            "importance":0,
            "period_year":2021,
            "revenue_est":"22000000.000",
            "eps_surprise":"-0.0600",
            "revenue_type":"GAAP",
            "revenue_prior":"7090000.000",
            "date_confirmed":1,
            "revenue_surprise":"1573000.0000",
            "eps_surprise_percent":"-0.0522",
            "revenue_surprise_percent":"0.0715"
         },
         "prev_quarter_earnings":{
            "id":"5eb10f1413dffb0001540bb5",
            "eps":"-1.060",
            "date":"2021-05-04",
            "name":"Deciphera Pharmaceuticals",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"DCPH",
            "eps_est":"-1.070",
            "revenue":"25156000.000",
            "updated":1620161018,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.360",
            "importance":0,
            "period_year":2021,
            "revenue_est":"22410000.000",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"62000.000",
            "date_confirmed":1,
            "revenue_surprise":"2746000.0000",
            "eps_surprise_percent":"0.0093",
            "revenue_surprise_percent":"0.1225"
         },
         "cash_equivalents_and_short_term_investments":395352000,
         "operating_cash_flow":-51967000,
         "monthly_cash_burn":-17322333,
         "est_live_cash":364749211,
         "est_months_cash":21.056586950499103,
         "total_liabilities":93910000,
         "net_cash":270839211,
         "enterpriseValue":1180750748,
         "total_debt_to_equity":0.070000000000000007,
         "float":41090493,
         "insiderholdingspct":0.29999999999999999
      },
      "updated_at_formatted":"03/08/2021"
   },
   {
      "id":5503,
      "name":"Gavo-cel (TC-210)",
      "craft_entry_id":23590,
      "indication":"Mesothelin-positive solid tumors",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-reports-second-quarter-2021-financial-results",
      "catalyst_date_text":"",
      "note":"Phase 1 new data to be presented at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"December 2021",
      "updated_at":"2021-08-05 06:57:22",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":635,
         "ticker":"TCRR",
         "name":"TCR2 Therapeutics Inc.",
         "exchange":null,
         "price":15.26,
         "change":0.87,
         "percent_change":6.0499999999999998,
         "number_of_shares":38182801,
         "market_cap":582669543,
         "short_ratio":null,
         "volume":298900,
         "average_daily_volume":343737,
         "relative_volume":0.87,
         "price_to_book":1.77,
         "open":14.43,
         "previous_close":14.390000000000001,
         "created_at":"2019-02-15T22:57:49.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology"
      ],
      "cashflow":{
         "id":507,
         "ticker":"TCRR",
         "earnings":{
            "id":"5f3b7cc66d76a20001793ad3",
            "eps":"-0.640",
            "date":"2021-08-05",
            "name":"TCR2 Therapeutics",
            "time":"06:45:00",
            "notes":"",
            "period":"Q2",
            "ticker":"TCRR",
            "eps_est":"-0.590",
            "revenue":"0.000",
            "updated":1628238247,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.670",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.0847",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ebe3e4754da7600011d0309",
            "eps":"-0.580",
            "date":"2021-05-13",
            "name":"TCR2 Therapeutics",
            "time":"06:45:00",
            "notes":"",
            "period":"Q1",
            "ticker":"TCRR",
            "eps_est":"",
            "revenue":"0.000",
            "updated":1621245919,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.650",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":317346000,
         "operating_cash_flow":-19044000,
         "monthly_cash_burn":-6348000,
         "est_live_cash":306131200,
         "est_months_cash":48.224826717076247,
         "total_liabilities":39249000,
         "net_cash":266882200,
         "enterpriseValue":292963543,
         "total_debt_to_equity":0.080000000000000002,
         "float":30268156,
         "insiderholdingspct":0.29999999999999999
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":7551,
      "name":"Oral paclitaxel and KEYTRUDA (pembrolizumab)",
      "craft_entry_id":93752,
      "indication":"Solid Tumors",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://ir.athenex.com/news-releases/news-release-details/athenex-provides-second-quarter-2021-corporate-and-financial",
      "catalyst_date_text":"",
      "note":"Phase 1 data to be presented September 16-21, 2021.",
      "estimated_primary_completion_date":"March 30, 2023",
      "updated_at":"2021-08-05 08:23:50",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":421,
         "ticker":"ATNX",
         "name":"Athenex Inc.",
         "exchange":null,
         "price":3.29,
         "change":0.11,
         "percent_change":3.46,
         "number_of_shares":109307740,
         "market_cap":359622465,
         "short_ratio":null,
         "volume":1183454,
         "average_daily_volume":1303788,
         "relative_volume":0.91000000000000003,
         "price_to_book":1.95,
         "open":3.1800000000000002,
         "previous_close":3.1800000000000002,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology"
      ],
      "cashflow":{
         "id":340,
         "ticker":"ATNX",
         "earnings":{
            "id":"5f2bad47713ee300019dfd69",
            "eps":"-0.330",
            "date":"2021-08-05",
            "name":"Athenex",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ATNX",
            "eps_est":"-0.370",
            "revenue":"21923000.000",
            "updated":1628172144,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.410",
            "importance":2,
            "period_year":2021,
            "revenue_est":"23440000.000",
            "eps_surprise":"0.0400",
            "revenue_type":"GAAP",
            "revenue_prior":"40172000.000",
            "date_confirmed":1,
            "revenue_surprise":"-1517000.0000",
            "eps_surprise_percent":"0.1081",
            "revenue_surprise_percent":"-0.0647"
         },
         "prev_quarter_earnings":{
            "id":"5eb3b1fe885f2800019b33d2",
            "eps":"-0.270",
            "date":"2021-05-06",
            "name":"Athenex",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ATNX",
            "eps_est":"-0.400",
            "revenue":"41025000.000",
            "updated":1620300508,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.240",
            "importance":2,
            "period_year":2021,
            "revenue_est":"24540000.000",
            "eps_surprise":"0.1300",
            "revenue_type":"GAAP",
            "revenue_prior":"46935000.000",
            "date_confirmed":1,
            "revenue_surprise":"16485000.0000",
            "eps_surprise_percent":"0.3250",
            "revenue_surprise_percent":"0.6718"
         },
         "cash_equivalents_and_short_term_investments":130224000,
         "operating_cash_flow":-39214000,
         "monthly_cash_burn":-13071333,
         "est_live_cash":107131311,
         "est_months_cash":8.1958979241061343,
         "total_liabilities":239077000,
         "net_cash":-131945689,
         "enterpriseValue":387830464,
         "total_debt_to_equity":0.85999999999999999,
         "float":77823836,
         "insiderholdingspct":6.0999999999999996
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":7559,
      "name":"NGM120, GEMZAR (gemcitabine) and ABRAXANE (nab-paclitaxel)",
      "craft_entry_id":94001,
      "indication":"Pancreatic Cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-provides-business-highlights-and-reports-second-0",
      "catalyst_date_text":"",
      "note":"Phase 1b data from dose-finding portion of trial due at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"January 2023",
      "updated_at":"2021-08-05 16:54:56",
      "stage":{
         "id":3,
         "label":"Phase 1b",
         "value":"phase1b"
      },
      "companies":{
         "id":650,
         "ticker":"NGM",
         "name":"NGM Biopharmaceuticals Inc.",
         "exchange":null,
         "price":21.690000000000001,
         "change":0.80000000000000004,
         "percent_change":3.8300000000000001,
         "number_of_shares":77338144,
         "market_cap":1677464343,
         "short_ratio":null,
         "volume":139507,
         "average_daily_volume":391759,
         "relative_volume":0.35999999999999999,
         "price_to_book":4.5,
         "open":20.800000000000001,
         "previous_close":20.890000000000001,
         "created_at":"2019-04-04T17:06:22.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Pancreatic cancer"
      ],
      "cashflow":{
         "id":521,
         "ticker":"NGM",
         "earnings":{
            "id":"5f34e5311ef0a0000183c342",
            "eps":"-0.480",
            "date":"2021-08-05",
            "name":"NGM Biopharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"NGM",
            "eps_est":"-0.370",
            "revenue":"16773000.000",
            "updated":1628210301,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.380",
            "importance":0,
            "period_year":2021,
            "revenue_est":"22860000.000",
            "eps_surprise":"-0.1100",
            "revenue_type":"GAAP",
            "revenue_prior":"19755000.000",
            "date_confirmed":1,
            "revenue_surprise":"-6087000.0000",
            "eps_surprise_percent":"-0.2973",
            "revenue_surprise_percent":"-0.2663"
         },
         "prev_quarter_earnings":{
            "id":"5ebcecb54b88bb0001fc2fa6",
            "eps":"-0.360",
            "date":"2021-05-06",
            "name":"NGM Biopharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"NGM",
            "eps_est":"-0.420",
            "revenue":"21575000.000",
            "updated":1620372036,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.280",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0600",
            "revenue_type":"GAAP",
            "revenue_prior":"24364000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.1429",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":390550000,
         "operating_cash_flow":-23310000,
         "monthly_cash_burn":-7770000,
         "est_live_cash":376823000,
         "est_months_cash":48.497168597168596,
         "total_liabilities":49936000,
         "net_cash":326887000,
         "enterpriseValue":1286914343,
         "total_debt_to_equity":"",
         "float":31576701,
         "insiderholdingspct":1.3
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":7575,
      "name":"GTB-3550",
      "craft_entry_id":95093,
      "indication":"Acute myeloid leukemia / myelodysplastic syndromes",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/gt-biopharma-provides-second-quarter-2021-business-update-301354858.html",
      "catalyst_date_text":"",
      "note":"Phase 1/2 interim data released March 29, 2021. Presentation at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"February 1, 2024",
      "updated_at":"2021-08-13 17:08:17",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":903,
         "ticker":"GTBP",
         "name":"GT Biopharma Inc.",
         "exchange":null,
         "price":7.5700000000000003,
         "change":-0.31999999999999995,
         "percent_change":-4.0600000000000005,
         "number_of_shares":21127718,
         "market_cap":159936825,
         "short_ratio":null,
         "volume":531864,
         "average_daily_volume":321024,
         "relative_volume":1.6600000000000001,
         "price_to_book":6.6399999999999997,
         "open":7.8399999999999999,
         "previous_close":7.8899999999999997,
         "created_at":"2021-03-06T22:35:38.000000Z",
         "updated_at":"2021-08-20T23:55:05.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Acute myeloid leukemia (AML) ",
         "Oncology",
         "Myelodysplastic syndromes (MDS)",
         "Leukemia"
      ],
      "cashflow":{
         "id":766,
         "ticker":"GTBP",
         "earnings":{
            "id":"607d654517ff280001060203",
            "eps":"",
            "date":"2021-08-13",
            "name":"GT Biopharma",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"GTBP",
            "eps_est":"-0.280",
            "revenue":"",
            "updated":1628446693,
            "currency":"USD",
            "eps_type":"",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"607d654617ff280001060207",
            "eps":"-3.400",
            "date":"2021-04-19",
            "name":"GT Biopharma",
            "time":"07:11:02",
            "notes":"",
            "period":"Q4",
            "ticker":"GTBP",
            "eps_est":"-0.240",
            "revenue":"0.000",
            "updated":1618905894,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2020,
            "revenue_est":"",
            "eps_surprise":"-3.1600",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-13.1667",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":27555000,
         "operating_cash_flow":-3684000,
         "monthly_cash_burn":-1228000,
         "est_live_cash":37660600,
         "est_months_cash":30.668241042345276,
         "total_liabilities":3626000,
         "net_cash":34034600,
         "enterpriseValue":183965457,
         "total_debt_to_equity":"",
         "float":14197981,
         "insiderholdingspct":4.2999999999999998
      },
      "updated_at_formatted":"13/08/2021"
   },
   {
      "id":2545,
      "name":"Zanidatamab (ZW25)",
      "craft_entry_id":5834,
      "indication":"HER2-positive Gastroesophageal Adenocarcinoma",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":1,
      "press_link":"https://www.businesswire.com/news/home/20210804006023/en/",
      "catalyst_date_text":"",
      "note":"Phase 2 data to be presented at ESMO September 16, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-04 16:30:54",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":430,
         "ticker":"ZYME",
         "name":"Zymeworks Inc.",
         "exchange":null,
         "price":31.420000000000002,
         "change":0.81999999999999995,
         "percent_change":2.6800000000000002,
         "number_of_shares":39309157,
         "market_cap":1457439605,
         "short_ratio":null,
         "volume":224752,
         "average_daily_volume":413900,
         "relative_volume":0.54000000000000004,
         "price_to_book":4.5300000000000002,
         "open":30.649999999999999,
         "previous_close":30.600000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Oncology",
         "Gastric cancer",
         "Esophageal cancer"
      ],
      "cashflow":{
         "id":348,
         "ticker":"ZYME",
         "earnings":{
            "id":"5f2bc9b5713ee300019e017d",
            "eps":"-1.310",
            "date":"2021-08-04",
            "name":"Zymeworks",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ZYME",
            "eps_est":"-1.050",
            "revenue":"1771000.000",
            "updated":1628153696,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NYSE",
            "eps_prior":"-0.770",
            "importance":0,
            "period_year":2021,
            "revenue_est":"6640000.000",
            "eps_surprise":"-0.2600",
            "revenue_type":"GAAP",
            "revenue_prior":"12359000.000",
            "date_confirmed":1,
            "revenue_surprise":"-4869000.0000",
            "eps_surprise_percent":"-0.2476",
            "revenue_surprise_percent":"-0.7333"
         },
         "prev_quarter_earnings":{
            "id":"5eb503e5f857860001768d6c",
            "eps":"-0.870",
            "date":"2021-05-05",
            "name":"Zymeworks",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ZYME",
            "eps_est":"-1.030",
            "revenue":"644000.000",
            "updated":1620284168,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NYSE",
            "eps_prior":"-0.640",
            "importance":0,
            "period_year":2021,
            "revenue_est":"644000.000",
            "eps_surprise":"0.1600",
            "revenue_type":"GAAP",
            "revenue_prior":"8269000.000",
            "date_confirmed":1,
            "revenue_surprise":"0.0000",
            "eps_surprise_percent":"0.1553",
            "revenue_surprise_percent":"0.0000"
         },
         "cash_equivalents_and_short_term_investments":359811000,
         "operating_cash_flow":-50352000,
         "monthly_cash_burn":-16784000,
         "est_live_cash":330159266,
         "est_months_cash":19.671071615824594,
         "total_liabilities":150482000,
         "net_cash":179677266,
         "enterpriseValue":1129471605,
         "total_debt_to_equity":0.10000000000000001,
         "float":37499663,
         "insiderholdingspct":1
      },
      "updated_at_formatted":"04/08/2021"
   },
   {
      "id":6140,
      "name":"SY-5609",
      "craft_entry_id":33132,
      "indication":"Solid tumors",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-16",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210805005216/en/",
      "catalyst_date_text":"",
      "note":"Phase 1 dose escalation data to be presented at ESMO September 16-21, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-05 07:23:22",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":332,
         "ticker":"SYRS",
         "name":"Syros Pharmaceuticals Inc.",
         "exchange":null,
         "price":4.2300000000000004,
         "change":0.14999999999999999,
         "percent_change":3.6800000000000002,
         "number_of_shares":61930800,
         "market_cap":261967284,
         "short_ratio":null,
         "volume":572123,
         "average_daily_volume":802373,
         "relative_volume":0.70999999999999996,
         "price_to_book":2.0099999999999998,
         "open":4.0800000000000001,
         "previous_close":4.0800000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology"
      ],
      "cashflow":{
         "id":264,
         "ticker":"SYRS",
         "earnings":{
            "id":"5f2bc5ec713ee300019e00e3",
            "eps":"-0.360",
            "date":"2021-08-05",
            "name":"Syros Pharmaceuticals",
            "time":"07:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"SYRS",
            "eps_est":"-0.370",
            "revenue":"5162000.000",
            "updated":1628165376,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.380",
            "importance":0,
            "period_year":2021,
            "revenue_est":"4130000.000",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"3188000.000",
            "date_confirmed":1,
            "revenue_surprise":"1032000.0000",
            "eps_surprise_percent":"0.0270",
            "revenue_surprise_percent":"0.2499"
         },
         "prev_quarter_earnings":{
            "id":"5eb3b24c885f2800019b373c",
            "eps":"-0.230",
            "date":"2021-05-06",
            "name":"Syros Pharmaceuticals",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"SYRS",
            "eps_est":"-0.460",
            "revenue":"4827000.000",
            "updated":1620302996,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.390",
            "importance":0,
            "period_year":2021,
            "revenue_est":"2670000.000",
            "eps_surprise":"0.2300",
            "revenue_type":"GAAP",
            "revenue_prior":"2379000.000",
            "date_confirmed":1,
            "revenue_surprise":"2157000.0000",
            "eps_surprise_percent":"0.5000",
            "revenue_surprise_percent":"0.8079"
         },
         "cash_equivalents_and_short_term_investments":182029000,
         "operating_cash_flow":-26454000,
         "monthly_cash_burn":-8818000,
         "est_live_cash":166450533,
         "est_months_cash":18.876222839646179,
         "total_liabilities":103757000,
         "net_cash":62693533,
         "enterpriseValue":145657284,
         "total_debt_to_equity":0.51000000000000001,
         "float":41620615,
         "insiderholdingspct":2.2999999999999998
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":7234,
      "name":"SB11",
      "craft_entry_id":74605,
      "indication":"Biosimilar (ranibizumab)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-17",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20201118005595/en/",
      "catalyst_date_text":"",
      "note":"BLA filing acceptance announced November 18, 2020. Estimated PDUFA September 17, 2021 based on 10-mth timeline.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-07-06 22:35:32",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":375,
         "ticker":"BIIB",
         "name":"Biogen Inc.",
         "exchange":null,
         "price":341.74000000000001,
         "change":3.1200000000000001,
         "percent_change":0.92000000000000004,
         "number_of_shares":149033443,
         "market_cap":50930688811,
         "short_ratio":null,
         "volume":795031,
         "average_daily_volume":1454543,
         "relative_volume":0.55000000000000004,
         "price_to_book":4.7400000000000002,
         "open":339.72000000000003,
         "previous_close":338.62,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Biosimilar"
      ],
      "cashflow":{
         "id":299,
         "ticker":"BIIB",
         "earnings":{
            "id":"5f17e4448caf190001e0207c",
            "eps":"5.680",
            "date":"2021-07-22",
            "name":"Biogen",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"BIIB",
            "eps_est":"4.550",
            "revenue":"2775000000.000",
            "updated":1626954855,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"10.260",
            "importance":5,
            "period_year":2021,
            "revenue_est":"2610000000.000",
            "eps_surprise":"1.1300",
            "revenue_type":"GAAP",
            "revenue_prior":"3682000000.000",
            "date_confirmed":1,
            "revenue_surprise":"165000000.0000",
            "eps_surprise_percent":"0.2484",
            "revenue_surprise_percent":"0.0632"
         },
         "prev_quarter_earnings":{
            "id":"5e9feb85eb75020001599e20",
            "eps":"5.340",
            "date":"2021-04-22",
            "name":"Biogen",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"BIIB",
            "eps_est":"5.040",
            "revenue":"2694000000.000",
            "updated":1619091598,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"9.140",
            "importance":5,
            "period_year":2021,
            "revenue_est":"2650000000.000",
            "eps_surprise":"0.3000",
            "revenue_type":"GAAP",
            "revenue_prior":"3534000000.000",
            "date_confirmed":1,
            "revenue_surprise":"44000000.0000",
            "eps_surprise_percent":"0.0595",
            "revenue_surprise_percent":"0.0166"
         },
         "cash_equivalents_and_short_term_investments":3050800000,
         "operating_cash_flow":1227300000,
         "monthly_cash_burn":409100000,
         "est_live_cash":3773543333,
         "est_months_cash":9.2240120581764842,
         "total_liabilities":13255600000,
         "net_cash":-9482056667,
         "enterpriseValue":55512988810,
         "total_debt_to_equity":0.70999999999999996,
         "float":132287800,
         "insiderholdingspct":1.3999999999999999
      },
      "updated_at_formatted":"06/07/2021"
   },
   {
      "id":4597,
      "name":"ATYR1923",
      "craft_entry_id":15276,
      "indication":"Pulmonary sarcoidosis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-17",
      "fda_calendar":0,
      "press_link":"https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-second-quarter-2021-results-and-provides",
      "catalyst_date_text":"Mid-September 2021",
      "note":"Phase 1/2 data due mid-September 2021.",
      "estimated_primary_completion_date":"June 29, 2021",
      "updated_at":"2021-08-10 19:34:15",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":185,
         "ticker":"LIFE",
         "name":"aTyr Pharma Inc.",
         "exchange":null,
         "price":4.5899999999999999,
         "change":0.070000000000000007,
         "percent_change":1.55,
         "number_of_shares":16919872,
         "market_cap":77662212,
         "short_ratio":null,
         "volume":89303,
         "average_daily_volume":206575,
         "relative_volume":0.42999999999999999,
         "price_to_book":1.8999999999999999,
         "open":4.5199999999999996,
         "previous_close":4.5199999999999996,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Pulmonary sarcoidosis"
      ],
      "cashflow":{
         "id":149,
         "ticker":"LIFE",
         "earnings":{
            "id":"5f34e5281ef0a0000183c318",
            "eps":"-0.640",
            "date":"2021-08-10",
            "name":"aTyr Pharma",
            "time":"16:05:00",
            "notes":"",
            "period":"Q2",
            "ticker":"LIFE",
            "eps_est":"-0.510",
            "revenue":"0.000",
            "updated":1628626698,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.690",
            "importance":0,
            "period_year":2021,
            "revenue_est":"620000.000",
            "eps_surprise":"-0.1300",
            "revenue_type":"GAAP",
            "revenue_prior":"189000.000",
            "date_confirmed":1,
            "revenue_surprise":"-620000.0000",
            "eps_surprise_percent":"-0.2549",
            "revenue_surprise_percent":"-1.0000"
         },
         "prev_quarter_earnings":{
            "id":"5eba49a9a2467b0001363497",
            "eps":"-0.510",
            "date":"2021-05-13",
            "name":"aTyr Pharma",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"LIFE",
            "eps_est":"-0.340",
            "revenue":"0.000",
            "updated":1620943025,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"0.250",
            "importance":0,
            "period_year":2021,
            "revenue_est":"3580000.000",
            "eps_surprise":"-0.1700",
            "revenue_type":"GAAP",
            "revenue_prior":"8065000.000",
            "date_confirmed":1,
            "revenue_surprise":"-3580000.0000",
            "eps_surprise_percent":"-0.5000",
            "revenue_surprise_percent":"-1.0000"
         },
         "cash_equivalents_and_short_term_investments":44061000,
         "operating_cash_flow":-7692000,
         "monthly_cash_burn":-2564000,
         "est_live_cash":39531266,
         "est_months_cash":15.417810452418097,
         "total_liabilities":8190000,
         "net_cash":31341266,
         "enterpriseValue":35426212,
         "total_debt_to_equity":0.040000000000000001,
         "float":14670697,
         "insiderholdingspct":5.0999999999999996
      },
      "updated_at_formatted":"10/08/2021"
   },
   {
      "id":6459,
      "name":"VS-6766 and Defactinib - FRAME",
      "craft_entry_id":42381,
      "indication":"KRAS mutant advanced solid tumors",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-19",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210802005716/en/",
      "catalyst_date_text":"",
      "note":"Phase 1/2 updated data due at ESMO September 19, 2021.",
      "estimated_primary_completion_date":"July 12, 2021",
      "updated_at":"2021-08-02 16:19:29",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":308,
         "ticker":"VSTM",
         "name":"Verastem Inc.",
         "exchange":null,
         "price":2.5600000000000001,
         "change":0.02,
         "percent_change":0.79000000000000004,
         "number_of_shares":180758269,
         "market_cap":462741169,
         "short_ratio":null,
         "volume":2249250,
         "average_daily_volume":2039950,
         "relative_volume":1.1000000000000001,
         "price_to_book":5.2199999999999998,
         "open":2.5099999999999998,
         "previous_close":2.54,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology"
      ],
      "cashflow":{
         "id":242,
         "ticker":"VSTM",
         "earnings":{
            "id":"5f3393c9b7c159000133e875",
            "eps":"-0.080",
            "date":"2021-08-02",
            "name":"Verastem Oncology",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"VSTM",
            "eps_est":"-0.080",
            "revenue":"500000.000",
            "updated":1627940887,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.120",
            "importance":0,
            "period_year":2021,
            "revenue_est":"50000.000",
            "eps_surprise":"0.0000",
            "revenue_type":"GAAP",
            "revenue_prior":"4307000.000",
            "date_confirmed":1,
            "revenue_surprise":"450000.0000",
            "eps_surprise_percent":"0.0000",
            "revenue_surprise_percent":"9.0000"
         },
         "prev_quarter_earnings":{
            "id":"5eb6554e84a80a00018b447e",
            "eps":"-0.070",
            "date":"2021-05-11",
            "name":"Verastem Oncology",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"VSTM",
            "eps_est":"-0.090",
            "revenue":"1006000.000",
            "updated":1620803692,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.200",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"5056000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.2222",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":108135000,
         "operating_cash_flow":-13424000,
         "monthly_cash_burn":-4474666,
         "est_live_cash":100229756,
         "est_months_cash":22.399382657834128,
         "total_liabilities":35685000,
         "net_cash":64544756,
         "enterpriseValue":378157168,
         "total_debt_to_equity":0.27000000000000002,
         "float":179887236,
         "insiderholdingspct":2.2999999999999998
      },
      "updated_at_formatted":"02/08/2021"
   },
   {
      "id":1883,
      "name":"Balstilimab (anti-PD-1) and Zalifrelimab - AGEN1884 (anti-CTLA-4)",
      "craft_entry_id":14241,
      "indication":"Cervical cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-19",
      "fda_calendar":0,
      "press_link":"https://investor.agenusbio.com/news-releases/news-release-details/agenus-corporate-update-and-second-quarter-2021-financial-report",
      "catalyst_date_text":"",
      "note":"Phase 2 data presented at ESMO September 18, 2020. Balstilimab (PD-1) monotherapy response rates of 14% in all treated patients and 19% in PD-L1 positive patients. Balstilimab (PD-1) + zalifrelimab (CTLA-4) combination trial response rates of 22% in all patients and 27% in PD-L1 positive patients. Data to be be presented at ESMO September 19, 2021.\r\n",
      "estimated_primary_completion_date":"May 4, 2022",
      "updated_at":"2021-08-09 08:38:24",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":324,
         "ticker":"AGEN",
         "name":"Agenus Inc.",
         "exchange":null,
         "price":6.0499999999999998,
         "change":0.29999999999999999,
         "percent_change":5.2199999999999998,
         "number_of_shares":233114645,
         "market_cap":1410343602,
         "short_ratio":null,
         "volume":4567430,
         "average_daily_volume":3108514,
         "relative_volume":1.47,
         "price_to_book":-5.71,
         "open":5.71,
         "previous_close":5.75,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology",
         "Cervical cancer"
      ],
      "cashflow":{
         "id":257,
         "ticker":"AGEN",
         "earnings":{
            "id":"5f2bab24713ee300019dfd21",
            "eps":"-0.370",
            "date":"2021-08-09",
            "name":"Agenus",
            "time":"07:45:00",
            "notes":"",
            "period":"Q2",
            "ticker":"AGEN",
            "eps_est":"-0.240",
            "revenue":"10730000.000",
            "updated":1628510463,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.280",
            "importance":1,
            "period_year":2021,
            "revenue_est":"20410000.000",
            "eps_surprise":"-0.1300",
            "revenue_type":"GAAP",
            "revenue_prior":"26945000.000",
            "date_confirmed":1,
            "revenue_surprise":"-9680000.0000",
            "eps_surprise_percent":"-0.5417",
            "revenue_surprise_percent":"-0.4743"
         },
         "prev_quarter_earnings":{
            "id":"5eb3b1f8885f2800019b338c",
            "eps":"-0.270",
            "date":"2021-05-06",
            "name":"Agenus",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"AGEN",
            "eps_est":"-0.310",
            "revenue":"11719000.000",
            "updated":1620308317,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.200",
            "importance":1,
            "period_year":2021,
            "revenue_est":"14530000.000",
            "eps_surprise":"0.0400",
            "revenue_type":"GAAP",
            "revenue_prior":"15128000.000",
            "date_confirmed":1,
            "revenue_surprise":"-2811000.0000",
            "eps_surprise_percent":"0.1290",
            "revenue_surprise_percent":"-0.1935"
         },
         "cash_equivalents_and_short_term_investments":73543000,
         "operating_cash_flow":-55557000,
         "monthly_cash_burn":-18519000,
         "est_live_cash":40826100,
         "est_months_cash":2.2045520816458772,
         "total_liabilities":448051000,
         "net_cash":-407224900,
         "enterpriseValue":1393651602,
         "total_debt_to_equity":"",
         "float":231178523,
         "insiderholdingspct":3.2999999999999998
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":5508,
      "name":"BRUKINSA (zanubrutinib)",
      "craft_entry_id":23614,
      "indication":"Marginal Zone Lymphoma",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-19",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210519005166/en/",
      "catalyst_date_text":"",
      "note":"PDUFA date under priority review September 19, 2021.",
      "estimated_primary_completion_date":"January 18, 2021",
      "updated_at":"2021-05-19 07:33:04",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":340,
         "ticker":"BGNE",
         "name":"BeiGene Ltd.",
         "exchange":null,
         "price":249.59999999999999,
         "change":-25.84,
         "percent_change":-9.3800000000000008,
         "number_of_shares":93159001,
         "market_cap":23252486650,
         "short_ratio":null,
         "volume":1445694,
         "average_daily_volume":315067,
         "relative_volume":4.5899999999999999,
         "price_to_book":6.4500000000000002,
         "open":274.30000000000001,
         "previous_close":275.44,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Lymphoma",
         "Marginal zone lymphoma"
      ],
      "cashflow":{
         "id":270,
         "ticker":"BGNE",
         "earnings":{
            "id":"5f2cfc06a3eee500019e8e6b",
            "eps":"-5.230",
            "date":"2021-08-05",
            "name":"BeiGene",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"BGNE",
            "eps_est":"-4.140",
            "revenue":"149992000.000",
            "updated":1628208251,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-4.310",
            "importance":1,
            "period_year":2021,
            "revenue_est":"215430000.000",
            "eps_surprise":"-1.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"65635000.000",
            "date_confirmed":1,
            "revenue_surprise":"-65438000.0000",
            "eps_surprise_percent":"-0.2633",
            "revenue_surprise_percent":"-0.3038"
         },
         "prev_quarter_earnings":{
            "id":"5eba4981a2467b00013633ef",
            "eps":"0.690",
            "date":"2021-05-06",
            "name":"BeiGene",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"BGNE",
            "eps_est":"-4.810",
            "revenue":"605872000.000",
            "updated":1620367871,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-4.700",
            "importance":1,
            "period_year":2021,
            "revenue_est":"91820000.000",
            "eps_surprise":"5.5000",
            "revenue_type":"GAAP",
            "revenue_prior":"52059000.000",
            "date_confirmed":1,
            "revenue_surprise":"514052000.0000",
            "eps_surprise_percent":"1.1435",
            "revenue_surprise_percent":"5.5985"
         },
         "cash_equivalents_and_short_term_investments":4381900000,
         "operating_cash_flow":-420266000,
         "monthly_cash_burn":-140088666,
         "est_live_cash":4134410023,
         "est_months_cash":29.512808859212065,
         "total_liabilities":1917341000,
         "net_cash":2217069023,
         "enterpriseValue":21094720121,
         "total_debt_to_equity":0.19,
         "float":89530472,
         "insiderholdingspct":0.29999999999999999
      },
      "updated_at_formatted":"19/05/2021"
   },
   {
      "id":4702,
      "name":"JAKAFI (Ruxolitinib)",
      "craft_entry_id":16479,
      "indication":"Atopic dermatitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-21",
      "fda_calendar":1,
      "press_link":"https://www.businesswire.com/news/home/20210611005030/en/",
      "catalyst_date_text":"",
      "note":"PDUFA date under priority review extended by three months to September 21, 2021.",
      "estimated_primary_completion_date":"December 23, 2019",
      "updated_at":"2021-06-11 07:32:39",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":167,
         "ticker":"INCY",
         "name":"Incyte Corporation",
         "exchange":null,
         "price":74.900000000000006,
         "change":0.39000000000000001,
         "percent_change":0.52000000000000002,
         "number_of_shares":220835269,
         "market_cap":16540561648,
         "short_ratio":null,
         "volume":772335,
         "average_daily_volume":1289837,
         "relative_volume":0.59999999999999998,
         "price_to_book":5.6399999999999997,
         "open":74.469999999999999,
         "previous_close":74.510000000000005,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Atopic dermatitis"
      ],
      "cashflow":{
         "id":138,
         "ticker":"INCY",
         "earnings":{
            "id":"5f2908e12902dd0001f85620",
            "eps":"0.800",
            "date":"2021-08-03",
            "name":"Incyte",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"INCY",
            "eps_est":"0.750",
            "revenue":"705709000.000",
            "updated":1627990115,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"1.240",
            "importance":3,
            "period_year":2021,
            "revenue_est":"686980000.000",
            "eps_surprise":"0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"688043000.000",
            "date_confirmed":1,
            "revenue_surprise":"18729000.0000",
            "eps_surprise_percent":"0.0667",
            "revenue_surprise_percent":"0.0273"
         },
         "prev_quarter_earnings":{
            "id":"5eb10f2a13dffb0001540c23",
            "eps":"0.670",
            "date":"2021-05-04",
            "name":"Incyte",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"INCY",
            "eps_est":"0.640",
            "revenue":"604718000.000",
            "updated":1620127319,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-2.860",
            "importance":0,
            "period_year":2021,
            "revenue_est":"659240000.000",
            "eps_surprise":"0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"568507000",
            "date_confirmed":1,
            "revenue_surprise":"-54522000.0000",
            "eps_surprise_percent":"0.0469",
            "revenue_surprise_percent":"-0.0827"
         },
         "cash_equivalents_and_short_term_investments":2080967000,
         "operating_cash_flow":172944000,
         "monthly_cash_burn":57648000,
         "est_live_cash":2182811800,
         "est_months_cash":37.864484457396614,
         "total_liabilities":968762000,
         "net_cash":1214049800,
         "enterpriseValue":14504835648,
         "total_debt_to_equity":0.02,
         "float":155219007,
         "insiderholdingspct":1.5
      },
      "updated_at_formatted":"11/06/2021"
   },
   {
      "id":6757,
      "name":"Rigosertib and OPDIVO (Nivolumab)",
      "craft_entry_id":51644,
      "indication":"KRAS+ Non-Small Cell Lung Cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-21",
      "fda_calendar":0,
      "press_link":"https://investor.onconova.com/news-releases/news-release-details/onconova-therapeutics-provides-update-phase-12a-trial-rigosertib",
      "catalyst_date_text":"",
      "note":"Phase 1/2a data to be presented at the RAS Targeted Drug Development Summit, September 21-23, 2021.",
      "estimated_primary_completion_date":"January 2022",
      "updated_at":"2021-06-28 08:14:22",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":229,
         "ticker":"ONTX",
         "name":"Onconova Therapeutics Inc.",
         "exchange":null,
         "price":4.6299999999999999,
         "change":0.16,
         "percent_change":3.5800000000000001,
         "number_of_shares":15780936,
         "market_cap":73065734,
         "short_ratio":null,
         "volume":139500,
         "average_daily_volume":413225,
         "relative_volume":0.34000000000000002,
         "price_to_book":1.97,
         "open":4.4299999999999997,
         "previous_close":4.4699999999999998,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Non-small cell lung cancer (NSCLC)",
         "Lung cancer"
      ],
      "cashflow":{
         "id":183,
         "ticker":"ONTX",
         "earnings":{
            "id":"5f3393afb7c159000133e7eb",
            "eps":"-0.270",
            "date":"2021-08-12",
            "name":"Onconova Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ONTX",
            "eps_est":"-0.280",
            "revenue":"57000.000",
            "updated":1628799468,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.040",
            "importance":0,
            "period_year":2021,
            "revenue_est":"20000.000",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"56000.000",
            "date_confirmed":1,
            "revenue_surprise":"37000.0000",
            "eps_surprise_percent":"0.0357",
            "revenue_surprise_percent":"1.8500"
         },
         "prev_quarter_earnings":{
            "id":"5ebcecb94b88bb0001fc2fb8",
            "eps":"-0.020",
            "date":"2021-05-17",
            "name":"Onconova Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ONTX",
            "eps_est":"-0.030",
            "revenue":"56000.000",
            "updated":1621285993,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.030",
            "importance":0,
            "period_year":2021,
            "revenue_est":"60000.000",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"52000.000",
            "date_confirmed":1,
            "revenue_surprise":"-4000.0000",
            "eps_surprise_percent":"0.3333",
            "revenue_surprise_percent":"-0.0667"
         },
         "cash_equivalents_and_short_term_investments":43709000,
         "operating_cash_flow":-4307000,
         "monthly_cash_burn":-1435666,
         "est_live_cash":41172656,
         "est_months_cash":28.678436349401601,
         "total_liabilities":11385000,
         "net_cash":29787656,
         "enterpriseValue":63566217,
         "total_debt_to_equity":"",
         "float":15709003,
         "insiderholdingspct":8.4000000000000004
      },
      "updated_at_formatted":"28/06/2021"
   },
   {
      "id":2722,
      "name":"JAKAFI (Ruxolitinib)",
      "craft_entry_id":4151,
      "indication":"Steroid-refractory chronic GVHD (Graft versus host disease)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-22",
      "fda_calendar":1,
      "press_link":"https://www.businesswire.com/news/home/20210608005435/en/",
      "catalyst_date_text":"",
      "note":"PDUFA date under priority review extended by three months to September 22, 2021.",
      "estimated_primary_completion_date":"May 8, 2020",
      "updated_at":"2021-06-11 00:24:05",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":167,
         "ticker":"INCY",
         "name":"Incyte Corporation",
         "exchange":null,
         "price":74.900000000000006,
         "change":0.39000000000000001,
         "percent_change":0.52000000000000002,
         "number_of_shares":220835269,
         "market_cap":16540561648,
         "short_ratio":null,
         "volume":772335,
         "average_daily_volume":1289837,
         "relative_volume":0.59999999999999998,
         "price_to_book":5.6399999999999997,
         "open":74.469999999999999,
         "previous_close":74.510000000000005,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Graft versus host disease (GvHD)"
      ],
      "cashflow":{
         "id":138,
         "ticker":"INCY",
         "earnings":{
            "id":"5f2908e12902dd0001f85620",
            "eps":"0.800",
            "date":"2021-08-03",
            "name":"Incyte",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"INCY",
            "eps_est":"0.750",
            "revenue":"705709000.000",
            "updated":1627990115,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"1.240",
            "importance":3,
            "period_year":2021,
            "revenue_est":"686980000.000",
            "eps_surprise":"0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"688043000.000",
            "date_confirmed":1,
            "revenue_surprise":"18729000.0000",
            "eps_surprise_percent":"0.0667",
            "revenue_surprise_percent":"0.0273"
         },
         "prev_quarter_earnings":{
            "id":"5eb10f2a13dffb0001540c23",
            "eps":"0.670",
            "date":"2021-05-04",
            "name":"Incyte",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"INCY",
            "eps_est":"0.640",
            "revenue":"604718000.000",
            "updated":1620127319,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-2.860",
            "importance":0,
            "period_year":2021,
            "revenue_est":"659240000.000",
            "eps_surprise":"0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"568507000",
            "date_confirmed":1,
            "revenue_surprise":"-54522000.0000",
            "eps_surprise_percent":"0.0469",
            "revenue_surprise_percent":"-0.0827"
         },
         "cash_equivalents_and_short_term_investments":2080967000,
         "operating_cash_flow":172944000,
         "monthly_cash_burn":57648000,
         "est_live_cash":2182811800,
         "est_months_cash":37.864484457396614,
         "total_liabilities":968762000,
         "net_cash":1214049800,
         "enterpriseValue":14504835648,
         "total_debt_to_equity":0.02,
         "float":155219007,
         "insiderholdingspct":1.5
      },
      "updated_at_formatted":"11/06/2021"
   },
   {
      "id":4886,
      "name":"VP-102",
      "craft_entry_id":17663,
      "indication":"Molluscum contagiosum",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-23",
      "fda_calendar":1,
      "press_link":"https://www.globenewswire.com/news-release/2021/05/28/2238179/0/en/Verrica-Pharmaceuticals-Announces-Extension-of-FDA-Review-Period-of-its-NDA-for-VP-102-for-the-Treatment-of-Molluscum-Contagiosum.html",
      "catalyst_date_text":"",
      "note":"CRL announced July 14, 2020. NDA resubmitted. Initial PDUFA date extended by three months to September 23, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-05-28 07:47:47",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":558,
         "ticker":"VRCA",
         "name":"Verrica Pharmaceuticals Inc.",
         "exchange":null,
         "price":9.8499999999999996,
         "change":0.29999999999999999,
         "percent_change":3.1400000000000001,
         "number_of_shares":27514720,
         "market_cap":271019992,
         "short_ratio":null,
         "volume":45448,
         "average_daily_volume":65692,
         "relative_volume":0.68999999999999995,
         "price_to_book":5.1799999999999997,
         "open":9.4700000000000006,
         "previous_close":9.5500000000000007,
         "created_at":"2018-06-17T02:34:49.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Molluscum Contagiosum"
      ],
      "cashflow":{
         "id":434,
         "ticker":"VRCA",
         "earnings":{
            "id":"5f2bc870713ee300019e0139",
            "eps":"-0.430",
            "date":"2021-08-10",
            "name":"Verrica Pharmaceuticals",
            "time":"07:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"VRCA",
            "eps_est":"",
            "revenue":"0.000",
            "updated":1628669519,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.380",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eb503e0f857860001768d60",
            "eps":"-0.040",
            "date":"2021-05-07",
            "name":"Verrica Pharmaceuticals",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"VRCA",
            "eps_est":"",
            "revenue":"12000000.000",
            "updated":1621496238,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.390",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":90129000,
         "operating_cash_flow":2499000,
         "monthly_cash_burn":833000,
         "est_live_cash":91600633,
         "est_months_cash":109.96474549819928,
         "total_liabilities":46874000,
         "net_cash":44726633,
         "enterpriseValue":223729992,
         "total_debt_to_equity":0.81999999999999995,
         "float":13027725,
         "insiderholdingspct":40.799999999999997
      },
      "updated_at_formatted":"28/05/2021"
   },
   {
      "id":3372,
      "name":"TransCon hGH (Lonapegsomatropin)",
      "craft_entry_id":1845,
      "indication":"Growth hormone deficiency in children",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-25",
      "fda_calendar":1,
      "press_link":"https://www.globenewswire.com/news-release/2021/06/11/2246137/0/en/Ascendis-Pharma-A-S-Announces-Extension-of-U-S-Food-and-Drug-Administration-Review-Period-for-TransCon-hGH-Lonapegsomatropin-for-Pediatric-Growth-Hormone-Deficiency.html",
      "catalyst_date_text":"",
      "note":"PDUFA date extended by three months to September 25, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-06-11 18:03:30",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":49,
         "ticker":"ASND",
         "name":"Ascendis Pharma A/S",
         "exchange":null,
         "price":120.45,
         "change":1.3700000000000001,
         "percent_change":1.1499999999999999,
         "number_of_shares":53829379,
         "market_cap":6483748701,
         "short_ratio":null,
         "volume":160465,
         "average_daily_volume":187416,
         "relative_volume":0.85999999999999999,
         "price_to_book":6.9000000000000004,
         "open":119.20999999999999,
         "previous_close":119.08,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Growth hormone deficiency"
      ],
      "cashflow":{
         "id":38,
         "ticker":"ASND",
         "earnings":{
            "id":"5fbf528395505d0001cd03ca",
            "eps":"",
            "date":"2021-08-25",
            "name":"Ascendis Pharma",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ASND",
            "eps_est":"",
            "revenue":"",
            "updated":1629231653,
            "currency":"USD",
            "eps_type":"",
            "exchange":"NASDAQ",
            "eps_prior":"-2.170",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"",
            "revenue_prior":"1581000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ec383fff10420000131a62b",
            "eps":"-1.410",
            "date":"2021-05-27",
            "name":"Ascendis Pharma",
            "time":"16:01:00",
            "notes":"fxc",
            "period":"Q1",
            "ticker":"ASND",
            "eps_est":"-2.080",
            "revenue":"899601.000",
            "updated":1622146577,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.460",
            "importance":0,
            "period_year":2021,
            "revenue_est":"2300000.000",
            "eps_surprise":"0.6700",
            "revenue_type":"GAAP",
            "revenue_prior":"2454000.000",
            "date_confirmed":1,
            "revenue_surprise":"-1400399.0000",
            "eps_surprise_percent":"0.3221",
            "revenue_surprise_percent":"-0.6089"
         },
         "cash_equivalents_and_short_term_investments":664706000,
         "operating_cash_flow":-81619000,
         "monthly_cash_burn":-27206333,
         "est_live_cash":534115601,
         "est_months_cash":19.632032034600179,
         "total_liabilities":162494000,
         "net_cash":371621601,
         "enterpriseValue":5820266189,
         "total_debt_to_equity":0.12,
         "float":53829379,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"11/06/2021"
   },
   {
      "id":5294,
      "name":"AGN-151587 (EDIT-101) - BRILLIANCE",
      "craft_entry_id":21297,
      "indication":"Leber Congenital Amaurosis type 10 (LCA10).",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-27",
      "fda_calendar":0,
      "press_link":"https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-enrollment-first-pediatric-cohort",
      "catalyst_date_text":"",
      "note":"Phase 1/2 initial data due to be presented at the International Symposium on Retinal Degeneration planned for September 27 \u2013 October 2, 2021.",
      "estimated_primary_completion_date":"March 22, 2024",
      "updated_at":"2021-06-23 07:33:10",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":616,
         "ticker":"EDIT",
         "name":"Editas Medicine Inc.",
         "exchange":null,
         "price":60.380000000000003,
         "change":2.2800000000000002,
         "percent_change":3.9199999999999999,
         "number_of_shares":68261255,
         "market_cap":4121614577,
         "short_ratio":null,
         "volume":902443,
         "average_daily_volume":2117209,
         "relative_volume":0.42999999999999999,
         "price_to_book":6.7199999999999998,
         "open":58.049999999999997,
         "previous_close":58.100000000000001,
         "created_at":"2018-12-01T04:30:15.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Leber's Congenital Amaurosis (LCA)"
      ],
      "cashflow":{
         "id":490,
         "ticker":"EDIT",
         "earnings":{
            "id":"5f2bb425713ee300019dfe61",
            "eps":"-0.810",
            "date":"2021-08-04",
            "name":"Editas Medicine",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"EDIT",
            "eps_est":"-0.830",
            "revenue":"379000.000",
            "updated":1628084028,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.430",
            "importance":0,
            "period_year":2021,
            "revenue_est":"6170000.000",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"10749000.000",
            "date_confirmed":1,
            "revenue_surprise":"-5791000.0000",
            "eps_surprise_percent":"0.0241",
            "revenue_surprise_percent":"-0.9386"
         },
         "prev_quarter_earnings":{
            "id":"5eb2609a7f47df0001e14c32",
            "eps":"-0.860",
            "date":"2021-05-05",
            "name":"Editas Medicine",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"EDIT",
            "eps_est":"-0.750",
            "revenue":"6499000.000",
            "updated":1620217913,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.690",
            "importance":0,
            "period_year":2021,
            "revenue_est":"5140000.000",
            "eps_surprise":"-0.1100",
            "revenue_type":"GAAP",
            "revenue_prior":"5723000.000",
            "date_confirmed":1,
            "revenue_surprise":"1359000.0000",
            "eps_surprise_percent":"-0.1467",
            "revenue_surprise_percent":"0.2644"
         },
         "cash_equivalents_and_short_term_investments":610553000,
         "operating_cash_flow":-38957000,
         "monthly_cash_burn":-12985666,
         "est_live_cash":587611656,
         "est_months_cash":45.250790833523673,
         "total_liabilities":142519000,
         "net_cash":445092656,
         "enterpriseValue":3541317576,
         "total_debt_to_equity":0.050000000000000003,
         "float":58072559,
         "insiderholdingspct":3.1000000000000001
      },
      "updated_at_formatted":"23/06/2021"
   },
   {
      "id":5932,
      "name":"Maralixibat",
      "craft_entry_id":29670,
      "indication":"Alagille Syndrome (ALGS)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-29",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210329005203/en/",
      "catalyst_date_text":"",
      "note":"PDUFA date under priority review September 29, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-03-29 09:04:09",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":685,
         "ticker":"MIRM",
         "name":"Mirum Pharmaceuticals Inc.",
         "exchange":null,
         "price":14.18,
         "change":-0.010000000000000009,
         "percent_change":-0.069999999999999951,
         "number_of_shares":30515833,
         "market_cap":432714512,
         "short_ratio":null,
         "volume":35072,
         "average_daily_volume":83207,
         "relative_volume":0.41999999999999998,
         "price_to_book":4.5199999999999996,
         "open":14.09,
         "previous_close":14.19,
         "created_at":"2019-07-18T22:06:46.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Alagille Syndrome (ALGS)"
      ],
      "cashflow":{
         "id":553,
         "ticker":"MIRM",
         "earnings":{
            "id":"5f2cfc2ca3eee500019e8f05",
            "eps":"-1.450",
            "date":"2021-08-05",
            "name":"Mirum Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"MIRM",
            "eps_est":"",
            "revenue":"11000000.000",
            "updated":1628198416,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.930",
            "importance":0,
            "period_year":2021,
            "revenue_est":"14500000.000",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"-3500000.0000",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":"-0.2414"
         },
         "prev_quarter_earnings":{
            "id":"5ec4d5b088a06b0001f81c29",
            "eps":"1.680",
            "date":"2021-05-06",
            "name":"Mirum Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"MIRM",
            "eps_est":"-0.690",
            "revenue":"0.000",
            "updated":1620343252,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.860",
            "importance":0,
            "period_year":2021,
            "revenue_est":"8330000.000",
            "eps_surprise":"2.3700",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"-8330000.0000",
            "eps_surprise_percent":"3.4348",
            "revenue_surprise_percent":"-1.0000"
         },
         "cash_equivalents_and_short_term_investments":223851000,
         "operating_cash_flow":-40199000,
         "monthly_cash_burn":-13399666,
         "est_live_cash":200178256,
         "est_months_cash":14.939048182245736,
         "total_liabilities":151931000,
         "net_cash":48247256,
         "enterpriseValue":211805511,
         "total_debt_to_equity":0.029999999999999999,
         "float":8253550,
         "insiderholdingspct":0.5
      },
      "updated_at_formatted":"29/03/2021"
   },
   {
      "id":3005,
      "name":"Atogepant",
      "craft_entry_id":3724,
      "indication":"Chronic migraine",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-29",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/us-fda-accepts-abbvies-new-drug-application-for-atogepant-for-the-preventive-treatment-of-migraine-301257758.html",
      "catalyst_date_text":"Late-3Q 2021",
      "note":"NDA acceptance announced March 30, 2021. PDUFA date late-3Q 2021.",
      "estimated_primary_completion_date":"June 19, 2020",
      "updated_at":"2021-03-30 08:07:14",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":369,
         "ticker":"ABBV",
         "name":"AbbVie Inc.",
         "exchange":null,
         "price":118.81999999999999,
         "change":0.89000000000000001,
         "percent_change":0.75,
         "number_of_shares":1767175532,
         "market_cap":209975796712,
         "short_ratio":null,
         "volume":4111104,
         "average_daily_volume":5727260,
         "relative_volume":0.71999999999999997,
         "price_to_book":16.710000000000001,
         "open":118.09999999999999,
         "previous_close":117.93000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Migraine"
      ],
      "cashflow":{
         "id":294,
         "ticker":"ABBV",
         "earnings":{
            "id":"5f23c177bcf9e90001c5cf49",
            "eps":"3.110",
            "date":"2021-07-30",
            "name":"AbbVie",
            "time":"07:44:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ABBV",
            "eps_est":"3.090",
            "revenue":"13959000000.000",
            "updated":1627645810,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"2.340",
            "importance":4,
            "period_year":2021,
            "revenue_est":"13630000000.000",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"10425000000.000",
            "date_confirmed":1,
            "revenue_surprise":"329000000.0000",
            "eps_surprise_percent":"0.0065",
            "revenue_surprise_percent":"0.0241"
         },
         "prev_quarter_earnings":{
            "id":"5eabc8fb7951770001128a03",
            "eps":"2.950",
            "date":"2021-04-30",
            "name":"AbbVie",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ABBV",
            "eps_est":"2.830",
            "revenue":"13010000000.000",
            "updated":1619783445,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"2.420",
            "importance":4,
            "period_year":2021,
            "revenue_est":"12760000000.000",
            "eps_surprise":"0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"8619000000.000",
            "date_confirmed":1,
            "revenue_surprise":"250000000.0000",
            "eps_surprise_percent":"0.0424",
            "revenue_surprise_percent":"0.0196"
         },
         "cash_equivalents_and_short_term_investments":8600000000,
         "operating_cash_flow":4890000000,
         "monthly_cash_burn":1630000000,
         "est_live_cash":11479666666,
         "est_months_cash":7.0427402858895709,
         "total_liabilities":135378000000,
         "net_cash":-123898333334,
         "enterpriseValue":283513796712,
         "total_debt_to_equity":6.5300000000000002,
         "float":1765652810,
         "insiderholdingspct":0.10000000000000001
      },
      "updated_at_formatted":"30/03/2021"
   },
   {
      "id":6899,
      "name":"RGX-314 (AAVIATE)",
      "craft_entry_id":58494,
      "indication":"Wet AMD using suprachoroidal delivery ",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-29",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2021-financial-results-and-operational-highlights-301351442.html",
      "catalyst_date_text":"",
      "note":"Phase 2 initial data to be presented at the Retina Society Annual Scientific Meeting, September 29-October 2, 2021.",
      "estimated_primary_completion_date":"February 15, 2021",
      "updated_at":"2021-08-09 17:02:12",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":263,
         "ticker":"RGNX",
         "name":"REGENXBIO Inc.",
         "exchange":null,
         "price":29.629999999999999,
         "change":0.54000000000000004,
         "percent_change":1.8599999999999999,
         "number_of_shares":42600528,
         "market_cap":1262253645,
         "short_ratio":null,
         "volume":322589,
         "average_daily_volume":336542,
         "relative_volume":0.95999999999999996,
         "price_to_book":2.4900000000000002,
         "open":28.829999999999998,
         "previous_close":29.09,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Wet age-related macular degeneration (AMD)"
      ],
      "cashflow":{
         "id":207,
         "ticker":"RGNX",
         "earnings":{
            "id":"5f2bc2c2713ee300019e0075",
            "eps":"-1.360",
            "date":"2021-08-09",
            "name":"Regenxbio",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"RGNX",
            "eps_est":"-1.120",
            "revenue":"22035000.000",
            "updated":1628545396,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.910",
            "importance":0,
            "period_year":2021,
            "revenue_est":"29020000.000",
            "eps_surprise":"-0.2400",
            "revenue_type":"GAAP",
            "revenue_prior":"16566000.000",
            "date_confirmed":1,
            "revenue_surprise":"-6985000.0000",
            "eps_surprise_percent":"-0.2143",
            "revenue_surprise_percent":"-0.2407"
         },
         "prev_quarter_earnings":{
            "id":"5eb3b241885f2800019b36e2",
            "eps":"-1.200",
            "date":"2021-05-05",
            "name":"Regenxbio",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"RGNX",
            "eps_est":"-1.280",
            "revenue":"18884000.000",
            "updated":1620253170,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.080",
            "importance":0,
            "period_year":2021,
            "revenue_est":"23230000.000",
            "eps_surprise":"0.0800",
            "revenue_type":"GAAP",
            "revenue_prior":"17644000.000",
            "date_confirmed":1,
            "revenue_surprise":"-4346000.0000",
            "eps_surprise_percent":"0.0625",
            "revenue_surprise_percent":"-0.1871"
         },
         "cash_equivalents_and_short_term_investments":374737000,
         "operating_cash_flow":-29872000,
         "monthly_cash_burn":-9957333,
         "est_live_cash":357145711,
         "est_months_cash":35.867607420581393,
         "total_liabilities":329157000,
         "net_cash":27988711,
         "enterpriseValue":971608644,
         "total_debt_to_equity":0.17000000000000001,
         "float":33768385,
         "insiderholdingspct":1.1000000000000001
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":6899,
      "name":"RGX-314 (AAVIATE)",
      "craft_entry_id":58494,
      "indication":"Wet AMD using suprachoroidal delivery ",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-29",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2021-financial-results-and-operational-highlights-301351442.html",
      "catalyst_date_text":"",
      "note":"Phase 2 initial data to be presented at the Retina Society Annual Scientific Meeting, September 29-October 2, 2021.",
      "estimated_primary_completion_date":"February 15, 2021",
      "updated_at":"2021-08-09 17:02:12",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":325,
         "ticker":"CLSD",
         "name":"Clearside Biomedical Inc.",
         "exchange":null,
         "price":5.6500000000000004,
         "change":0.029999999999999999,
         "percent_change":0.53000000000000003,
         "number_of_shares":59479568,
         "market_cap":336059559,
         "short_ratio":null,
         "volume":796270,
         "average_daily_volume":3936957,
         "relative_volume":0.20000000000000001,
         "price_to_book":17.120000000000001,
         "open":5.5,
         "previous_close":5.6200000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Wet age-related macular degeneration (AMD)"
      ],
      "cashflow":{
         "id":258,
         "ticker":"CLSD",
         "earnings":{
            "id":"5f30f08aa7bff3000162b22f",
            "eps":"-0.110",
            "date":"2021-08-10",
            "name":"Clearside Biomedical",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CLSD",
            "eps_est":"-0.120",
            "revenue":"780000.000",
            "updated":1628629366,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.130",
            "importance":2,
            "period_year":2021,
            "revenue_est":"690000.000",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"354000.000",
            "date_confirmed":1,
            "revenue_surprise":"90000.0000",
            "eps_surprise_percent":"0.0833",
            "revenue_surprise_percent":"0.1304"
         },
         "prev_quarter_earnings":{
            "id":"5eb6550c84a80a00018b4424",
            "eps":"-0.130",
            "date":"2021-05-17",
            "name":"Clearside Biomedical",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"CLSD",
            "eps_est":"-0.100",
            "revenue":"34000.000",
            "updated":1621283204,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.070",
            "importance":2,
            "period_year":2021,
            "revenue_est":"2120000.000",
            "eps_surprise":"-0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"4097000.000",
            "date_confirmed":1,
            "revenue_surprise":"-2086000.0000",
            "eps_surprise_percent":"-0.3000",
            "revenue_surprise_percent":"-0.9840"
         },
         "cash_equivalents_and_short_term_investments":26414000,
         "operating_cash_flow":-6950000,
         "monthly_cash_burn":-2316666,
         "est_live_cash":22321223,
         "est_months_cash":9.6350630604498022,
         "total_liabilities":9254000,
         "net_cash":13067223,
         "enterpriseValue":310483559,
         "total_debt_to_equity":0.040000000000000001,
         "float":47643724,
         "insiderholdingspct":9
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":7424,
      "name":"Mim8",
      "craft_entry_id":86945,
      "indication":"Hemophilia A ",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investor.novonordisk.com/Q1-2021-presentation/?page=27",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1/2 data due 3Q 2021.",
      "estimated_primary_completion_date":"January 29, 2024",
      "updated_at":"2021-06-16 18:53:43",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":385,
         "ticker":"NVO",
         "name":"Novo Nordisk A/S",
         "exchange":null,
         "price":106.62,
         "change":1.01,
         "percent_change":0.95999999999999996,
         "number_of_shares":2291903114,
         "market_cap":244362710015,
         "short_ratio":null,
         "volume":932152,
         "average_daily_volume":957534,
         "relative_volume":0.96999999999999997,
         "price_to_book":23.690000000000001,
         "open":106.02,
         "previous_close":105.61,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Hemophilia",
         "Hemophilia A"
      ],
      "cashflow":{
         "id":309,
         "ticker":"NVO",
         "earnings":{
            "id":"5f37882cdc44030001439438",
            "eps":"0.850",
            "date":"2021-08-05",
            "name":"Novo Nordisk",
            "time":"08:00:00",
            "notes":"fxc",
            "period":"Q2",
            "ticker":"NVO",
            "eps_est":"0.770",
            "revenue":"5322000000.000",
            "updated":1628173101,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NYSE",
            "eps_prior":"0.670",
            "importance":0,
            "period_year":2021,
            "revenue_est":"5110000000.000",
            "eps_surprise":"0.0800",
            "revenue_type":"GAAP",
            "revenue_prior":"4429000000.000",
            "date_confirmed":1,
            "revenue_surprise":"212000000.0000",
            "eps_surprise_percent":"0.1039",
            "revenue_surprise_percent":"0.0415"
         },
         "prev_quarter_earnings":{
            "id":"5ebb9b320f28ed00017097e3",
            "eps":"0.880",
            "date":"2021-05-05",
            "name":"Novo Nordisk",
            "time":"08:00:00",
            "notes":"FXC",
            "period":"Q1",
            "ticker":"NVO",
            "eps_est":"0.830",
            "revenue":"5480000000.000",
            "updated":1620255321,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NYSE",
            "eps_prior":"0.760",
            "importance":3,
            "period_year":2021,
            "revenue_est":"5290000000.000",
            "eps_surprise":"0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"5081000000.000",
            "date_confirmed":1,
            "revenue_surprise":"190000000.0000",
            "eps_surprise_percent":"0.0602",
            "revenue_surprise_percent":"0.0359"
         },
         "cash_equivalents_and_short_term_investments":27216000000,
         "operating_cash_flow":25255000000,
         "monthly_cash_burn":8418333333,
         "est_live_cash":42088388888,
         "est_months_cash":4.9996106382498358,
         "total_liabilities":92536000000,
         "net_cash":-50447611112,
         "enterpriseValue":242708508104,
         "total_debt_to_equity":0.20999999999999999,
         "float":2291903114,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"16/06/2021"
   },
   {
      "id":5636,
      "name":"Oral amphotericin b (MAT2203) - (EnACT)",
      "craft_entry_id":25305,
      "indication":"Cryptococcal meningitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.matinasbiopharma.com/investors/news-events/press-releases/detail/401/matinas-biopharma-reports-second-quarter-2021-financial",
      "catalyst_date_text":"September 2021",
      "note":"Phase 1/2 DSMB evaluation of safety and efficacy data due September 2021.",
      "estimated_primary_completion_date":"May 2022",
      "updated_at":"2021-08-10 06:36:03",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":405,
         "ticker":"MTNB",
         "name":"Matinas Biopharma Holdings Inc.",
         "exchange":null,
         "price":0.67000000000000004,
         "change":-0.010000000000000009,
         "percent_change":-0.89000000000000001,
         "number_of_shares":214741422,
         "market_cap":143919701,
         "short_ratio":null,
         "volume":1197204,
         "average_daily_volume":1099170,
         "relative_volume":1.0900000000000001,
         "price_to_book":2.3100000000000001,
         "open":0.68000000000000005,
         "previous_close":0.68000000000000005,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Meningitis"
      ],
      "cashflow":{
         "id":328,
         "ticker":"MTNB",
         "earnings":{
            "id":"5f30f0aea7bff3000162b2d7",
            "eps":"-0.020",
            "date":"2021-08-10",
            "name":"Matinas BioPharma Hldgs",
            "time":"06:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"MTNB",
            "eps_est":"-0.030",
            "revenue":"0.000",
            "updated":1628592007,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"AMEX",
            "eps_prior":"-0.030",
            "importance":0,
            "period_year":2021,
            "revenue_est":"30000.000",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"-30000.0000",
            "eps_surprise_percent":"0.3333",
            "revenue_surprise_percent":"-1.0000"
         },
         "prev_quarter_earnings":{
            "id":"5ed9edaee60b06000150518d",
            "eps":"-0.030",
            "date":"2021-05-10",
            "name":"Matinas BioPharma Hldgs",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"MTNB",
            "eps_est":"-0.030",
            "revenue":"33333.000",
            "updated":1620644077,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"AMEX",
            "eps_prior":"-0.030",
            "importance":0,
            "period_year":2021,
            "revenue_est":"20000.000",
            "eps_surprise":"0.0000",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"13333.0000",
            "eps_surprise_percent":"0.0000",
            "revenue_surprise_percent":"0.6666"
         },
         "cash_equivalents_and_short_term_investments":59842789,
         "operating_cash_flow":-864655,
         "monthly_cash_burn":-288218,
         "est_live_cash":59333603,
         "est_months_cash":205.86362753193762,
         "total_liabilities":7067579,
         "net_cash":52266024,
         "enterpriseValue":87590029,
         "total_debt_to_equity":0.059999999999999998,
         "float":206957714,
         "insiderholdingspct":5.5
      },
      "updated_at_formatted":"10/08/2021"
   },
   {
      "id":6669,
      "name":"BLU-5937 (SOOTHE)",
      "craft_entry_id":48956,
      "indication":"Chronic cough",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.benzinga.com/pressreleases/21/08/b22454325/bellus-health-reports-second-quarter-2021-financial-results-and-business-highlights",
      "catalyst_date_text":"September 2021",
      "note":"Phase 2b initiation announced December 8, 2020. Administrative interim analysis expected September 2021, with top-line results expected 4Q 2021",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-11 18:59:13",
      "stage":{
         "id":7,
         "label":"Phase 2b",
         "value":"phase2b"
      },
      "companies":{
         "id":758,
         "ticker":"BLU",
         "name":"BELLUS Health Inc.",
         "exchange":null,
         "price":3.0499999999999998,
         "change":0.02,
         "percent_change":0.66000000000000003,
         "number_of_shares":78337361,
         "market_cap":238928951,
         "short_ratio":null,
         "volume":226787,
         "average_daily_volume":419149,
         "relative_volume":0.54000000000000004,
         "price_to_book":2.0699999999999998,
         "open":3.1299999999999999,
         "previous_close":3.0299999999999998,
         "created_at":"2020-05-26T12:49:44.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Chronic cough"
      ],
      "cashflow":{
         "id":623,
         "ticker":"BLU",
         "earnings":{
            "id":"5f36368363170b0001c87833",
            "eps":"-0.230",
            "date":"2021-08-11",
            "name":"BELLUS Health",
            "time":"16:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"BLU",
            "eps_est":"",
            "revenue":"4000.000",
            "updated":1628722013,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.140",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"4000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ebe3e0254da7600011d024f",
            "eps":"-0.200",
            "date":"2021-05-10",
            "name":"BELLUS Health",
            "time":"16:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"BLU",
            "eps_est":"",
            "revenue":"4000.000",
            "updated":1620683429,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.180",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"4000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":72333000,
         "operating_cash_flow":-9681000,
         "monthly_cash_burn":-3227000,
         "est_live_cash":66631966,
         "est_months_cash":20.648269600247907,
         "total_liabilities":9778000,
         "net_cash":56853966,
         "enterpriseValue":164773403,
         "total_debt_to_equity":0,
         "float":78337361,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"11/08/2021"
   },
   {
      "id":7439,
      "name":"Tebentafusp",
      "craft_entry_id":87142,
      "indication":"Uveal melanoma",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://ir.immunocore.com/news-releases/news-release-details/immunocore-reports-second-quarter-2021-financial-results-and",
      "catalyst_date_text":"",
      "note":"BLA filing due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-11 07:13:59",
      "stage":{
         "id":12,
         "label":"BLA Filing",
         "value":"blaFiling"
      },
      "companies":{
         "id":880,
         "ticker":"IMCR",
         "name":"Immunocore Holdings plc",
         "exchange":null,
         "price":27.98,
         "change":-0.020000000000000018,
         "percent_change":-0.069999999999999951,
         "number_of_shares":43786088,
         "market_cap":1225134742,
         "short_ratio":null,
         "volume":38523,
         "average_daily_volume":65925,
         "relative_volume":0.57999999999999996,
         "price_to_book":4.0099999999999998,
         "open":28.210000000000001,
         "previous_close":28,
         "created_at":"2021-02-03T00:14:15.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Melanoma"
      ],
      "cashflow":{
         "id":741,
         "ticker":"IMCR",
         "earnings":{
            "id":"6021492e879cba00013656f3",
            "eps":"-1.450",
            "date":"2021-08-11",
            "name":"Immunocore Holdings",
            "time":"07:00:00",
            "notes":"FXC",
            "period":"Q2",
            "ticker":"IMCR",
            "eps_est":"-0.950",
            "revenue":"11060000.000",
            "updated":1628760103,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"7690000.000",
            "eps_surprise":"-0.5000",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"3370000.0000",
            "eps_surprise_percent":"-0.5263",
            "revenue_surprise_percent":"0.4382"
         },
         "prev_quarter_earnings":{
            "id":"6021492f879cba00013656f5",
            "eps":"-1.040",
            "date":"2021-05-12",
            "name":"Immunocore Holdings",
            "time":"09:22:39",
            "notes":"",
            "period":"Q1",
            "ticker":"IMCR",
            "eps_est":"",
            "revenue":"11408000.000",
            "updated":1620916950,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":278870000,
         "operating_cash_flow":-32596000,
         "monthly_cash_burn":-10865333,
         "est_live_cash":259674578,
         "est_months_cash":23.899366729027079,
         "total_liabilities":130874000,
         "net_cash":128800578,
         "enterpriseValue":931195324,
         "total_debt_to_equity":0.28000000000000003,
         "float":43786088,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"11/08/2021"
   },
   {
      "id":2324,
      "name":"Etranacogene dezaparvovec (AMT-061) - HOPE-B",
      "craft_entry_id":10418,
      "indication":"Hemophilia B",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3936723&lang=en-GB&companycode=nl-qure&v=",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 top-line data released June 22, 2021. FIX levels sustained at a mean of 41.5% at 52 weeks. 78-week follow-up visits to be completed 3Q 2021 at which point the non-inferiority analysis of annualized bleeding rates (ABR) for the primary endpoint will be conducted. BLA filing due 1Q 2022.",
      "estimated_primary_completion_date":"March 2021",
      "updated_at":"2021-07-26 07:20:36",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":257,
         "ticker":"QURE",
         "name":"uniQure N.V.",
         "exchange":null,
         "price":26.800000000000001,
         "change":0.31,
         "percent_change":1.1699999999999999,
         "number_of_shares":46073373,
         "market_cap":1234766396,
         "short_ratio":null,
         "volume":735863,
         "average_daily_volume":382927,
         "relative_volume":1.9199999999999999,
         "price_to_book":1.95,
         "open":26.649999999999999,
         "previous_close":26.489999999999998,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Hemophilia",
         "Hemophilia B"
      ],
      "cashflow":{
         "id":201,
         "ticker":"QURE",
         "earnings":{
            "id":"5f23c444bcf9e90001c5d01d",
            "eps":"8.510",
            "date":"2021-07-26",
            "name":"uniQure",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"QURE",
            "eps_est":"2.960",
            "revenue":"463868000.000",
            "updated":1627302243,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.960",
            "importance":1,
            "period_year":2021,
            "revenue_est":"190020000.000",
            "eps_surprise":"5.5500",
            "revenue_type":"GAAP",
            "revenue_prior":"1535000.000",
            "date_confirmed":1,
            "revenue_surprise":"273848000.0000",
            "eps_surprise_percent":"1.8750",
            "revenue_surprise_percent":"1.4412"
         },
         "prev_quarter_earnings":{
            "id":"5eaa77c7981f9a00015741cd",
            "eps":"-0.910",
            "date":"2021-05-10",
            "name":"uniQure",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"QURE",
            "eps_est":"1.580",
            "revenue":"454000.000",
            "updated":1620719387,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.630",
            "importance":0,
            "period_year":2021,
            "revenue_est":"118890000",
            "eps_surprise":"-2.4900",
            "revenue_type":"GAAP",
            "revenue_prior":"104000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-1.5759",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":677330000,
         "operating_cash_flow":416479000,
         "monthly_cash_burn":138826333,
         "est_live_cash":922589854,
         "est_months_cash":6.6456401610780862,
         "total_liabilities":150656000,
         "net_cash":771933854,
         "enterpriseValue":664502396,
         "total_debt_to_equity":0.17000000000000001,
         "float":45794257,
         "insiderholdingspct":2.6000000000000001
      },
      "updated_at_formatted":"26/07/2021"
   },
   {
      "id":7221,
      "name":"GB-102 (ALTISSIMO)",
      "craft_entry_id":74021,
      "indication":"Wet age-related macular degeneration",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.benzinga.com/pressreleases/21/08/g22453150/graybug-vision-announces-financial-results-for-the-three-and-six-months-ended-june-30-2021-and-rec",
      "catalyst_date_text":"September 2021",
      "note":"Phase 2b data released March 9, 2021. BCVA approx 9 letters lower across all time points, on average, than that observed in the control (aflibercept) arm. Extension trial top-line data due September 2021. 12-month data to be presented at AAO meeting, November 12-15, 2021.",
      "estimated_primary_completion_date":"December 15, 2020",
      "updated_at":"2021-08-11 18:56:29",
      "stage":{
         "id":7,
         "label":"Phase 2b",
         "value":"phase2b"
      },
      "companies":{
         "id":848,
         "ticker":"GRAY",
         "name":"Graybug Vision Inc.",
         "exchange":null,
         "price":3.52,
         "change":-0.030000000000000027,
         "percent_change":-0.84999999999999998,
         "number_of_shares":21284676,
         "market_cap":74922060,
         "short_ratio":null,
         "volume":142115,
         "average_daily_volume":2506627,
         "relative_volume":0.059999999999999998,
         "price_to_book":0.94999999999999996,
         "open":3.5499999999999998,
         "previous_close":3.5499999999999998,
         "created_at":"2020-11-13T13:35:36.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Wet age-related macular degeneration (AMD)"
      ],
      "cashflow":{
         "id":711,
         "ticker":"GRAY",
         "earnings":{
            "id":"5f75d3c5a442ba0001d9f16d",
            "eps":"-0.360",
            "date":"2021-08-11",
            "name":"Graybug Vision",
            "time":"16:51:00",
            "notes":"",
            "period":"Q2",
            "ticker":"GRAY",
            "eps_est":"-0.470",
            "revenue":"0.000",
            "updated":1628759538,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-6.790",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.1100",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.2340",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5f75d3c6a442ba0001d9f16f",
            "eps":"-0.540",
            "date":"2021-05-12",
            "name":"Graybug Vision",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"GRAY",
            "eps_est":"-0.470",
            "revenue":"0.000",
            "updated":1620894751,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0700",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.1489",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":73586000,
         "operating_cash_flow":-7781000,
         "monthly_cash_burn":-2593666,
         "est_live_cash":69003856,
         "est_months_cash":26.60475789866544,
         "total_liabilities":4154000,
         "net_cash":64849856,
         "enterpriseValue":1336059,
         "total_debt_to_equity":"",
         "float":11762794,
         "insiderholdingspct":0
      },
      "updated_at_formatted":"11/08/2021"
   },
   {
      "id":5174,
      "name":"ALXN1840 (WTX101)",
      "craft_entry_id":20289,
      "indication":"Wilson disease",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210430005085/en/",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 top-line data due 3Q 2021.",
      "estimated_primary_completion_date":"February 2021",
      "updated_at":"2021-08-12 00:52:33",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":374,
         "ticker":"AZN",
         "name":"AstraZeneca PLC",
         "exchange":null,
         "price":59.390000000000001,
         "change":0.20000000000000001,
         "percent_change":0.34000000000000002,
         "number_of_shares":3098232698,
         "market_cap":184004039934,
         "short_ratio":null,
         "volume":3501974,
         "average_daily_volume":11668460,
         "relative_volume":0.29999999999999999,
         "price_to_book":11.74,
         "open":59.329999999999998,
         "previous_close":59.189999999999998,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Wilson disease"
      ],
      "cashflow":{
         "id":298,
         "ticker":"AZN",
         "earnings":{
            "id":"5f22702244c96f00014e75f3",
            "eps":"0.450",
            "date":"2021-07-29",
            "name":"AstraZeneca",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"AZN",
            "eps_est":"0.430",
            "revenue":"8220000000.000",
            "updated":1627572614,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"0.480",
            "importance":5,
            "period_year":2021,
            "revenue_est":"7360000000.000",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"6275000000.000",
            "date_confirmed":1,
            "revenue_surprise":"860000000.0000",
            "eps_surprise_percent":"0.0465",
            "revenue_surprise_percent":"0.1168"
         },
         "prev_quarter_earnings":{
            "id":"5ea926020561160001c22d50",
            "eps":"0.820",
            "date":"2021-04-30",
            "name":"AstraZeneca",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"AZN",
            "eps_est":"0.750",
            "revenue":"7320000000.000",
            "updated":1619776693,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"1.050",
            "importance":5,
            "period_year":2021,
            "revenue_est":"7080000000.000",
            "eps_surprise":"0.0700",
            "revenue_type":"GAAP",
            "revenue_prior":"6354000000.000",
            "date_confirmed":1,
            "revenue_surprise":"240000000.0000",
            "eps_surprise_percent":"0.0933",
            "revenue_surprise_percent":"0.0339"
         },
         "cash_equivalents_and_short_term_investments":15629000000,
         "operating_cash_flow":892000000,
         "monthly_cash_burn":297333333,
         "est_live_cash":16154288888,
         "est_months_cash":54.330568069877316,
         "total_liabilities":57948000000,
         "net_cash":-41793711112,
         "enterpriseValue":196212222162,
         "total_debt_to_equity":1.75,
         "float":3096187832,
         "insiderholdingspct":0.10000000000000001
      },
      "updated_at_formatted":"12/08/2021"
   },
   {
      "id":3641,
      "name":"MARGENZA (margetuximab)",
      "craft_entry_id":2315,
      "indication":"Metastatic breast cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":1,
      "press_link":"http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-5",
      "catalyst_date_text":"3Q 2021",
      "note":"FDA approval announced December 16, 2020. Final overall survival data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-07-29 16:45:35",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":197,
         "ticker":"MGNX",
         "name":"MacroGenics Inc.",
         "exchange":null,
         "price":21.98,
         "change":0.29999999999999999,
         "percent_change":1.3799999999999999,
         "number_of_shares":61107288,
         "market_cap":1343138190,
         "short_ratio":null,
         "volume":468799,
         "average_daily_volume":644591,
         "relative_volume":0.72999999999999998,
         "price_to_book":4.21,
         "open":21.510000000000002,
         "previous_close":21.68,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Breast cancer",
         "Oncology"
      ],
      "cashflow":{
         "id":160,
         "ticker":"MGNX",
         "earnings":{
            "id":"5f2270dc44c96f00014e7787",
            "eps":"-0.660",
            "date":"2021-07-29",
            "name":"Macrogenics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"MGNX",
            "eps_est":"-0.460",
            "revenue":"30757000.000",
            "updated":1627590316,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.940",
            "importance":0,
            "period_year":2021,
            "revenue_est":"30030000.000",
            "eps_surprise":"-0.2000",
            "revenue_type":"GAAP",
            "revenue_prior":"20257000.000",
            "date_confirmed":1,
            "revenue_surprise":"727000.0000",
            "eps_surprise_percent":"-0.4348",
            "revenue_surprise_percent":"0.0242"
         },
         "prev_quarter_earnings":{
            "id":"5eb10f3613dffb0001540c81",
            "eps":"-0.900",
            "date":"2021-04-29",
            "name":"Macrogenics",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"MGNX",
            "eps_est":"-0.610",
            "revenue":"16881000.000",
            "updated":1619729300,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.910",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.2900",
            "revenue_type":"GAAP",
            "revenue_prior":"13682000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.4754",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":297316000,
         "operating_cash_flow":-45690000,
         "monthly_cash_burn":-15230000,
         "est_live_cash":270409666,
         "est_months_cash":17.75506671043992,
         "total_liabilities":106866000,
         "net_cash":163543666,
         "enterpriseValue":1073397190,
         "total_debt_to_equity":0.089999999999999997,
         "float":59522546,
         "insiderholdingspct":2.3999999999999999
      },
      "updated_at_formatted":"29/07/2021"
   },
   {
      "id":3641,
      "name":"MARGENZA (margetuximab)",
      "craft_entry_id":2315,
      "indication":"Metastatic breast cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":1,
      "press_link":"http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-5",
      "catalyst_date_text":"3Q 2021",
      "note":"FDA approval announced December 16, 2020. Final overall survival data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-07-29 16:45:35",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":484,
         "ticker":"ZLAB",
         "name":"Zai Lab Limited",
         "exchange":null,
         "price":134.16999999999999,
         "change":4.1699999999999999,
         "percent_change":3.21,
         "number_of_shares":75375511,
         "market_cap":10113132311,
         "short_ratio":null,
         "volume":968918,
         "average_daily_volume":536617,
         "relative_volume":1.8100000000000001,
         "price_to_book":31.199999999999999,
         "open":127,
         "previous_close":130,
         "created_at":"2018-01-24T06:32:57.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Breast cancer",
         "Oncology"
      ],
      "cashflow":{
         "id":392,
         "ticker":"ZLAB",
         "earnings":{
            "id":"6087b6c95df3990001db17a9",
            "eps":"-1.760",
            "date":"2021-08-09",
            "name":"Zai Lab",
            "time":"16:00:00",
            "notes":"",
            "period":"H1",
            "ticker":"ZLAB",
            "eps_est":"-1.300",
            "revenue":"36935000.000",
            "updated":1628545101,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.370",
            "importance":0,
            "period_year":2021,
            "revenue_est":"28260000.000",
            "eps_surprise":"-0.4600",
            "revenue_type":"GAAP",
            "revenue_prior":"3420000.000",
            "date_confirmed":1,
            "revenue_surprise":"8675000.0000",
            "eps_surprise_percent":"-0.3538",
            "revenue_surprise_percent":"0.3070"
         },
         "prev_quarter_earnings":{
            "id":"609a847af7862d0001457cde",
            "eps":"-2.640",
            "date":"2021-05-10",
            "name":"Zai Lab",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ZLAB",
            "eps_est":"-1.350",
            "revenue":"20103000.000",
            "updated":1620740689,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"32600000.000",
            "eps_surprise":"-1.2900",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"-12497000.0000",
            "eps_surprise_percent":"-0.9556",
            "revenue_surprise_percent":"-0.3833"
         },
         "cash_equivalents_and_short_term_investments":1766573000,
         "operating_cash_flow":-65848000,
         "monthly_cash_burn":-21949333,
         "est_live_cash":1727795845,
         "est_months_cash":78.717464671933314,
         "total_liabilities":223517000,
         "net_cash":1504278845,
         "enterpriseValue":1783381173,
         "total_debt_to_equity":0.01,
         "float":75375511,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"29/07/2021"
   },
   {
      "id":7485,
      "name":"Sarconeos (BIO101) - COVA",
      "craft_entry_id":89123,
      "indication":"COVID-19",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.biophytis.com/en/august-16-2021/",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2 second interim analysis 3Q 2021",
      "estimated_primary_completion_date":"July 2021",
      "updated_at":"2021-08-16 08:03:14",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":893,
         "ticker":"BPTS",
         "name":"Biophytis SA",
         "exchange":null,
         "price":8.4900000000000002,
         "change":0,
         "percent_change":null,
         "number_of_shares":12207947,
         "market_cap":103645470,
         "short_ratio":null,
         "volume":4,
         "average_daily_volume":2405,
         "relative_volume":0,
         "price_to_book":12.859999999999999,
         "open":null,
         "previous_close":8.4900000000000002,
         "created_at":"2021-02-10T21:54:26.000000Z",
         "updated_at":"2021-08-20T23:55:05.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Coronavirus",
         "COVID-19"
      ],
      "cashflow":{
         "id":756,
         "ticker":"BPTS",
         "earnings":{
            "id":"602679fcd522ea0001c1c4b2",
            "eps":"",
            "date":"2021-09-03",
            "name":"Biophytis",
            "time":"07:52:12",
            "notes":"",
            "period":"Q1",
            "ticker":"BPTS",
            "eps_est":"",
            "revenue":"",
            "updated":1629525614,
            "currency":"USD",
            "eps_type":"",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"",
            "revenue_prior":"",
            "date_confirmed":0,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"602679fdd522ea0001c1c4b4",
            "eps":"-1.280",
            "date":"2021-02-26",
            "name":"Biophytis",
            "time":"02:00:00",
            "notes":"",
            "period":"FY",
            "ticker":"BPTS",
            "eps_est":"",
            "revenue":"0.000",
            "updated":1622545368,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2020,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":18771000,
         "operating_cash_flow":null,
         "monthly_cash_burn":null,
         "est_live_cash":19958613,
         "est_months_cash":null,
         "total_liabilities":20378000,
         "net_cash":-419387,
         "enterpriseValue":91448301,
         "total_debt_to_equity":1.3300000000000001,
         "float":12207947,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"16/08/2021"
   },
   {
      "id":2112,
      "name":"Linzagolix (OBE2109)",
      "craft_entry_id":13928,
      "indication":"Uterine fibroids",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":1,
      "press_link":"https://ml-eu.globenewswire.com/Resource/Download/b4635e4d-f1fd-44fa-8dc6-5444bf128711",
      "catalyst_date_text":"3Q 2021",
      "note":"NDA filing due 3Q 2021.",
      "estimated_primary_completion_date":"September 16, 2019",
      "updated_at":"2021-08-05 06:19:35",
      "stage":{
         "id":10,
         "label":"NDA Filing",
         "value":"ndaFiling"
      },
      "companies":{
         "id":395,
         "ticker":"OBSV",
         "name":"ObsEva SA",
         "exchange":null,
         "price":2.5699999999999998,
         "change":0.080000000000000002,
         "percent_change":3.21,
         "number_of_shares":77950431,
         "market_cap":200332608,
         "short_ratio":null,
         "volume":568147,
         "average_daily_volume":2084273,
         "relative_volume":0.27000000000000002,
         "price_to_book":4.8499999999999996,
         "open":2.54,
         "previous_close":2.4900000000000002,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Uterine Fibroids"
      ],
      "cashflow":{
         "id":319,
         "ticker":"OBSV",
         "earnings":{
            "id":"5f2cfc34a3eee500019e8f33",
            "eps":"-0.280",
            "date":"2021-08-05",
            "name":"ObsEva",
            "time":"01:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"OBSV",
            "eps_est":"-0.250",
            "revenue":"4000.000",
            "updated":1628170333,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"0.380",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"4000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.1200",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eb6553384a80a00018b4444",
            "eps":"-0.290",
            "date":"2021-05-06",
            "name":"ObsEva",
            "time":"01:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"OBSV",
            "eps_est":"-0.250",
            "revenue":"6000.000",
            "updated":1622538090,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.480",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0400",
            "revenue_type":"GAAP",
            "revenue_prior":"4000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.1600",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":58923000,
         "operating_cash_flow":-18769000,
         "monthly_cash_burn":-6256333,
         "est_live_cash":47870145,
         "est_months_cash":7.6514701183584695,
         "total_liabilities":53558000,
         "net_cash":-5687855,
         "enterpriseValue":168189607,
         "total_debt_to_equity":0.64000000000000001,
         "float":64232245,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":7232,
      "name":"PTC518",
      "craft_entry_id":74489,
      "indication":"Healthy volunteers",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-a-corporate-update-and-reports-second-quarter-2021-financial-results-301344644.html",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1 trial data due 3Q 2021. Phase 2 trial to be initiated YE 2021. ",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-07-29 16:35:26",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":251,
         "ticker":"PTCT",
         "name":"PTC Therapeutics Inc.",
         "exchange":null,
         "price":38.200000000000003,
         "change":1.1899999999999999,
         "percent_change":3.2200000000000002,
         "number_of_shares":70604925,
         "market_cap":2697108135,
         "short_ratio":null,
         "volume":464039,
         "average_daily_volume":412722,
         "relative_volume":1.1200000000000001,
         "price_to_book":13.74,
         "open":36.899999999999999,
         "previous_close":37.009999999999998,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         
      ],
      "cashflow":{
         "id":197,
         "ticker":"PTCT",
         "earnings":{
            "id":"5f2a5acafa4662000194a07a",
            "eps":"-1.680",
            "date":"2021-07-29",
            "name":"PTC Therapeutics",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"PTCT",
            "eps_est":"-1.820",
            "revenue":"116676000.000",
            "updated":1627590024,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-2.620",
            "importance":0,
            "period_year":2021,
            "revenue_est":"110500000.000",
            "eps_surprise":"0.1400",
            "revenue_type":"GAAP",
            "revenue_prior":"75239000.000",
            "date_confirmed":1,
            "revenue_surprise":"6176000.0000",
            "eps_surprise_percent":"0.0769",
            "revenue_surprise_percent":"0.0559"
         },
         "prev_quarter_earnings":{
            "id":"5eaa77c6981f9a00015741c5",
            "eps":"-1.830",
            "date":"2021-05-04",
            "name":"PTC Therapeutics",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"PTCT",
            "eps_est":"-1.510",
            "revenue":"117942000.000",
            "updated":1620159149,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.810",
            "importance":0,
            "period_year":2021,
            "revenue_est":"98800000.000",
            "eps_surprise":"-0.3200",
            "revenue_type":"GAAP",
            "revenue_prior":"68259000.000",
            "date_confirmed":1,
            "revenue_surprise":"19142000.0000",
            "eps_surprise_percent":"-0.2119",
            "revenue_surprise_percent":"0.1937"
         },
         "cash_equivalents_and_short_term_investments":947081000,
         "operating_cash_flow":-31145000,
         "monthly_cash_burn":-10381666,
         "est_live_cash":928740056,
         "est_months_cash":89.459635476618104,
         "total_liabilities":1862092000,
         "net_cash":-933351944,
         "enterpriseValue":2286457135,
         "total_debt_to_equity":2.73,
         "float":49392128,
         "insiderholdingspct":0.90000000000000002
      },
      "updated_at_formatted":"29/07/2021"
   },
   {
      "id":7497,
      "name":"Lomecel-B (HERA)",
      "craft_entry_id":89490,
      "indication":"Aging Frailty",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.longeveron.com/news/News/news-details/2021/Longeveron-Inc.-Provides-Corporate-Update-and-Reports-Second-Quarter-2021-Financial-Results/default.aspx",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2 data due 3Q 2021.",
      "estimated_primary_completion_date":"April 2021",
      "updated_at":"2021-08-13 07:28:02",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":897,
         "ticker":"LGVN",
         "name":"Longeveron Inc.",
         "exchange":null,
         "price":3.5699999999999998,
         "change":-0.22999999999999998,
         "percent_change":-6.0499999999999998,
         "number_of_shares":19114630,
         "market_cap":68239229,
         "short_ratio":null,
         "volume":141941,
         "average_daily_volume":170986,
         "relative_volume":0.82999999999999996,
         "price_to_book":2.77,
         "open":3.7999999999999998,
         "previous_close":3.7999999999999998,
         "created_at":"2021-02-12T01:10:23.000000Z",
         "updated_at":"2021-08-20T23:55:05.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Aging Frailty"
      ],
      "cashflow":{
         "id":760,
         "ticker":"LGVN",
         "earnings":{
            "id":"602f724c5864de0001cb780b",
            "eps":"-0.260",
            "date":"2021-08-13",
            "name":"Longeveron",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"LGVN",
            "eps_est":"",
            "revenue":"489000.000",
            "updated":1628853491,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"602f724c5864de0001cb780d",
            "eps":"-0.180",
            "date":"2021-05-14",
            "name":"Longeveron",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"LGVN",
            "eps_est":"",
            "revenue":"376000.000",
            "updated":1620994708,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":21388000,
         "operating_cash_flow":-2952000,
         "monthly_cash_burn":-984000,
         "est_live_cash":19649600,
         "est_months_cash":19.96910569105691,
         "total_liabilities":5207000,
         "net_cash":14442600,
         "enterpriseValue":50402228,
         "total_debt_to_equity":0.14000000000000001,
         "float":3279966,
         "insiderholdingspct":45.399999999999999
      },
      "updated_at_formatted":"13/08/2021"
   },
   {
      "id":6475,
      "name":"CERC-006",
      "craft_entry_id":43313,
      "indication":"Lymphatic Malformations",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://ir.cerecor.com/press-releases/detail/133/cerecor-reports-second-quarter-2021-financial-results-and",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1/2 data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-02 16:29:14",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":85,
         "ticker":"CERC",
         "name":"Cerecor Inc.",
         "exchange":null,
         "price":2.77,
         "change":0.12,
         "percent_change":4.5300000000000002,
         "number_of_shares":96008951,
         "market_cap":265944794,
         "short_ratio":null,
         "volume":398177,
         "average_daily_volume":600170,
         "relative_volume":0.66000000000000003,
         "price_to_book":12.59,
         "open":2.6200000000000001,
         "previous_close":2.6499999999999999,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Lymphatic Malformations (LMs)"
      ],
      "cashflow":{
         "id":69,
         "ticker":"CERC",
         "earnings":{
            "id":"5f2cfc0aa3eee500019e8e7b",
            "eps":"-0.180",
            "date":"2021-08-02",
            "name":"Cerecor",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CERC",
            "eps_est":"-0.160",
            "revenue":"3355000.000",
            "updated":1627996891,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.180",
            "importance":0,
            "period_year":2021,
            "revenue_est":"4200000.000",
            "eps_surprise":"-0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"1338000.000",
            "date_confirmed":1,
            "revenue_surprise":"-845000.0000",
            "eps_surprise_percent":"-0.1250",
            "revenue_surprise_percent":"-0.2012"
         },
         "prev_quarter_earnings":{
            "id":"5eb5038af857860001768c2e",
            "eps":"-0.320",
            "date":"2021-05-13",
            "name":"Cerecor",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"CERC",
            "eps_est":"-0.160",
            "revenue":"473000.000",
            "updated":1620978808,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.360",
            "importance":0,
            "period_year":2021,
            "revenue_est":"4200000.000",
            "eps_surprise":"-0.1600",
            "revenue_type":"GAAP",
            "revenue_prior":"2754000.000",
            "date_confirmed":1,
            "revenue_surprise":"-3727000.0000",
            "eps_surprise_percent":"-1.0000",
            "revenue_surprise_percent":"-0.8874"
         },
         "cash_equivalents_and_short_term_investments":40435000,
         "operating_cash_flow":-19187000,
         "monthly_cash_burn":-6395666,
         "est_live_cash":29135990,
         "est_months_cash":4.5555834216483477,
         "total_liabilities":42497000,
         "net_cash":-13361010,
         "enterpriseValue":246423080,
         "total_debt_to_equity":0.81000000000000005,
         "float":56006748,
         "insiderholdingspct":2.7999999999999998
      },
      "updated_at_formatted":"02/08/2021"
   },
   {
      "id":3661,
      "name":"Roluperidone (MIN-101)",
      "craft_entry_id":2356,
      "indication":"Schizophrenia",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-reports-second-quarter-2021-financial",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 data did not meet primary endpoint - May 29, 2020. Top-line data from pivotal bioequivalence study due 3Q 2021.",
      "estimated_primary_completion_date":"May 26, 2020",
      "updated_at":"2021-08-02 07:50:22",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":211,
         "ticker":"NERV",
         "name":"Minerva Neurosciences Inc",
         "exchange":null,
         "price":1.8300000000000001,
         "change":0.029999999999999999,
         "percent_change":1.6699999999999999,
         "number_of_shares":42721566,
         "market_cap":78180466,
         "short_ratio":null,
         "volume":499054,
         "average_daily_volume":624274,
         "relative_volume":0.80000000000000004,
         "price_to_book":2.1499999999999999,
         "open":1.8199999999999998,
         "previous_close":1.8,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Schizophrenia"
      ],
      "cashflow":{
         "id":171,
         "ticker":"NERV",
         "earnings":{
            "id":"5f27b73db052b30001c1d0a5",
            "eps":"-0.250",
            "date":"2021-08-02",
            "name":"Minerva Neurosciences",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"NERV",
            "eps_est":"-0.170",
            "revenue":"0.000",
            "updated":1627903966,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"0.730",
            "importance":0,
            "period_year":2021,
            "revenue_est":"570000.000",
            "eps_surprise":"-0.0800",
            "revenue_type":"GAAP",
            "revenue_prior":"41176000.000",
            "date_confirmed":1,
            "revenue_surprise":"-570000.0000",
            "eps_surprise_percent":"-0.4706",
            "revenue_surprise_percent":"-1.0000"
         },
         "prev_quarter_earnings":{
            "id":"5eafc3af39af700001db26f8",
            "eps":"-0.210",
            "date":"2021-05-12",
            "name":"Minerva Neurosciences",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"NERV",
            "eps_est":"",
            "revenue":"0.000",
            "updated":1620820630,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.310",
            "importance":0,
            "period_year":2021,
            "revenue_est":"30000000.000",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"-30000000.0000",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":"-1.0000"
         },
         "cash_equivalents_and_short_term_investments":74214767,
         "operating_cash_flow":-5924826,
         "monthly_cash_burn":-1974942,
         "est_live_cash":70725702,
         "est_months_cash":35.811533705799967,
         "total_liabilities":69155661,
         "net_cash":1570041,
         "enterpriseValue":3981986,
         "total_debt_to_equity":"",
         "float":25628585,
         "insiderholdingspct":1.7
      },
      "updated_at_formatted":"02/08/2021"
   },
   {
      "id":6221,
      "name":"Avasopasem (GC4419)",
      "craft_entry_id":34290,
      "indication":"Pancreatic cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.galeratx.com/news-releases/news-release-details/galera-reports-second-quarter-2021-financial-results-and-recent",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1b/2a median overall survival (OS) 20.1 months compared to 10.9 months for placebo - April 28, 2021. No statistically significant differences in progression-free survival (PFS) compared with placebo (HR=0.6; p=0.29) - October 27, 2020. Final data due 3Q 2021.",
      "estimated_primary_completion_date":"August 26, 2020",
      "updated_at":"2021-08-10 07:51:29",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":719,
         "ticker":"GRTX",
         "name":"Galera Therapeutics Inc.",
         "exchange":null,
         "price":8.4600000000000009,
         "change":0.46999999999999997,
         "percent_change":5.8799999999999999,
         "number_of_shares":26365632,
         "market_cap":223053247,
         "short_ratio":null,
         "volume":42276,
         "average_daily_volume":127097,
         "relative_volume":0.33000000000000002,
         "price_to_book":-8.7200000000000006,
         "open":7.8700000000000001,
         "previous_close":7.9900000000000002,
         "created_at":"2019-11-13T09:07:03.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Pancreatic cancer"
      ],
      "cashflow":{
         "id":586,
         "ticker":"GRTX",
         "earnings":{
            "id":"5f339399b7c159000133e791",
            "eps":"-0.880",
            "date":"2021-08-10",
            "name":"Galera Therapeutics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"GRTX",
            "eps_est":"-0.830",
            "revenue":"0.000",
            "updated":1628595916,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.750",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.0602",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ebb9b1a0f28ed0001709797",
            "eps":"-0.750",
            "date":"2021-05-11",
            "name":"Galera Therapeutics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"GRTX",
            "eps_est":"-0.880",
            "revenue":"0.000",
            "updated":1620804389,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.740",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.1300",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.1477",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":66527000,
         "operating_cash_flow":-16805000,
         "monthly_cash_burn":-5601666,
         "est_live_cash":56630723,
         "est_months_cash":10.10962149474817,
         "total_liabilities":140786000,
         "net_cash":-84155277,
         "enterpriseValue":156982246,
         "total_debt_to_equity":0.089999999999999997,
         "float":15528662,
         "insiderholdingspct":1.3999999999999999
      },
      "updated_at_formatted":"10/08/2021"
   },
   {
      "id":3408,
      "name":"Betibeglogene autotemcel (beti-cel) (LentiGlobin)",
      "craft_entry_id":1898,
      "indication":"\u03b2-Thalassemia",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210809005334/en/",
      "catalyst_date_text":"3Q 2021",
      "note":"BLA filing to be completed 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-09 08:44:22",
      "stage":{
         "id":12,
         "label":"BLA Filing",
         "value":"blaFiling"
      },
      "companies":{
         "id":68,
         "ticker":"BLUE",
         "name":"bluebird bio Inc.",
         "exchange":null,
         "price":17.59,
         "change":0.23000000000000001,
         "percent_change":1.3200000000000001,
         "number_of_shares":67578549,
         "market_cap":1188706677,
         "short_ratio":null,
         "volume":928255,
         "average_daily_volume":1493022,
         "relative_volume":0.62,
         "price_to_book":1.21,
         "open":17.25,
         "previous_close":17.359999999999999,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Beta-Thalassemia"
      ],
      "cashflow":{
         "id":54,
         "ticker":"BLUE",
         "earnings":{
            "id":"5f2bae61713ee300019dfda9",
            "eps":"-3.430",
            "date":"2021-08-09",
            "name":"bluebird bio",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"BLUE",
            "eps_est":"-3.190",
            "revenue":"7472000.000",
            "updated":1628508021,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.360",
            "importance":0,
            "period_year":2021,
            "revenue_est":"19680000.000",
            "eps_surprise":"-0.2400",
            "revenue_type":"GAAP",
            "revenue_prior":"198890000.000",
            "date_confirmed":1,
            "revenue_surprise":"-12208000.0000",
            "eps_surprise_percent":"-0.0752",
            "revenue_surprise_percent":"-0.6203"
         },
         "prev_quarter_earnings":{
            "id":"5eb8f805470dcc00012d9db9",
            "eps":"-3.070",
            "date":"2021-05-05",
            "name":"bluebird bio",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"BLUE",
            "eps_est":"-3.010",
            "revenue":"12794000.000",
            "updated":1620258930,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-3.640",
            "importance":0,
            "period_year":2021,
            "revenue_est":"11370000.000",
            "eps_surprise":"-0.0600",
            "revenue_type":"GAAP",
            "revenue_prior":"21863000.000",
            "date_confirmed":1,
            "revenue_surprise":"1424000.0000",
            "eps_surprise_percent":"-0.0199",
            "revenue_surprise_percent":"0.1252"
         },
         "cash_equivalents_and_short_term_investments":839701000,
         "operating_cash_flow":-145648000,
         "monthly_cash_burn":-48549333,
         "est_live_cash":863930511,
         "est_months_cash":17.794899695120424,
         "total_liabilities":469898000,
         "net_cash":394032511,
         "enterpriseValue":547607676,
         "total_debt_to_equity":0.20000000000000001,
         "float":53343921,
         "insiderholdingspct":1.3
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":6742,
      "name":"Tacrolimus Inhalation Powder",
      "craft_entry_id":51188,
      "indication":"Lung transplant (post)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://ir.tffpharma.com/news-releases/news-release-details/tff-pharmaceuticals-reports-second-quarter-2021-financial",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1 safety data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-12 21:39:11",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":726,
         "ticker":"TFFP",
         "name":"TFF Pharmaceuticals Inc - Ordinary Shares",
         "exchange":null,
         "price":8.0399999999999991,
         "change":0.029999999999999999,
         "percent_change":0.37,
         "number_of_shares":25371781,
         "market_cap":203989119,
         "short_ratio":null,
         "volume":178087,
         "average_daily_volume":171500,
         "relative_volume":1.04,
         "price_to_book":3.6699999999999999,
         "open":7.9500000000000002,
         "previous_close":8.0099999999999998,
         "created_at":"2019-11-25T13:15:50.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Prophylaxis"
      ],
      "cashflow":{
         "id":593,
         "ticker":"TFFP",
         "earnings":{
            "id":"5f34e54a1ef0a0000183c3a2",
            "eps":"-0.180",
            "date":"2021-08-12",
            "name":"TFF Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"TFFP",
            "eps_est":"-0.300",
            "revenue":"1850000.000",
            "updated":1628801872,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.200",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.4000",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ebceccf4b88bb0001fc3008",
            "eps":"-0.330",
            "date":"2021-05-13",
            "name":"TFF Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"TFFP",
            "eps_est":"-0.240",
            "revenue":"24315.000",
            "updated":1620938509,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.200",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.3750",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":52067339,
         "operating_cash_flow":-5890513,
         "monthly_cash_burn":-1963504,
         "est_live_cash":48598481,
         "est_months_cash":24.750894828836611,
         "total_liabilities":1534224,
         "net_cash":47064257,
         "enterpriseValue":151921780,
         "total_debt_to_equity":"",
         "float":23906511,
         "insiderholdingspct":0.59999999999999998
      },
      "updated_at_formatted":"12/08/2021"
   },
   {
      "id":3416,
      "name":"OpRegen",
      "craft_entry_id":1912,
      "indication":"Dry age-related macular degeneration (AMD)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":1,
      "press_link":"https://www.businesswire.com/news/home/20210713005126/en/",
      "catalyst_date_text":"",
      "note":"Phase 1/2a updated data to be presented at Annual Retina Society Meeting September 30, 2021,",
      "estimated_primary_completion_date":"December 2021",
      "updated_at":"2021-07-13 08:04:52",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":698,
         "ticker":"LCTX",
         "name":"Lineage Cell Therapeutics, Inc.",
         "exchange":null,
         "price":2.29,
         "change":-0.040000000000000036,
         "percent_change":-1.72,
         "number_of_shares":149981347,
         "market_cap":343457285,
         "short_ratio":null,
         "volume":713112,
         "average_daily_volume":1186614,
         "relative_volume":0.59999999999999998,
         "price_to_book":2.9399999999999999,
         "open":2.2999999999999998,
         "previous_close":2.3300000000000001,
         "created_at":"2019-09-05T03:11:12.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Age-related macular degeneration (AMD)"
      ],
      "cashflow":{
         "id":566,
         "ticker":"LCTX",
         "earnings":{
            "id":"5f2bbc3a713ee300019dff65",
            "eps":"-0.030",
            "date":"2021-08-12",
            "name":"Lineage Cell Therapeutics",
            "time":"16:05:00",
            "notes":"",
            "period":"Q2",
            "ticker":"LCTX",
            "eps_est":"-0.040",
            "revenue":"512000.000",
            "updated":1628803312,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"AMEX",
            "eps_prior":"-0.040",
            "importance":0,
            "period_year":2021,
            "revenue_est":"480000.000",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"386000.000",
            "date_confirmed":1,
            "revenue_surprise":"32000.0000",
            "eps_surprise_percent":"0.2500",
            "revenue_surprise_percent":"0.0667"
         },
         "prev_quarter_earnings":{
            "id":"5eb3b229885f2800019b35c8",
            "eps":"-0.010",
            "date":"2021-05-13",
            "name":"Lineage Cell Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"LCTX",
            "eps_est":"-0.040",
            "revenue":"391000.000",
            "updated":1620942724,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"AMEX",
            "eps_prior":"-0.060",
            "importance":0,
            "period_year":2021,
            "revenue_est":"790000.000",
            "eps_surprise":"0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"514000.000",
            "date_confirmed":1,
            "revenue_surprise":"-399000.0000",
            "eps_surprise_percent":"0.7500",
            "revenue_surprise_percent":"-0.5051"
         },
         "cash_equivalents_and_short_term_investments":68746000,
         "operating_cash_flow":-5416000,
         "monthly_cash_burn":-1805333,
         "est_live_cash":65556578,
         "est_months_cash":36.312734548141535,
         "total_liabilities":11153000,
         "net_cash":54403578,
         "enterpriseValue":125413944,
         "total_debt_to_equity":0.050000000000000003,
         "float":107005592,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"13/07/2021"
   },
   {
      "id":6233,
      "name":"AR-15512 (AVX-012) - COMET-1",
      "craft_entry_id":34450,
      "indication":"Dry eye disease",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210804005757/en/",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2b top-line data due 3Q 2021.",
      "estimated_primary_completion_date":"July 2021",
      "updated_at":"2021-08-04 17:29:52",
      "stage":{
         "id":7,
         "label":"Phase 2b",
         "value":"phase2b"
      },
      "companies":{
         "id":20,
         "ticker":"AERI",
         "name":"Aerie Pharmaceuticals Inc.",
         "exchange":null,
         "price":14.5,
         "change":0.44,
         "percent_change":3.1299999999999999,
         "number_of_shares":47233646,
         "market_cap":684887867,
         "short_ratio":null,
         "volume":361674,
         "average_daily_volume":468628,
         "relative_volume":0.77000000000000002,
         "price_to_book":-17.260000000000002,
         "open":13.960000000000001,
         "previous_close":14.06,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Dry eye disease"
      ],
      "cashflow":{
         "id":17,
         "ticker":"AERI",
         "earnings":{
            "id":"5f2baad2713ee300019dfd1d",
            "eps":"-0.670",
            "date":"2021-08-04",
            "name":"Aerie Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"AERI",
            "eps_est":"-0.640",
            "revenue":"27185000.000",
            "updated":1628155374,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-1.050",
            "importance":0,
            "period_year":2021,
            "revenue_est":"26280000.000",
            "eps_surprise":"-0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"18033000.000",
            "date_confirmed":1,
            "revenue_surprise":"905000.0000",
            "eps_surprise_percent":"-0.0469",
            "revenue_surprise_percent":"0.0344"
         },
         "prev_quarter_earnings":{
            "id":"5eb2607e7f47df0001e14b56",
            "eps":"-0.720",
            "date":"2021-05-05",
            "name":"Aerie Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"AERI",
            "eps_est":"-0.680",
            "revenue":"22970000.000",
            "updated":1620249576,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.840",
            "importance":0,
            "period_year":2021,
            "revenue_est":"22780000.000",
            "eps_surprise":"-0.0400",
            "revenue_type":"GAAP",
            "revenue_prior":"20341000.000",
            "date_confirmed":1,
            "revenue_surprise":"190000.0000",
            "eps_surprise_percent":"-0.0588",
            "revenue_surprise_percent":"0.0083"
         },
         "cash_equivalents_and_short_term_investments":188287000,
         "operating_cash_flow":-20140000,
         "monthly_cash_burn":-6713333,
         "est_live_cash":176426778,
         "est_months_cash":26.280057610727788,
         "total_liabilities":395142000,
         "net_cash":-218715222,
         "enterpriseValue":732542867,
         "total_debt_to_equity":9.4100000000000001,
         "float":46152464,
         "insiderholdingspct":2.3999999999999999
      },
      "updated_at_formatted":"04/08/2021"
   },
   {
      "id":5212,
      "name":"EDP1815",
      "craft_entry_id":20522,
      "indication":"Mild to moderate psoriasis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://ir.evelobio.com/static-files/aca18e7a-0b98-4e1e-a951-25faf8572d9d",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2b data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-07-29 08:12:33",
      "stage":{
         "id":7,
         "label":"Phase 2b",
         "value":"phase2b"
      },
      "companies":{
         "id":551,
         "ticker":"EVLO",
         "name":"Evelo Biosciences Inc.",
         "exchange":null,
         "price":9.4199999999999999,
         "change":0.31,
         "percent_change":3.3999999999999999,
         "number_of_shares":53398292,
         "market_cap":503011911,
         "short_ratio":null,
         "volume":94516,
         "average_daily_volume":190471,
         "relative_volume":0.5,
         "price_to_book":8.1199999999999992,
         "open":9.0199999999999996,
         "previous_close":9.1099999999999994,
         "created_at":"2018-05-13T20:53:22.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Psoriasis"
      ],
      "cashflow":{
         "id":428,
         "ticker":"EVLO",
         "earnings":{
            "id":"5f22707744c96f00014e76b9",
            "eps":"-0.530",
            "date":"2021-07-29",
            "name":"Evelo Biosciences",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"EVLO",
            "eps_est":"-0.540",
            "revenue":"0.000",
            "updated":1627637253,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.630",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0185",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eb8f816470dcc00012d9e2f",
            "eps":"-0.550",
            "date":"2021-04-29",
            "name":"Evelo Biosciences",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"EVLO",
            "eps_est":"-0.510",
            "revenue":"0.000",
            "updated":1619698507,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.710",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0400",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.0784",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":123333000,
         "operating_cash_flow":-15432000,
         "monthly_cash_burn":-5144000,
         "est_live_cash":114245266,
         "est_months_cash":22.209421850699844,
         "total_liabilities":82965000,
         "net_cash":31280266,
         "enterpriseValue":436896910,
         "total_debt_to_equity":0.92000000000000004,
         "float":23304546,
         "insiderholdingspct":0.5
      },
      "updated_at_formatted":"29/07/2021"
   },
   {
      "id":7772,
      "name":"OPN-019",
      "craft_entry_id":108006,
      "indication":"COVID-19",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"http://ir.optinose.com/news-releases/news-release-details/optinose-reports-first-quarter-2021-financial-results-and",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1 top-line data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-07-01 21:04:06",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":482,
         "ticker":"OPTN",
         "name":"OptiNose Inc.",
         "exchange":null,
         "price":2.5099999999999998,
         "change":-0.010000000000000009,
         "percent_change":-0.40000000000000002,
         "number_of_shares":53309012,
         "market_cap":133805620,
         "short_ratio":null,
         "volume":86700,
         "average_daily_volume":436209,
         "relative_volume":0.20000000000000001,
         "price_to_book":-3.5899999999999999,
         "open":2.5499999999999998,
         "previous_close":2.52,
         "created_at":"2018-01-24T06:32:57.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Coronavirus",
         "COVID-19"
      ],
      "cashflow":{
         "id":390,
         "ticker":"OPTN",
         "earnings":{
            "id":"5f29095b2902dd0001f856a4",
            "eps":"-0.440",
            "date":"2021-08-11",
            "name":"OptiNose",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"OPTN",
            "eps_est":"-0.430",
            "revenue":"18357000.000",
            "updated":1628680059,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.560",
            "importance":0,
            "period_year":2021,
            "revenue_est":"17400000.000",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"10272000.000",
            "date_confirmed":1,
            "revenue_surprise":"957000.0000",
            "eps_surprise_percent":"-0.0233",
            "revenue_surprise_percent":"0.0550"
         },
         "prev_quarter_earnings":{
            "id":"5eb3b238885f2800019b3676",
            "eps":"-0.490",
            "date":"2021-05-05",
            "name":"OptiNose",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"OPTN",
            "eps_est":"-0.530",
            "revenue":"11960000.000",
            "updated":1620214512,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.630",
            "importance":0,
            "period_year":2021,
            "revenue_est":"11200000.000",
            "eps_surprise":"0.0400",
            "revenue_type":"GAAP",
            "revenue_prior":"7062000.000",
            "date_confirmed":1,
            "revenue_surprise":"760000.0000",
            "eps_surprise_percent":"0.0755",
            "revenue_surprise_percent":"0.0679"
         },
         "cash_equivalents_and_short_term_investments":93916000,
         "operating_cash_flow":-22494000,
         "monthly_cash_burn":-7498000,
         "est_live_cash":80669533,
         "est_months_cash":10.758806748466258,
         "total_liabilities":176588000,
         "net_cash":-95918467,
         "enterpriseValue":168056620,
         "total_debt_to_equity":18.760000000000002,
         "float":30507396,
         "insiderholdingspct":3.1000000000000001
      },
      "updated_at_formatted":"01/07/2021"
   },
   {
      "id":2653,
      "name":"FINTEPLA (fenfluramine)",
      "craft_entry_id":4678,
      "indication":"Lennox-Gastaut syndrome",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.globenewswire.com/news-release/2021/08/05/2275948/0/en/Zogenix-Provides-Corporate-Update-and-Reports-Second-Quarter-2021-Financial-Results.html",
      "catalyst_date_text":"3Q 2021",
      "note":"sNDA filing due 3Q 2021.",
      "estimated_primary_completion_date":"March 2024",
      "updated_at":"2021-08-05 21:05:02",
      "stage":{
         "id":11,
         "label":"sNDA Filing",
         "value":"sndaFiling"
      },
      "companies":{
         "id":320,
         "ticker":"ZGNX",
         "name":"Zogenix Inc.",
         "exchange":null,
         "price":13.74,
         "change":0.63,
         "percent_change":4.8100000000000005,
         "number_of_shares":55897678,
         "market_cap":768034096,
         "short_ratio":null,
         "volume":865479,
         "average_daily_volume":1071923,
         "relative_volume":0.81000000000000005,
         "price_to_book":2.8199999999999998,
         "open":13.050000000000001,
         "previous_close":13.109999999999999,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Lennox-Gastaut syndrome"
      ],
      "cashflow":{
         "id":253,
         "ticker":"ZGNX",
         "earnings":{
            "id":"5f2a5b50fa4662000194a174",
            "eps":"-1.050",
            "date":"2021-08-05",
            "name":"Zogenix",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ZGNX",
            "eps_est":"-0.940",
            "revenue":"18789000.000",
            "updated":1628197079,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.960",
            "importance":0,
            "period_year":2021,
            "revenue_est":"17080000.000",
            "eps_surprise":"-0.1100",
            "revenue_type":"GAAP",
            "revenue_prior":"1032000.000",
            "date_confirmed":1,
            "revenue_surprise":"1709000.0000",
            "eps_surprise_percent":"-0.1170",
            "revenue_surprise_percent":"0.1001"
         },
         "prev_quarter_earnings":{
            "id":"5eb10f6513dffb0001540d89",
            "eps":"-1.000",
            "date":"2021-05-06",
            "name":"Zogenix",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ZGNX",
            "eps_est":"-1.020",
            "revenue":"13684000.000",
            "updated":1620334612,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.540",
            "importance":0,
            "period_year":2021,
            "revenue_est":"12330000.000",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"1249000.000",
            "date_confirmed":1,
            "revenue_surprise":"1354000.0000",
            "eps_surprise_percent":"0.0196",
            "revenue_surprise_percent":"0.1098"
         },
         "cash_equivalents_and_short_term_investments":393282000,
         "operating_cash_flow":-42932000,
         "monthly_cash_burn":-14310666,
         "est_live_cash":367999823,
         "est_months_cash":25.715073148936604,
         "total_liabilities":267213000,
         "net_cash":100786823,
         "enterpriseValue":539665095,
         "total_debt_to_equity":0.59999999999999998,
         "float":55653891,
         "insiderholdingspct":2
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":6751,
      "name":"S-Trimer COVID-19 Vaccine + CpG 1018 adjuvant plus alum (SPECTRA)",
      "craft_entry_id":51315,
      "indication":"COVID-19 vaccine",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.dynavax.com/static-files/6e046557-2a31-4635-bd67-799c74e594b1",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2/3 interim analysis due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-04 17:52:35",
      "stage":{
         "id":8,
         "label":"Phase 2/3",
         "value":"phase23"
      },
      "companies":{
         "id":120,
         "ticker":"DVAX",
         "name":"Dynavax Technologies Corporation",
         "exchange":null,
         "price":12.039999999999999,
         "change":0.41999999999999998,
         "percent_change":3.6099999999999999,
         "number_of_shares":114760092,
         "market_cap":1381711508,
         "short_ratio":null,
         "volume":2604849,
         "average_daily_volume":2277815,
         "relative_volume":1.1400000000000001,
         "price_to_book":16.489999999999998,
         "open":11.67,
         "previous_close":11.619999999999999,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Coronavirus",
         "COVID-19",
         "COVID-19 vaccine"
      ],
      "cashflow":{
         "id":98,
         "ticker":"DVAX",
         "earnings":{
            "id":"5f2cfc13a3eee500019e8ea3",
            "eps":"0.060",
            "date":"2021-08-04",
            "name":"Dynavax Technologies",
            "time":"16:02:00",
            "notes":"",
            "period":"Q2",
            "ticker":"DVAX",
            "eps_est":"-0.040",
            "revenue":"52767000.000",
            "updated":1628117142,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.530",
            "importance":0,
            "period_year":2021,
            "revenue_est":"41590000.000",
            "eps_surprise":"0.1000",
            "revenue_type":"GAAP",
            "revenue_prior":"2668000.000",
            "date_confirmed":1,
            "revenue_surprise":"11177000.0000",
            "eps_surprise_percent":"2.5000",
            "revenue_surprise_percent":"0.2687"
         },
         "prev_quarter_earnings":{
            "id":"5eb3b211885f2800019b349a",
            "eps":"0.010",
            "date":"2021-05-06",
            "name":"Dynavax Technologies",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"DVAX",
            "eps_est":"-0.020",
            "revenue":"83335000.000",
            "updated":1620338414,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.250",
            "importance":0,
            "period_year":2021,
            "revenue_est":"59110000.000",
            "eps_surprise":"0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"10919000.000",
            "date_confirmed":1,
            "revenue_surprise":"24225000.0000",
            "eps_surprise_percent":"1.5000",
            "revenue_surprise_percent":"0.4098"
         },
         "cash_equivalents_and_short_term_investments":345804000,
         "operating_cash_flow":110788000,
         "monthly_cash_burn":36929333,
         "est_live_cash":411045821,
         "est_months_cash":11.130605066709437,
         "total_liabilities":564529000,
         "net_cash":-153483179,
         "enterpriseValue":1292252507,
         "total_debt_to_equity":3.0699999999999998,
         "float":90823786,
         "insiderholdingspct":1.6000000000000001
      },
      "updated_at_formatted":"04/08/2021"
   },
   {
      "id":6751,
      "name":"S-Trimer COVID-19 Vaccine + CpG 1018 adjuvant plus alum (SPECTRA)",
      "craft_entry_id":51315,
      "indication":"COVID-19 vaccine",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.dynavax.com/static-files/6e046557-2a31-4635-bd67-799c74e594b1",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2/3 interim analysis due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-04 17:52:35",
      "stage":{
         "id":8,
         "label":"Phase 2/3",
         "value":"phase23"
      },
      "companies":{
         "id":379,
         "ticker":"GSK",
         "name":"GlaxoSmithKline PLC",
         "exchange":null,
         "price":41.850000000000001,
         "change":0.040000000000000001,
         "percent_change":0.10000000000000001,
         "number_of_shares":2515857461,
         "market_cap":105288634743,
         "short_ratio":null,
         "volume":1928559,
         "average_daily_volume":4175903,
         "relative_volume":0.46000000000000002,
         "price_to_book":4.9800000000000004,
         "open":41.740000000000002,
         "previous_close":41.810000000000002,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Coronavirus",
         "COVID-19",
         "COVID-19 vaccine"
      ],
      "cashflow":{
         "id":303,
         "ticker":"GSK",
         "earnings":{
            "id":"5f211f0caedc510001ba9cfe",
            "eps":"0.390",
            "date":"2021-07-28",
            "name":"GlaxoSmithKline",
            "time":"07:00:00",
            "notes":"fxc",
            "period":"Q2",
            "ticker":"GSK",
            "eps_est":"0.570",
            "revenue":"11329000000.000",
            "updated":1627474376,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"0.240",
            "importance":4,
            "period_year":2021,
            "revenue_est":"10540000000.000",
            "eps_surprise":"-0.1800",
            "revenue_type":"GAAP",
            "revenue_prior":"9459000000.000",
            "date_confirmed":1,
            "revenue_surprise":"789000000.0000",
            "eps_surprise_percent":"-0.3158",
            "revenue_surprise_percent":"0.0749"
         },
         "prev_quarter_earnings":{
            "id":"5ed0b321fd72e50001876b5d",
            "eps":"0.320",
            "date":"2021-04-28",
            "name":"GlaxoSmithKline",
            "time":"07:11:00",
            "notes":"fxc",
            "period":"Q1",
            "ticker":"GSK",
            "eps_est":"0.610",
            "revenue":"10237000000.000",
            "updated":1619617038,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"0.480",
            "importance":4,
            "period_year":2021,
            "revenue_est":"11060000000.000",
            "eps_surprise":"-0.2900",
            "revenue_type":"GAAP",
            "revenue_prior":"11644000000.000",
            "date_confirmed":1,
            "revenue_surprise":"-823000000.0000",
            "eps_surprise_percent":"-0.4754",
            "revenue_surprise_percent":"-0.0744"
         },
         "cash_equivalents_and_short_term_investments":3562000000,
         "operating_cash_flow":1292000000,
         "monthly_cash_burn":430666666,
         "est_live_cash":4322844443,
         "est_months_cash":10.037564511668057,
         "total_liabilities":55433000000,
         "net_cash":-51110155557,
         "enterpriseValue":133804931669,
         "total_debt_to_equity":1.6599999999999999,
         "float":2506785977,
         "insiderholdingspct":0.20000000000000001
      },
      "updated_at_formatted":"04/08/2021"
   },
   {
      "id":7265,
      "name":"SIG-001",
      "craft_entry_id":76802,
      "indication":"Hemophilia A",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.globenewswire.com/news-release/2021/08/10/2277801/0/en/Sigilon-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Business-Highlights.html",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1/2 clinical hold announced July 9, 2021. 9 month follow-up data for three patients due 3Q 2021.",
      "estimated_primary_completion_date":"September 2026",
      "updated_at":"2021-08-10 07:25:54",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":860,
         "ticker":"SGTX",
         "name":"Sigilon Therapeutics Inc.",
         "exchange":null,
         "price":4.5700000000000003,
         "change":0.14999999999999999,
         "percent_change":3.3900000000000001,
         "number_of_shares":32057253,
         "market_cap":146501646,
         "short_ratio":null,
         "volume":154979,
         "average_daily_volume":293634,
         "relative_volume":0.53000000000000003,
         "price_to_book":1.3200000000000001,
         "open":4.3799999999999999,
         "previous_close":4.4199999999999999,
         "created_at":"2020-12-04T19:35:25.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Hemophilia",
         "Hemophilia A"
      ],
      "cashflow":{
         "id":723,
         "ticker":"SGTX",
         "earnings":{
            "id":"5fcde6d9accf740001581a19",
            "eps":"-0.650",
            "date":"2021-08-10",
            "name":"Sigilon Therapeutics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"SGTX",
            "eps_est":"-0.630",
            "revenue":"2704000.000",
            "updated":1628595748,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-2.540",
            "importance":0,
            "period_year":2021,
            "revenue_est":"3100000.000",
            "eps_surprise":"-0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"1951000.000",
            "date_confirmed":1,
            "revenue_surprise":"-396000.0000",
            "eps_surprise_percent":"-0.0317",
            "revenue_surprise_percent":"-0.1277"
         },
         "prev_quarter_earnings":{
            "id":"5fcde6daaccf740001581a1b",
            "eps":"-0.600",
            "date":"2021-05-10",
            "name":"Sigilon Therapeutics",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"SGTX",
            "eps_est":"-0.590",
            "revenue":"2958000.000",
            "updated":1620720901,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.0169",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":162406000,
         "operating_cash_flow":-15987000,
         "monthly_cash_burn":-5329000,
         "est_live_cash":152991433,
         "est_months_cash":28.709219928692061,
         "total_liabilities":75054000,
         "net_cash":77937433,
         "enterpriseValue":19390646,
         "total_debt_to_equity":0.32000000000000001,
         "float":19339106,
         "insiderholdingspct":6.5
      },
      "updated_at_formatted":"10/08/2021"
   },
   {
      "id":8036,
      "name":"TAK-906",
      "craft_entry_id":123630,
      "indication":"Gastroparesis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.takeda.com/4a21eb/siteassets/system/investors/report/quarterlyannouncements/fy2021/qr2021_q1_p01_en.pdf",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2b data due 3Q 2021.",
      "estimated_primary_completion_date":"June 14, 2021",
      "updated_at":"2021-07-30 03:13:23",
      "stage":{
         "id":7,
         "label":"Phase 2b",
         "value":"phase2b"
      },
      "companies":{
         "id":751,
         "ticker":"TAK",
         "name":"Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)",
         "exchange":null,
         "price":16.68,
         "change":0.089999999999999997,
         "percent_change":0.54000000000000004,
         "number_of_shares":3145059016,
         "market_cap":52459584387,
         "short_ratio":null,
         "volume":966440,
         "average_daily_volume":1875590,
         "relative_volume":0.52000000000000002,
         "price_to_book":1.1000000000000001,
         "open":16.609999999999999,
         "previous_close":16.59,
         "created_at":"2020-05-04T06:35:24.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Gastroparesis"
      ],
      "cashflow":{
         "id":616,
         "ticker":"TAK",
         "earnings":{
            "id":"5f23c4c0bcf9e90001c5d047",
            "eps":"1.030",
            "date":"2021-07-30",
            "name":"Takeda Pharmaceutical",
            "time":"15:00:00",
            "notes":"FXC",
            "period":"Q1",
            "ticker":"TAK",
            "eps_est":"",
            "revenue":"8641000000.000",
            "updated":1628087142,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"1.140",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"7458000000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ec4d5cd88a06b0001f81c6d",
            "eps":"0.820",
            "date":"2021-05-11",
            "name":"Takeda Pharmaceutical",
            "time":"15:00:00",
            "notes":"FXC",
            "period":"Q4",
            "ticker":"TAK",
            "eps_est":"",
            "revenue":"7241000000.000",
            "updated":1622023626,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"0.010",
            "importance":3,
            "period_year":2020,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"7079000000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":684850000000,
         "operating_cash_flow":166858000000,
         "monthly_cash_burn":55619333333,
         "est_live_cash":783110822221,
         "est_months_cash":14.079831153897805,
         "total_liabilities":7418591000000,
         "net_cash":-6635480177779,
         "enterpriseValue":86297643852,
         "total_debt_to_equity":0.82999999999999996,
         "float":3145059016,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"30/07/2021"
   },
   {
      "id":4453,
      "name":"SB206 - B-SIMPLE4",
      "craft_entry_id":15087,
      "indication":"Molluscum",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.globenewswire.com/news-release/2021/08/12/2279643/0/en/Novan-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 trial met primary endpoint. Further data due 3Q 2021. NDA filing due no later than 3Q 2022.",
      "estimated_primary_completion_date":"April 28, 2021",
      "updated_at":"2021-08-12 08:02:39",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":354,
         "ticker":"NOVN",
         "name":"Novan Inc.",
         "exchange":null,
         "price":8.7899999999999991,
         "change":0.10000000000000001,
         "percent_change":1.1499999999999999,
         "number_of_shares":18813192,
         "market_cap":165367958,
         "short_ratio":null,
         "volume":268377,
         "average_daily_volume":4781476,
         "relative_volume":0.059999999999999998,
         "price_to_book":5.1100000000000003,
         "open":8.7200000000000006,
         "previous_close":8.6899999999999995,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Molluscum Contagiosum"
      ],
      "cashflow":{
         "id":280,
         "ticker":"NOVN",
         "earnings":{
            "id":"5fbf52a395505d0001cd1de4",
            "eps":"-0.450",
            "date":"2021-08-12",
            "name":"Novan",
            "time":"07:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"NOVN",
            "eps_est":"-0.530",
            "revenue":"747000.000",
            "updated":1628773490,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.070",
            "importance":0,
            "period_year":2021,
            "revenue_est":"840000.000",
            "eps_surprise":"0.0800",
            "revenue_type":"GAAP",
            "revenue_prior":"1321000.000",
            "date_confirmed":1,
            "revenue_surprise":"-93000.0000",
            "eps_surprise_percent":"0.1509",
            "revenue_surprise_percent":"-0.1107"
         },
         "prev_quarter_earnings":{
            "id":"5ecf61b662ccfe000151fe4c",
            "eps":"-0.060",
            "date":"2021-05-11",
            "name":"Novan",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"NOVN",
            "eps_est":"-0.050",
            "revenue":"819000.000",
            "updated":1622537866,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.170",
            "importance":0,
            "period_year":2021,
            "revenue_est":"960000.000",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"1024000.000",
            "date_confirmed":1,
            "revenue_surprise":"-141000.0000",
            "eps_surprise_percent":"-0.2000",
            "revenue_surprise_percent":"-0.1469"
         },
         "cash_equivalents_and_short_term_investments":65802000,
         "operating_cash_flow":-2388000,
         "monthly_cash_burn":-796000,
         "est_live_cash":64395733,
         "est_months_cash":80.899162060301506,
         "total_liabilities":47390000,
         "net_cash":17005733,
         "enterpriseValue":102660957,
         "total_debt_to_equity":0.10000000000000001,
         "float":18701214,
         "insiderholdingspct":10.6
      },
      "updated_at_formatted":"12/08/2021"
   },
   {
      "id":6246,
      "name":"Vonoprazan PHALCON-HP",
      "craft_entry_id":35201,
      "indication":"H. pylori",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.phathompharma.com/news-releases/news-release-details/phathom-pharmaceuticals-reports-second-quarter-2021-results-and",
      "catalyst_date_text":"September 2021",
      "note":"Phase 3 top-line data met primary endpoints - April 29, 2021. NDA filing due September 2021,",
      "estimated_primary_completion_date":"March 10, 2021",
      "updated_at":"2021-08-10 08:11:20",
      "stage":{
         "id":10,
         "label":"NDA Filing",
         "value":"ndaFiling"
      },
      "companies":{
         "id":713,
         "ticker":"PHAT",
         "name":"Phathom Pharmaceuticals Inc.",
         "exchange":null,
         "price":31.550000000000001,
         "change":0.73999999999999999,
         "percent_change":2.3999999999999999,
         "number_of_shares":31356465,
         "market_cap":989296471,
         "short_ratio":null,
         "volume":76122,
         "average_daily_volume":97667,
         "relative_volume":0.78000000000000003,
         "price_to_book":7.4900000000000002,
         "open":30.550000000000001,
         "previous_close":30.809999999999999,
         "created_at":"2019-10-25T03:29:08.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "H. pylori"
      ],
      "cashflow":{
         "id":580,
         "ticker":"PHAT",
         "earnings":{
            "id":"5f2cfc38a3eee500019e8f47",
            "eps":"-1.000",
            "date":"2021-08-10",
            "name":"Phathom Pharmaceuticals",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"PHAT",
            "eps_est":"-1.070",
            "revenue":"0.000",
            "updated":1628597960,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.640",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0700",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0654",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ebb9b370f28ed00017097f9",
            "eps":"-0.960",
            "date":"2021-05-11",
            "name":"Phathom Pharmaceuticals",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"PHAT",
            "eps_est":"-1.190",
            "revenue":"0.000",
            "updated":1620804433,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.620",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.2300",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.1933",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":209669000,
         "operating_cash_flow":-28364000,
         "monthly_cash_burn":-9454666,
         "est_live_cash":192965756,
         "est_months_cash":20.409579354786302,
         "total_liabilities":82451000,
         "net_cash":110514756,
         "enterpriseValue":829167470,
         "total_debt_to_equity":0.37,
         "float":20563110,
         "insiderholdingspct":8.0999999999999996
      },
      "updated_at_formatted":"10/08/2021"
   },
   {
      "id":7019,
      "name":"CRN04777",
      "craft_entry_id":66548,
      "indication":"Congenital hyperinsulinism (HI)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://crinetics.com/crinetics-second-quarter-2021-financial-results-corporate-update/",
      "catalyst_date_text":"September 2021",
      "note":"Phase 1 preliminary safety and pharmacological effect data due September 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-10 17:11:52",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":576,
         "ticker":"CRNX",
         "name":"Crinetics Pharmaceuticals Inc.",
         "exchange":null,
         "price":20.870000000000001,
         "change":-0.43000000000000005,
         "percent_change":-2.02,
         "number_of_shares":39414966,
         "market_cap":822590340,
         "short_ratio":null,
         "volume":210418,
         "average_daily_volume":200627,
         "relative_volume":1.05,
         "price_to_book":4.0800000000000001,
         "open":21.09,
         "previous_close":21.300000000000001,
         "created_at":"2018-07-20T00:35:21.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Congenital hyperinsulinism"
      ],
      "cashflow":{
         "id":452,
         "ticker":"CRNX",
         "earnings":{
            "id":"5f2e4d8ab046af000120da27",
            "eps":"-0.700",
            "date":"2021-08-10",
            "name":"Crinetics Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CRNX",
            "eps_est":"-0.610",
            "revenue":"0.000",
            "updated":1628631095,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.530",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0900",
            "revenue_type":"",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.1475",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eb6550e84a80a00018b4426",
            "eps":"-0.690",
            "date":"2021-05-06",
            "name":"Crinetics Pharmaceuticals",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"CRNX",
            "eps_est":"-0.660",
            "revenue":"0.000",
            "updated":1620344303,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.710",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"71000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.0455",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":203762000,
         "operating_cash_flow":-19949000,
         "monthly_cash_burn":-6649666,
         "est_live_cash":207014256,
         "est_months_cash":31.13152690676494,
         "total_liabilities":15489000,
         "net_cash":191525256,
         "enterpriseValue":622386340,
         "total_debt_to_equity":0.02,
         "float":29019031,
         "insiderholdingspct":0.69999999999999996
      },
      "updated_at_formatted":"10/08/2021"
   },
   {
      "id":7787,
      "name":"Brensocatib",
      "craft_entry_id":108182,
      "indication":"COVID-19",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/insmed-reports-first-quarter-2021-financial-results-and-provides-business-update-301285103.html",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 top-line data due 3Q 2021.",
      "estimated_primary_completion_date":"February 28, 2021",
      "updated_at":"2021-07-01 21:02:57",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":171,
         "ticker":"INSM",
         "name":"Insmed Inc.",
         "exchange":null,
         "price":23.57,
         "change":1.1100000000000001,
         "percent_change":4.9399999999999995,
         "number_of_shares":115246666,
         "market_cap":2716363918,
         "short_ratio":null,
         "volume":753088,
         "average_daily_volume":772729,
         "relative_volume":0.96999999999999997,
         "price_to_book":5.1100000000000003,
         "open":22.25,
         "previous_close":22.460000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Coronavirus",
         "COVID-19"
      ],
      "cashflow":{
         "id":141,
         "ticker":"INSM",
         "earnings":{
            "id":"5f2bb9dd713ee300019dff2b",
            "eps":"-0.910",
            "date":"2021-08-05",
            "name":"Insmed",
            "time":"07:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"INSM",
            "eps_est":"-0.850",
            "revenue":"45366000.000",
            "updated":1628170340,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.640",
            "importance":1,
            "period_year":2021,
            "revenue_est":"43720000.000",
            "eps_surprise":"-0.0600",
            "revenue_type":"GAAP",
            "revenue_prior":"42495000.000",
            "date_confirmed":1,
            "revenue_surprise":"1646000.0000",
            "eps_surprise_percent":"-0.0706",
            "revenue_surprise_percent":"0.0376"
         },
         "prev_quarter_earnings":{
            "id":"5eaa77a9981f9a0001574139",
            "eps":"-0.890",
            "date":"2021-05-06",
            "name":"Insmed",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"INSM",
            "eps_est":"-0.880",
            "revenue":"40214000.000",
            "updated":1620302976,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.740",
            "importance":0,
            "period_year":2021,
            "revenue_est":"41640000.000",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"36860000.000",
            "date_confirmed":1,
            "revenue_surprise":"-1426000.0000",
            "eps_surprise_percent":"-0.0114",
            "revenue_surprise_percent":"-0.0342"
         },
         "cash_equivalents_and_short_term_investments":928327000,
         "operating_cash_flow":-75444000,
         "monthly_cash_burn":-25148000,
         "est_live_cash":883898866,
         "est_months_cash":35.147879195164627,
         "total_liabilities":698730000,
         "net_cash":185168866,
         "enterpriseValue":2381387917,
         "total_debt_to_equity":1.1200000000000001,
         "float":91607437,
         "insiderholdingspct":4.9000000000000004
      },
      "updated_at_formatted":"01/07/2021"
   },
   {
      "id":6525,
      "name":"MRT5500",
      "craft_entry_id":44384,
      "indication":"COVID-19 vaccine",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.translate.bio/news-releases/news-release-details/translate-bio-announces-first-quarter-2021-financial-results-and",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1/2 interim data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-05-06 20:49:17",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":389,
         "ticker":"SNY",
         "name":"Sanofi",
         "exchange":null,
         "price":53.119999999999997,
         "change":0.63,
         "percent_change":1.2,
         "number_of_shares":2510366030,
         "market_cap":133350643514,
         "short_ratio":null,
         "volume":2258162,
         "average_daily_volume":1654247,
         "relative_volume":1.3700000000000001,
         "price_to_book":1.8,
         "open":52.789999999999999,
         "previous_close":52.490000000000002,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Coronavirus",
         "COVID-19",
         "COVID-19 vaccine"
      ],
      "cashflow":{
         "id":313,
         "ticker":"SNY",
         "earnings":{
            "id":"5f211facaedc510001ba9df4",
            "eps":"1.660",
            "date":"2021-07-29",
            "name":"Sanofi",
            "time":"08:00:00",
            "notes":"FXC",
            "period":"Q2",
            "ticker":"SNY",
            "eps_est":"0.750",
            "revenue":"10533000000.000",
            "updated":1627568442,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"1.410",
            "importance":0,
            "period_year":2021,
            "revenue_est":"10160000000.000",
            "eps_surprise":"0.9100",
            "revenue_type":"GAAP",
            "revenue_prior":"9038000000.000",
            "date_confirmed":1,
            "revenue_surprise":"373000000.0000",
            "eps_surprise_percent":"1.2133",
            "revenue_surprise_percent":"0.0367"
         },
         "prev_quarter_earnings":{
            "id":"5edb3f3fca75b400018fbc98",
            "eps":"1.940",
            "date":"2021-04-28",
            "name":"Sanofi",
            "time":"08:00:00",
            "notes":"FXC",
            "period":"Q1",
            "ticker":"SNY",
            "eps_est":"0.780",
            "revenue":"10360000000.000",
            "updated":1619616618,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"1.800",
            "importance":0,
            "period_year":2021,
            "revenue_est":"10430000000.000",
            "eps_surprise":"1.1600",
            "revenue_type":"GAAP",
            "revenue_prior":"9897000000.000",
            "date_confirmed":1,
            "revenue_surprise":"-70000000.0000",
            "eps_surprise_percent":"1.4872",
            "revenue_surprise_percent":"-0.0067"
         },
         "cash_equivalents_and_short_term_investments":9722000000,
         "operating_cash_flow":null,
         "monthly_cash_burn":null,
         "est_live_cash":9722000000,
         "est_months_cash":null,
         "total_liabilities":48957000000,
         "net_cash":-39235000000,
         "enterpriseValue":146900562509,
         "total_debt_to_equity":0.34000000000000002,
         "float":2510366030,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"06/05/2021"
   },
   {
      "id":6525,
      "name":"MRT5500",
      "craft_entry_id":44384,
      "indication":"COVID-19 vaccine",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.translate.bio/news-releases/news-release-details/translate-bio-announces-first-quarter-2021-financial-results-and",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1/2 interim data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-05-06 20:49:17",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":570,
         "ticker":"TBIO",
         "name":"Translate Bio Inc.",
         "exchange":null,
         "price":37.770000000000003,
         "change":0.14999999999999999,
         "percent_change":0.40000000000000002,
         "number_of_shares":75586714,
         "market_cap":2854910188,
         "short_ratio":null,
         "volume":2431650,
         "average_daily_volume":2980644,
         "relative_volume":0.81999999999999995,
         "price_to_book":6.9199999999999999,
         "open":37.659999999999997,
         "previous_close":37.619999999999997,
         "created_at":"2018-07-04T23:04:46.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Coronavirus",
         "COVID-19",
         "COVID-19 vaccine"
      ],
      "cashflow":{
         "id":446,
         "ticker":"TBIO",
         "earnings":{
            "id":"5f2e4dc1b046af000120da63",
            "eps":"0.230",
            "date":"2021-08-05",
            "name":"Translate Bio",
            "time":"17:11:00",
            "notes":"",
            "period":"Q2",
            "ticker":"TBIO",
            "eps_est":"-0.230",
            "revenue":"72649000.000",
            "updated":1628208319,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.580",
            "importance":0,
            "period_year":2021,
            "revenue_est":"31810000.000",
            "eps_surprise":"0.4600",
            "revenue_type":"GAAP",
            "revenue_prior":"16319000.000",
            "date_confirmed":1,
            "revenue_surprise":"40839000.0000",
            "eps_surprise_percent":"2.0000",
            "revenue_surprise_percent":"1.2838"
         },
         "prev_quarter_earnings":{
            "id":"5eb6554684a80a00018b446e",
            "eps":"0.340",
            "date":"2021-05-06",
            "name":"Translate Bio",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"TBIO",
            "eps_est":"-0.070",
            "revenue":"34600000.000",
            "updated":1620371311,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.240",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.4100",
            "revenue_type":"GAAP",
            "revenue_prior":"4654000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"5.8571",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":667198000,
         "operating_cash_flow":13005000,
         "monthly_cash_burn":4335000,
         "est_live_cash":674856500,
         "est_months_cash":155.67623990772779,
         "total_liabilities":492233000,
         "net_cash":182623500,
         "enterpriseValue":2245568187,
         "total_debt_to_equity":0.14000000000000001,
         "float":53617413,
         "insiderholdingspct":1.3999999999999999
      },
      "updated_at_formatted":"06/05/2021"
   },
   {
      "id":2430,
      "name":"EDP-305 ARGON-2",
      "craft_entry_id":7543,
      "indication":"Non-alcoholic steatohepatitis (NASH)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":1,
      "press_link":"https://www.businesswire.com/news/home/20210805005808/en/",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2b interim analysis due 3Q 2021.",
      "estimated_primary_completion_date":"November 2022",
      "updated_at":"2021-08-05 20:45:28",
      "stage":{
         "id":7,
         "label":"Phase 2b",
         "value":"phase2b"
      },
      "companies":{
         "id":131,
         "ticker":"ENTA",
         "name":"Enanta Pharmaceuticals Inc.",
         "exchange":null,
         "price":51.32,
         "change":2.7400000000000002,
         "percent_change":5.6399999999999997,
         "number_of_shares":20214850,
         "market_cap":1037426102,
         "short_ratio":null,
         "volume":440624,
         "average_daily_volume":171554,
         "relative_volume":2.5699999999999998,
         "price_to_book":2.48,
         "open":48.950000000000003,
         "previous_close":48.579999999999998,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Nonalcoholic steatohepatitis (NASH)"
      ],
      "cashflow":{
         "id":105,
         "ticker":"ENTA",
         "earnings":{
            "id":"5f2908412902dd0001f855b2",
            "eps":"-1.190",
            "date":"2021-08-05",
            "name":"Enanta Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q3",
            "ticker":"ENTA",
            "eps_est":"-1.260",
            "revenue":"21624000.000",
            "updated":1628194987,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.710",
            "importance":0,
            "period_year":2021,
            "revenue_est":"22140000.000",
            "eps_surprise":"0.0700",
            "revenue_type":"GAAP",
            "revenue_prior":"18653000.000",
            "date_confirmed":1,
            "revenue_surprise":"-516000.0000",
            "eps_surprise_percent":"0.0556",
            "revenue_surprise_percent":"-0.0233"
         },
         "prev_quarter_earnings":{
            "id":"5eb2609c7f47df0001e14c3a",
            "eps":"-1.090",
            "date":"2021-05-06",
            "name":"Enanta Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ENTA",
            "eps_est":"-0.970",
            "revenue":"20132000.000",
            "updated":1620339795,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.300",
            "importance":0,
            "period_year":2021,
            "revenue_est":"24850000.000",
            "eps_surprise":"-0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"27619000.000",
            "date_confirmed":1,
            "revenue_surprise":"-4718000.0000",
            "eps_surprise_percent":"-0.1237",
            "revenue_surprise_percent":"-0.1899"
         },
         "cash_equivalents_and_short_term_investments":256824000,
         "operating_cash_flow":-29506000,
         "monthly_cash_burn":-9835333,
         "est_live_cash":239448245,
         "est_months_cash":24.345718136843967,
         "total_liabilities":32586000,
         "net_cash":206862245,
         "enterpriseValue":787273102,
         "total_debt_to_equity":0.02,
         "float":15917284,
         "insiderholdingspct":5.9000000000000004
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":7295,
      "name":"CERC-007",
      "craft_entry_id":79778,
      "indication":"Adult Onset Still\u2019s Disease",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://ir.cerecor.com/press-releases/detail/133/cerecor-reports-second-quarter-2021-financial-results-and",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1b initial data due 3Q 2021.",
      "estimated_primary_completion_date":"March 30, 2022",
      "updated_at":"2021-08-02 16:31:34",
      "stage":{
         "id":3,
         "label":"Phase 1b",
         "value":"phase1b"
      },
      "companies":{
         "id":85,
         "ticker":"CERC",
         "name":"Cerecor Inc.",
         "exchange":null,
         "price":2.77,
         "change":0.12,
         "percent_change":4.5300000000000002,
         "number_of_shares":96008951,
         "market_cap":265944794,
         "short_ratio":null,
         "volume":398177,
         "average_daily_volume":600170,
         "relative_volume":0.66000000000000003,
         "price_to_book":12.59,
         "open":2.6200000000000001,
         "previous_close":2.6499999999999999,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Still\u2019s disease"
      ],
      "cashflow":{
         "id":69,
         "ticker":"CERC",
         "earnings":{
            "id":"5f2cfc0aa3eee500019e8e7b",
            "eps":"-0.180",
            "date":"2021-08-02",
            "name":"Cerecor",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CERC",
            "eps_est":"-0.160",
            "revenue":"3355000.000",
            "updated":1627996891,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.180",
            "importance":0,
            "period_year":2021,
            "revenue_est":"4200000.000",
            "eps_surprise":"-0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"1338000.000",
            "date_confirmed":1,
            "revenue_surprise":"-845000.0000",
            "eps_surprise_percent":"-0.1250",
            "revenue_surprise_percent":"-0.2012"
         },
         "prev_quarter_earnings":{
            "id":"5eb5038af857860001768c2e",
            "eps":"-0.320",
            "date":"2021-05-13",
            "name":"Cerecor",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"CERC",
            "eps_est":"-0.160",
            "revenue":"473000.000",
            "updated":1620978808,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.360",
            "importance":0,
            "period_year":2021,
            "revenue_est":"4200000.000",
            "eps_surprise":"-0.1600",
            "revenue_type":"GAAP",
            "revenue_prior":"2754000.000",
            "date_confirmed":1,
            "revenue_surprise":"-3727000.0000",
            "eps_surprise_percent":"-1.0000",
            "revenue_surprise_percent":"-0.8874"
         },
         "cash_equivalents_and_short_term_investments":40435000,
         "operating_cash_flow":-19187000,
         "monthly_cash_burn":-6395666,
         "est_live_cash":29135990,
         "est_months_cash":4.5555834216483477,
         "total_liabilities":42497000,
         "net_cash":-13361010,
         "enterpriseValue":246423080,
         "total_debt_to_equity":0.81000000000000005,
         "float":56006748,
         "insiderholdingspct":2.7999999999999998
      },
      "updated_at_formatted":"02/08/2021"
   },
   {
      "id":6022,
      "name":"SLATE",
      "craft_entry_id":30643,
      "indication":"Non-small cell lung cancer (NSCLC)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://ir.gritstoneoncology.com/news-releases/news-release-details/gritstone-reports-fourth-quarter-and-full-year-2020-financial",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2 data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-05-06 09:58:28",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":592,
         "ticker":"GRTS",
         "name":"Gritstone bio Inc.",
         "exchange":null,
         "price":7.5300000000000002,
         "change":0.11,
         "percent_change":1.48,
         "number_of_shares":49447693,
         "market_cap":372341128,
         "short_ratio":null,
         "volume":770589,
         "average_daily_volume":653651,
         "relative_volume":1.1799999999999999,
         "price_to_book":2.0800000000000001,
         "open":7.5700000000000003,
         "previous_close":7.4199999999999999,
         "created_at":"2018-10-02T03:31:09.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Non-small cell lung cancer (NSCLC)",
         "Lung cancer"
      ],
      "cashflow":{
         "id":467,
         "ticker":"GRTS",
         "earnings":{
            "id":"5f2bb7ca713ee300019dfed9",
            "eps":"-0.330",
            "date":"2021-08-05",
            "name":"Gritstone Oncology",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"GRTS",
            "eps_est":"-0.580",
            "revenue":"2843000.000",
            "updated":1628208653,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.690",
            "importance":0,
            "period_year":2021,
            "revenue_est":"2240000.000",
            "eps_surprise":"0.2500",
            "revenue_type":"GAAP",
            "revenue_prior":"488000.000",
            "date_confirmed":1,
            "revenue_surprise":"603000.0000",
            "eps_surprise_percent":"0.4310",
            "revenue_surprise_percent":"0.2692"
         },
         "prev_quarter_earnings":{
            "id":"5eb503a2f857860001768c7c",
            "eps":"0.100",
            "date":"2021-05-06",
            "name":"Gritstone Bio",
            "time":"09:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"GRTS",
            "eps_est":"-0.580",
            "revenue":"39693000.000",
            "updated":1620370199,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.710",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.6800",
            "revenue_type":"GAAP",
            "revenue_prior":"1262000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"1.1724",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":171182000,
         "operating_cash_flow":-22682000,
         "monthly_cash_burn":-7560666,
         "est_live_cash":157824823,
         "est_months_cash":20.874460398065462,
         "total_liabilities":45399000,
         "net_cash":112425823,
         "enterpriseValue":223506128,
         "total_debt_to_equity":0.12,
         "float":40257957,
         "insiderholdingspct":1.5
      },
      "updated_at_formatted":"06/05/2021"
   },
   {
      "id":5513,
      "name":"Semorinemab (LAURIET)",
      "craft_entry_id":23642,
      "indication":"Alzheimer\u2019s disease",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://ir.acimmune.com/news-releases/news-release-details/ac-immune-reports-second-quarter-2021-financial-results-and",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2 primary completion (estimated last patient, last visit) 3Q 2021.",
      "estimated_primary_completion_date":"September 24, 2021",
      "updated_at":"2021-08-04 19:15:42",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":352,
         "ticker":"ACIU",
         "name":"AC Immune SA",
         "exchange":null,
         "price":6.5,
         "change":0.20999999999999999,
         "percent_change":3.3399999999999999,
         "number_of_shares":72652654,
         "market_cap":472242251,
         "short_ratio":null,
         "volume":76875,
         "average_daily_volume":483181,
         "relative_volume":0.16,
         "price_to_book":2.2800000000000002,
         "open":6.3399999999999999,
         "previous_close":6.29,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Alzheimer\u2019s disease"
      ],
      "cashflow":{
         "id":279,
         "ticker":"ACIU",
         "earnings":{
            "id":"5f2baa7d713ee300019dfd0d",
            "eps":"-0.260",
            "date":"2021-08-04",
            "name":"AC Immune",
            "time":"08:00:00",
            "notes":"FXC",
            "period":"Q2",
            "ticker":"ACIU",
            "eps_est":"-0.270",
            "revenue":"0.000",
            "updated":1628085847,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.210",
            "importance":2,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"1326000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0370",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eb10efb13dffb0001540b01",
            "eps":"-0.230",
            "date":"2021-04-28",
            "name":"AC Immune",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ACIU",
            "eps_est":"-0.250",
            "revenue":"0.000",
            "updated":1619612606,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.110",
            "importance":2,
            "period_year":2021,
            "revenue_est":"3660000.000",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"12921000.000",
            "date_confirmed":1,
            "revenue_surprise":"-3660000.0000",
            "eps_surprise_percent":"0.0800",
            "revenue_surprise_percent":"-1.0000"
         },
         "cash_equivalents_and_short_term_investments":199135000,
         "operating_cash_flow":-16023000,
         "monthly_cash_burn":-5341000,
         "est_live_cash":189699233,
         "est_months_cash":35.517549709792171,
         "total_liabilities":21808000,
         "net_cash":167891233,
         "enterpriseValue":258491278,
         "total_debt_to_equity":0.01,
         "float":31782720,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"04/08/2021"
   },
   {
      "id":5515,
      "name":"CB-280",
      "craft_entry_id":23658,
      "indication":"Cystic fibrosis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-reports-second-quarter-2021-financial",
      "catalyst_date_text":"",
      "note":"Phase 1b interim data due at the  2021 North American Cystic Fibrosis Conference September 30 - October 2, 2021.",
      "estimated_primary_completion_date":"December 2021",
      "updated_at":"2021-08-05 18:42:04",
      "stage":{
         "id":3,
         "label":"Phase 1b",
         "value":"phase1b"
      },
      "companies":{
         "id":334,
         "ticker":"CALA",
         "name":"Calithera Biosciences Inc.",
         "exchange":null,
         "price":2.1499999999999999,
         "change":0,
         "percent_change":null,
         "number_of_shares":74114399,
         "market_cap":159345958,
         "short_ratio":null,
         "volume":713405,
         "average_daily_volume":810934,
         "relative_volume":0.88,
         "price_to_book":1.9199999999999999,
         "open":2.1299999999999999,
         "previous_close":2.1499999999999999,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Cystic fibrosis"
      ],
      "cashflow":{
         "id":266,
         "ticker":"CALA",
         "earnings":{
            "id":"5f30f086a7bff3000162b20b",
            "eps":"-0.190",
            "date":"2021-08-05",
            "name":"Calithera Biosciences",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CALA",
            "eps_est":"-0.240",
            "revenue":"3000000.000",
            "updated":1628196120,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.290",
            "importance":2,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.2083",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eb3b205885f2800019b3418",
            "eps":"-0.280",
            "date":"2021-05-06",
            "name":"Calithera Biosciences",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"CALA",
            "eps_est":"-0.250",
            "revenue":"0.000",
            "updated":1620367361,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.380",
            "importance":2,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.1200",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":92205000,
         "operating_cash_flow":-11121000,
         "monthly_cash_burn":-3707000,
         "est_live_cash":85655966,
         "est_months_cash":23.106545994065282,
         "total_liabilities":14846000,
         "net_cash":70809966,
         "enterpriseValue":70810957,
         "total_debt_to_equity":0.040000000000000001,
         "float":51184451,
         "insiderholdingspct":1
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":3218,
      "name":"Ublituximab - ULTIMATE I",
      "craft_entry_id":3020,
      "indication":"Multiple Sclerosis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":1,
      "press_link":"https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-provides-business-update-and-reports-second-1",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 trial met primary endpoint - December 10. 2020. BLA filing due 3Q 2021.",
      "estimated_primary_completion_date":"July 23, 2020",
      "updated_at":"2021-08-02 07:04:41",
      "stage":{
         "id":12,
         "label":"BLA Filing",
         "value":"blaFiling"
      },
      "companies":{
         "id":292,
         "ticker":"TGTX",
         "name":"TG Therapeutics Inc.",
         "exchange":null,
         "price":24,
         "change":2.2200000000000002,
         "percent_change":10.19,
         "number_of_shares":142831983,
         "market_cap":3427967592,
         "short_ratio":null,
         "volume":2553768,
         "average_daily_volume":1377937,
         "relative_volume":1.8500000000000001,
         "price_to_book":8.9600000000000009,
         "open":22.309999999999999,
         "previous_close":21.780000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Multiple Sclerosis (MS)"
      ],
      "cashflow":{
         "id":230,
         "ticker":"TGTX",
         "earnings":{
            "id":"5f30f0caa7bff3000162b361",
            "eps":"-0.590",
            "date":"2021-08-02",
            "name":"TG Therapeutics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"TGTX",
            "eps_est":"-0.500",
            "revenue":"1545000.000",
            "updated":1627903207,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.470",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"38000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.1800",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eba49cba2467b0001363505",
            "eps":"-0.690",
            "date":"2021-05-10",
            "name":"TG Therapeutics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"TGTX",
            "eps_est":"-0.490",
            "revenue":"793000.000",
            "updated":1620646965,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.480",
            "importance":0,
            "period_year":2021,
            "revenue_est":"650000.000",
            "eps_surprise":"-0.2000",
            "revenue_type":"GAAP",
            "revenue_prior":"38000.000",
            "date_confirmed":1,
            "revenue_surprise":"143000.0000",
            "eps_surprise_percent":"-0.4082",
            "revenue_surprise_percent":"0.2200"
         },
         "cash_equivalents_and_short_term_investments":443459000,
         "operating_cash_flow":-60169000,
         "monthly_cash_burn":-20056333,
         "est_live_cash":408026145,
         "est_months_cash":20.344005307450768,
         "total_liabilities":98270000,
         "net_cash":309756145,
         "enterpriseValue":3019352592,
         "total_debt_to_equity":0.089999999999999997,
         "float":114156621,
         "insiderholdingspct":16.199999999999999
      },
      "updated_at_formatted":"02/08/2021"
   },
   {
      "id":6034,
      "name":"ALT-801",
      "craft_entry_id":30691,
      "indication":"Non-alcoholic steatohepatitis (NASH) - Healthy Overweight and Obese Volunteers",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-second-quarter-2021-financial-results-and",
      "catalyst_date_text":"September 2021",
      "note":"Phase 1 6-week MAD released June 16, 2021. Weight loss of 5.4% achieved at 6 weeks of treatment with 1.8 mg once weekly dose. 12-week data September 2021. Phase 2 obesity and NASH trials expected to initiate in Q1 2022.",
      "estimated_primary_completion_date":"September 2021",
      "updated_at":"2021-08-10 19:33:20",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":460,
         "ticker":"ALT",
         "name":"Altimmune Inc.",
         "exchange":null,
         "price":12.68,
         "change":1.1000000000000001,
         "percent_change":9.5,
         "number_of_shares":39705884,
         "market_cap":503470609,
         "short_ratio":null,
         "volume":1312912,
         "average_daily_volume":2238274,
         "relative_volume":0.58999999999999997,
         "price_to_book":2.0899999999999999,
         "open":11.720000000000001,
         "previous_close":11.58,
         "created_at":"2018-01-24T06:32:57.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Nonalcoholic steatohepatitis (NASH)",
         "Obesity"
      ],
      "cashflow":{
         "id":372,
         "ticker":"ALT",
         "earnings":{
            "id":"5f33937bb7c159000133e6fb",
            "eps":"-0.410",
            "date":"2021-08-10",
            "name":"Altimmune",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ALT",
            "eps_est":"-0.500",
            "revenue":"137623.000",
            "updated":1628631877,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.940",
            "importance":2,
            "period_year":2021,
            "revenue_est":"1840000.000",
            "eps_surprise":"0.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"721636.000",
            "date_confirmed":1,
            "revenue_surprise":"-1702377.0000",
            "eps_surprise_percent":"0.1800",
            "revenue_surprise_percent":"-0.9252"
         },
         "prev_quarter_earnings":{
            "id":"5ebcec7f4b88bb0001fc2ece",
            "eps":"-0.380",
            "date":"2021-05-17",
            "name":"Altimmune",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ALT",
            "eps_est":"-0.470",
            "revenue":"837516.000",
            "updated":1621251132,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.260",
            "importance":2,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"2213000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.1915",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":217826222,
         "operating_cash_flow":-18926628,
         "monthly_cash_burn":-6308876,
         "est_live_cash":206680541,
         "est_months_cash":32.760279485600918,
         "total_liabilities":15982878,
         "net_cash":190697663,
         "enterpriseValue":287295604,
         "total_debt_to_equity":0.01,
         "float":39275708,
         "insiderholdingspct":13.199999999999999
      },
      "updated_at_formatted":"10/08/2021"
   },
   {
      "id":2458,
      "name":"VAL-083",
      "craft_entry_id":6772,
      "indication":"Glioblastoma Multiforme (GBM) - Adjuvant",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://d1io3yog0oux5.cloudfront.net/_df97e7926a026f05fcdbaf030eee7813/kintara/db/241/1956/pdf/Kintara+Therapeutics+May+2021.pdf",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2 top-line data due 3Q 2021.",
      "estimated_primary_completion_date":"June 2021",
      "updated_at":"2021-05-14 08:49:21",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":807,
         "ticker":"KTRA",
         "name":"Kintara Therapeutics Inc.",
         "exchange":null,
         "price":1.47,
         "change":0.02,
         "percent_change":1.3799999999999999,
         "number_of_shares":32617939,
         "market_cap":47948370,
         "short_ratio":null,
         "volume":169571,
         "average_daily_volume":832725,
         "relative_volume":0.20000000000000001,
         "price_to_book":-13.359999999999999,
         "open":1.4199999999999999,
         "previous_close":1.45,
         "created_at":"2020-08-21T12:19:14.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Glioblastoma Multiforme (GBM)"
      ],
      "cashflow":{
         "id":671,
         "ticker":"KTRA",
         "earnings":{
            "id":"5fbf529c95505d0001cd186c",
            "eps":"",
            "date":"2021-09-20",
            "name":"Kintara Therapeutics",
            "time":"08:00:00",
            "notes":"",
            "period":"Q4",
            "ticker":"KTRA",
            "eps_est":"",
            "revenue":"",
            "updated":1606374044,
            "currency":"USD",
            "eps_type":"",
            "exchange":"NASDAQ",
            "eps_prior":"0.350",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"",
            "revenue_prior":"0.000",
            "date_confirmed":0,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5f44b576c0a0c30001c26a71",
            "eps":"-0.230",
            "date":"2021-05-14",
            "name":"Kintara Therapeutics",
            "time":"08:00:00",
            "notes":"",
            "period":"Q3",
            "ticker":"KTRA",
            "eps_est":"-0.170",
            "revenue":"0.000",
            "updated":1621238039,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.170",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0600",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.3529",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":15718000,
         "operating_cash_flow":-4630000,
         "monthly_cash_burn":-1543333,
         "est_live_cash":8310001,
         "est_months_cash":5.3844510549570312,
         "total_liabilities":2735000,
         "net_cash":5575001,
         "enterpriseValue":52459370,
         "total_debt_to_equity":"",
         "float":32038772,
         "insiderholdingspct":5.5999999999999996
      },
      "updated_at_formatted":"14/05/2021"
   },
   {
      "id":6298,
      "name":"EDP-297",
      "craft_entry_id":38169,
      "indication":"Non-alcoholic steatohepatitis (NASH)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210805005808/en/",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1 data due 3Q 2021.",
      "estimated_primary_completion_date":"February 2021",
      "updated_at":"2021-08-05 20:45:54",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":131,
         "ticker":"ENTA",
         "name":"Enanta Pharmaceuticals Inc.",
         "exchange":null,
         "price":51.32,
         "change":2.7400000000000002,
         "percent_change":5.6399999999999997,
         "number_of_shares":20214850,
         "market_cap":1037426102,
         "short_ratio":null,
         "volume":440624,
         "average_daily_volume":171554,
         "relative_volume":2.5699999999999998,
         "price_to_book":2.48,
         "open":48.950000000000003,
         "previous_close":48.579999999999998,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Nonalcoholic steatohepatitis (NASH)"
      ],
      "cashflow":{
         "id":105,
         "ticker":"ENTA",
         "earnings":{
            "id":"5f2908412902dd0001f855b2",
            "eps":"-1.190",
            "date":"2021-08-05",
            "name":"Enanta Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q3",
            "ticker":"ENTA",
            "eps_est":"-1.260",
            "revenue":"21624000.000",
            "updated":1628194987,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.710",
            "importance":0,
            "period_year":2021,
            "revenue_est":"22140000.000",
            "eps_surprise":"0.0700",
            "revenue_type":"GAAP",
            "revenue_prior":"18653000.000",
            "date_confirmed":1,
            "revenue_surprise":"-516000.0000",
            "eps_surprise_percent":"0.0556",
            "revenue_surprise_percent":"-0.0233"
         },
         "prev_quarter_earnings":{
            "id":"5eb2609c7f47df0001e14c3a",
            "eps":"-1.090",
            "date":"2021-05-06",
            "name":"Enanta Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ENTA",
            "eps_est":"-0.970",
            "revenue":"20132000.000",
            "updated":1620339795,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.300",
            "importance":0,
            "period_year":2021,
            "revenue_est":"24850000.000",
            "eps_surprise":"-0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"27619000.000",
            "date_confirmed":1,
            "revenue_surprise":"-4718000.0000",
            "eps_surprise_percent":"-0.1237",
            "revenue_surprise_percent":"-0.1899"
         },
         "cash_equivalents_and_short_term_investments":256824000,
         "operating_cash_flow":-29506000,
         "monthly_cash_burn":-9835333,
         "est_live_cash":239448245,
         "est_months_cash":24.345718136843967,
         "total_liabilities":32586000,
         "net_cash":206862245,
         "enterpriseValue":787273102,
         "total_debt_to_equity":0.02,
         "float":15917284,
         "insiderholdingspct":5.9000000000000004
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":6816,
      "name":"YELIVA (Opaganib)",
      "craft_entry_id":55279,
      "indication":"COVID-19",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/redhill-biopharma-announces-last-patient-out-for-phase-23-covid-19-study-of-oral-opaganib-301336304.html",
      "catalyst_date_text":"3Q 2021 est",
      "note":"Phase 2/3 trial to be completed in the coming weeks - noted July 19, 2021.",
      "estimated_primary_completion_date":"July 18, 2021",
      "updated_at":"2021-07-19 07:34:11",
      "stage":{
         "id":8,
         "label":"Phase 2/3",
         "value":"phase23"
      },
      "companies":{
         "id":259,
         "ticker":"RDHL",
         "name":"Redhill Biopharma Ltd.",
         "exchange":null,
         "price":6.8799999999999999,
         "change":0.28000000000000003,
         "percent_change":4.2400000000000002,
         "number_of_shares":46720013,
         "market_cap":321433689,
         "short_ratio":null,
         "volume":206086,
         "average_daily_volume":274925,
         "relative_volume":0.75,
         "price_to_book":6.04,
         "open":6.5999999999999996,
         "previous_close":6.5999999999999996,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Coronavirus",
         "COVID-19"
      ],
      "cashflow":{
         "id":203,
         "ticker":"RDHL",
         "earnings":{
            "id":"5f3636c063170b0001c878ed",
            "eps":"",
            "date":"2021-08-26",
            "name":"Redhill Biopharma",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"RDHL",
            "eps_est":"",
            "revenue":"",
            "updated":1629372807,
            "currency":"USD",
            "eps_type":"",
            "exchange":"NASDAQ",
            "eps_prior":"0.040",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"",
            "revenue_prior":"20899000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ece103e917d7d00011b65d4",
            "eps":"-0.050",
            "date":"2021-05-27",
            "name":"Redhill Biopharma",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"RDHL",
            "eps_est":"-0.340",
            "revenue":"20575000.000",
            "updated":1622114343,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.050",
            "importance":0,
            "period_year":2021,
            "revenue_est":"22700000.000",
            "eps_surprise":"0.2900",
            "revenue_type":"GAAP",
            "revenue_prior":"1056000.000",
            "date_confirmed":1,
            "revenue_surprise":"-2125000.0000",
            "eps_surprise_percent":"0.8529",
            "revenue_surprise_percent":"-0.0936"
         },
         "cash_equivalents_and_short_term_investments":75988000,
         "operating_cash_flow":-12267000,
         "monthly_cash_burn":-4089000,
         "est_live_cash":56360800,
         "est_months_cash":13.783516752262166,
         "total_liabilities":167082000,
         "net_cash":-110721200,
         "enterpriseValue":332996692,
         "total_debt_to_equity":1.6499999999999999,
         "float":46720013,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"19/07/2021"
   },
   {
      "id":2725,
      "name":"CEVA101",
      "craft_entry_id":4148,
      "indication":"Severe Traumatic Brain Injury",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":1,
      "press_link":"https://d1io3yog0oux5.cloudfront.net/_57a9ebbefa562ec94907d436281246c9/fortressbiotech/db/640/5686/pdf/FBIO+Corporate+Presentation+-+May+2021+1.pdf",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2 data in children due 3Q 2021.",
      "estimated_primary_completion_date":"September 16, 2020",
      "updated_at":"2021-07-01 21:02:32",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":140,
         "ticker":"FBIO",
         "name":"Fortress Biotech Inc.",
         "exchange":null,
         "price":3.0600000000000001,
         "change":0.040000000000000001,
         "percent_change":1.3200000000000001,
         "number_of_shares":101061865,
         "market_cap":309249307,
         "short_ratio":null,
         "volume":338997,
         "average_daily_volume":507497,
         "relative_volume":0.67000000000000004,
         "price_to_book":2.8599999999999999,
         "open":2.9300000000000002,
         "previous_close":3.02,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Brain injury"
      ],
      "cashflow":{
         "id":113,
         "ticker":"FBIO",
         "earnings":{
            "id":"5f3242109c32ef000199d524",
            "eps":"-0.170",
            "date":"2021-08-16",
            "name":"Fortress Biotech",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"FBIO",
            "eps_est":"-0.120",
            "revenue":"17843000.000",
            "updated":1629154246,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.050",
            "importance":0,
            "period_year":2021,
            "revenue_est":"14690000.000",
            "eps_surprise":"-0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"9457000.000",
            "date_confirmed":1,
            "revenue_surprise":"3153000.0000",
            "eps_surprise_percent":"-0.4167",
            "revenue_surprise_percent":"0.2146"
         },
         "prev_quarter_earnings":{
            "id":"5eba4996a2467b0001363443",
            "eps":"-0.090",
            "date":"2021-05-16",
            "name":"Fortress Biotech",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"FBIO",
            "eps_est":"-0.160",
            "revenue":"11587000.000",
            "updated":1621248126,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.070",
            "importance":0,
            "period_year":2021,
            "revenue_est":"13410000",
            "eps_surprise":"0.0700",
            "revenue_type":"GAAP",
            "revenue_prior":"12918000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.4375",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":274992000,
         "operating_cash_flow":-34460000,
         "monthly_cash_burn":-11486666,
         "est_live_cash":254698890,
         "est_months_cash":22.173439185922181,
         "total_liabilities":169857000,
         "net_cash":84841890,
         "enterpriseValue":120760306,
         "total_debt_to_equity":0.80000000000000004,
         "float":76232955,
         "insiderholdingspct":27.399999999999999
      },
      "updated_at_formatted":"01/07/2021"
   },
   {
      "id":6827,
      "name":"Abivertinib",
      "craft_entry_id":55968,
      "indication":"COVID-19",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2 data due 3Q 2021.",
      "estimated_primary_completion_date":"May 5, 2021",
      "updated_at":"2021-06-22 09:04:40",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":284,
         "ticker":"SRNE",
         "name":"Sorrento Therapeutics Inc.",
         "exchange":null,
         "price":8.3499999999999996,
         "change":0.10000000000000001,
         "percent_change":1.21,
         "number_of_shares":298099574,
         "market_cap":2489131443,
         "short_ratio":null,
         "volume":6359842,
         "average_daily_volume":6604666,
         "relative_volume":0.95999999999999996,
         "price_to_book":13.470000000000001,
         "open":8.2799999999999994,
         "previous_close":8.25,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Coronavirus",
         "COVID-19"
      ],
      "cashflow":{
         "id":222,
         "ticker":"SRNE",
         "earnings":{
            "id":"5fbf52b195505d0001cd27b2",
            "eps":"-0.570",
            "date":"2021-08-06",
            "name":"Sorrento Therapeutics",
            "time":"17:31:00",
            "notes":"",
            "period":"Q2",
            "ticker":"SRNE",
            "eps_est":"",
            "revenue":"13511000.000",
            "updated":1628512381,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.360",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"9007000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ec8ca4454ac14000191c09e",
            "eps":"0.010",
            "date":"2021-05-05",
            "name":"Sorrento Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"SRNE",
            "eps_est":"",
            "revenue":"14255000.000",
            "updated":1620917754,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.360",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"7721000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":111701000,
         "operating_cash_flow":-78515000,
         "monthly_cash_burn":-26171666,
         "est_live_cash":65464390,
         "est_months_cash":2.501345921195846,
         "total_liabilities":593389000,
         "net_cash":-527924610,
         "enterpriseValue":2542172442,
         "total_debt_to_equity":0.88,
         "float":293559311,
         "insiderholdingspct":35.100000000000001
      },
      "updated_at_formatted":"22/06/2021"
   },
   {
      "id":5549,
      "name":"Verdiperstat",
      "craft_entry_id":23913,
      "indication":"Multiple system atrophy (MSA)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/biohaven-reports-second-quarter-2021-financial-results-and-recent-business-developments-301350770.html",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 top-line data due 3Q 2021.",
      "estimated_primary_completion_date":"October 20, 2021",
      "updated_at":"2021-08-09 07:31:12",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":409,
         "ticker":"BHVN",
         "name":"Biohaven Pharmaceutical Holding Company Ltd.",
         "exchange":null,
         "price":122.84,
         "change":4.7300000000000004,
         "percent_change":4,
         "number_of_shares":65401228,
         "market_cap":8033886848,
         "short_ratio":null,
         "volume":520610,
         "average_daily_volume":735490,
         "relative_volume":0.70999999999999996,
         "price_to_book":-17.699999999999999,
         "open":118.47,
         "previous_close":118.11,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Multiple system atrophy (MSA)"
      ],
      "cashflow":{
         "id":332,
         "ticker":"BHVN",
         "earnings":{
            "id":"5f2f9f024ad10600012c8e90",
            "eps":"-2.620",
            "date":"2021-08-09",
            "name":"Biohaven Pharmaceutical",
            "time":"07:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"BHVN",
            "eps_est":"-2.740",
            "revenue":"92933000.000",
            "updated":1628508314,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"-2.550",
            "importance":0,
            "period_year":2021,
            "revenue_est":"78130000.000",
            "eps_surprise":"0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"9698000.000",
            "date_confirmed":1,
            "revenue_surprise":"14803000.0000",
            "eps_surprise_percent":"0.0438",
            "revenue_surprise_percent":"0.1895"
         },
         "prev_quarter_earnings":{
            "id":"5eb50385f857860001768c1c",
            "eps":"-2.970",
            "date":"2021-05-10",
            "name":"Biohaven Pharmaceutical",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"BHVN",
            "eps_est":"-2.820",
            "revenue":"43823000.000",
            "updated":1620646983,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"-2.390",
            "importance":0,
            "period_year":2021,
            "revenue_est":"40630000.000",
            "eps_surprise":"-0.1500",
            "revenue_type":"GAAP",
            "revenue_prior":"1151000.000",
            "date_confirmed":1,
            "revenue_surprise":"3193000.0000",
            "eps_surprise_percent":"-0.0532",
            "revenue_surprise_percent":"0.0786"
         },
         "cash_equivalents_and_short_term_investments":366107000,
         "operating_cash_flow":-227042000,
         "monthly_cash_burn":-75680666,
         "est_live_cash":232404490,
         "est_months_cash":3.0708568288762152,
         "total_liabilities":1302489000,
         "net_cash":-1070084510,
         "enterpriseValue":7941917847,
         "total_debt_to_equity":"",
         "float":58034591,
         "insiderholdingspct":8.5
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":7600,
      "name":"Amilo-5MER",
      "craft_entry_id":97615,
      "indication":"Chronic inflammatory diseases",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-provides-business-update-and-reports-second-quarter-2021-financial-results-301349181.html",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1 top-line data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-05 07:43:25",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":151,
         "ticker":"GLMD",
         "name":"Galmed Pharmaceuticals Ltd.",
         "exchange":null,
         "price":2.8100000000000001,
         "change":-0.089999999999999969,
         "percent_change":-3.1000000000000001,
         "number_of_shares":21113066,
         "market_cap":59327715,
         "short_ratio":null,
         "volume":61588,
         "average_daily_volume":302024,
         "relative_volume":0.20000000000000001,
         "price_to_book":0.77000000000000002,
         "open":2.8700000000000001,
         "previous_close":2.8999999999999999,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         
      ],
      "cashflow":{
         "id":123,
         "ticker":"GLMD",
         "earnings":{
            "id":"5f2bb772713ee300019dfecd",
            "eps":"-0.330",
            "date":"2021-08-05",
            "name":"Galmed Pharmaceuticals",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"GLMD",
            "eps_est":"-0.380",
            "revenue":"0.000",
            "updated":1628164740,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.260",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.1316",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ebcec9f4b88bb0001fc2f56",
            "eps":"-0.380",
            "date":"2021-05-13",
            "name":"Galmed Pharmaceuticals",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"GLMD",
            "eps_est":"-0.390",
            "revenue":"0.000",
            "updated":1620907371,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.290",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0256",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":51065000,
         "operating_cash_flow":-7631000,
         "monthly_cash_burn":-2543666,
         "est_live_cash":46571190,
         "est_months_cash":18.308689112485681,
         "total_liabilities":7326000,
         "net_cash":39245190,
         "enterpriseValue":29236925,
         "total_debt_to_equity":0.01,
         "float":17575161,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":4534,
      "name":"Izencitinib",
      "craft_entry_id":15186,
      "indication":"Ulcerative Colitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/theravance-biopharma-inc-reports-second-quarter-2021-financial-results-and-provides-business-update-301347426.html",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2b data due 3Q 2021.",
      "estimated_primary_completion_date":"June 2025",
      "updated_at":"2021-08-12 00:58:45",
      "stage":{
         "id":7,
         "label":"Phase 2b",
         "value":"phase2b"
      },
      "companies":{
         "id":289,
         "ticker":"TBPH",
         "name":"Theravance Biopharma Inc.",
         "exchange":null,
         "price":14.050000000000001,
         "change":0.56000000000000005,
         "percent_change":4.1500000000000004,
         "number_of_shares":73470151,
         "market_cap":1032255622,
         "short_ratio":null,
         "volume":773329,
         "average_daily_volume":432890,
         "relative_volume":1.79,
         "price_to_book":-3.4399999999999999,
         "open":13.369999999999999,
         "previous_close":13.49,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Ulcerative Colitis"
      ],
      "cashflow":{
         "id":227,
         "ticker":"TBPH",
         "earnings":{
            "id":"5f2bc603713ee300019e00e7",
            "eps":"-0.800",
            "date":"2021-08-03",
            "name":"Theravance Biopharma",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"TBPH",
            "eps_est":"-1.010",
            "revenue":"12914000.000",
            "updated":1628022099,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.000",
            "importance":0,
            "period_year":2021,
            "revenue_est":"15410000.000",
            "eps_surprise":"0.2100",
            "revenue_type":"GAAP",
            "revenue_prior":"15008000.000",
            "date_confirmed":1,
            "revenue_surprise":"-2496000.0000",
            "eps_surprise_percent":"0.2079",
            "revenue_surprise_percent":"-0.1620"
         },
         "prev_quarter_earnings":{
            "id":"5eb260dd7f47df0001e14e20",
            "eps":"-1.240",
            "date":"2021-05-04",
            "name":"Theravance Biopharma",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"TBPH",
            "eps_est":"-1.050",
            "revenue":"14257000.000",
            "updated":1620161157,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.140",
            "importance":0,
            "period_year":2021,
            "revenue_est":"17270000.000",
            "eps_surprise":"-0.1900",
            "revenue_type":"GAAP",
            "revenue_prior":"19862000.000",
            "date_confirmed":1,
            "revenue_surprise":"-3013000.0000",
            "eps_surprise_percent":"-0.1810",
            "revenue_surprise_percent":"-0.1745"
         },
         "cash_equivalents_and_short_term_investments":264953000,
         "operating_cash_flow":-50113000,
         "monthly_cash_burn":-16704333,
         "est_live_cash":235442011,
         "est_months_cash":14.094666994485802,
         "total_liabilities":729625000,
         "net_cash":-494182989,
         "enterpriseValue":1435616621,
         "total_debt_to_equity":"",
         "float":41813005,
         "insiderholdingspct":7.5999999999999996
      },
      "updated_at_formatted":"12/08/2021"
   },
   {
      "id":3258,
      "name":"VB-111",
      "craft_entry_id":2958,
      "indication":"Recurrent platinum resistant ovarian cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":1,
      "press_link":"https://www.globenewswire.com/news-release/2021/08/16/2280945/0/en/VBL-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 DSMB review recommended trial to continue as planned - February 22, 2021. Next review 3Q 2021. PFS endpoint readout expected in 2022.",
      "estimated_primary_completion_date":"December 2022",
      "updated_at":"2021-08-16 07:19:39",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":301,
         "ticker":"VBLT",
         "name":"Vascular Biogenics Ltd.",
         "exchange":null,
         "price":1.98,
         "change":0.029999999999999999,
         "percent_change":1.54,
         "number_of_shares":62036525,
         "market_cap":122832320,
         "short_ratio":null,
         "volume":67739,
         "average_daily_volume":402013,
         "relative_volume":0.17000000000000001,
         "price_to_book":2.2000000000000002,
         "open":1.9100000000000001,
         "previous_close":1.95,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Ovarian cancer",
         "Oncology"
      ],
      "cashflow":{
         "id":237,
         "ticker":"VBLT",
         "earnings":{
            "id":"5f34e54f1ef0a0000183c3ba",
            "eps":"-0.120",
            "date":"2021-08-16",
            "name":"Vascular Biogenics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"VBLT",
            "eps_est":"-0.110",
            "revenue":"188000.000",
            "updated":1629112203,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.140",
            "importance":0,
            "period_year":2021,
            "revenue_est":"320000.000",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"158000.000",
            "date_confirmed":1,
            "revenue_surprise":"-132000.0000",
            "eps_surprise_percent":"-0.0909",
            "revenue_surprise_percent":"-0.4125"
         },
         "prev_quarter_earnings":{
            "id":"5ebcecd54b88bb0001fc301c",
            "eps":"-0.120",
            "date":"2021-05-11",
            "name":"Vascular Biogenics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"VBLT",
            "eps_est":"-0.130",
            "revenue":"185000.000",
            "updated":1620732224,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.150",
            "importance":0,
            "period_year":2021,
            "revenue_est":"200000.000",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"366000.000",
            "date_confirmed":1,
            "revenue_surprise":"-15000.0000",
            "eps_surprise_percent":"0.0769",
            "revenue_surprise_percent":"-0.0750"
         },
         "cash_equivalents_and_short_term_investments":56791000,
         "operating_cash_flow":-5462000,
         "monthly_cash_burn":-1820666,
         "est_live_cash":81874490,
         "est_months_cash":44.969527634393131,
         "total_liabilities":11485000,
         "net_cash":70389490,
         "enterpriseValue":68464319,
         "total_debt_to_equity":0.040000000000000001,
         "float":47358345,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"16/08/2021"
   },
   {
      "id":2235,
      "name":"EMPAVELI (pegcetacoplan) - OAKS",
      "craft_entry_id":13241,
      "indication":"Geographic atrophy (GA) associated with age-related macular degeneration (AMD)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-reports-second-quarter-2021-financial",
      "catalyst_date_text":"September 2021",
      "note":"Phase 3 data due September 2021.",
      "estimated_primary_completion_date":"July 30, 2021",
      "updated_at":"2021-08-09 20:09:32",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":465,
         "ticker":"APLS",
         "name":"Apellis Pharmaceuticals Inc.",
         "exchange":null,
         "price":61.25,
         "change":0.97999999999999998,
         "percent_change":1.6299999999999999,
         "number_of_shares":87003285,
         "market_cap":5328951206,
         "short_ratio":null,
         "volume":1035065,
         "average_daily_volume":859922,
         "relative_volume":1.2,
         "price_to_book":-37.579999999999998,
         "open":59.409999999999997,
         "previous_close":60.270000000000003,
         "created_at":"2018-01-24T06:32:57.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Geographic atrophy (GA)"
      ],
      "cashflow":{
         "id":375,
         "ticker":"APLS",
         "earnings":{
            "id":"5f251314bfce6200014a693d",
            "eps":"-2.720",
            "date":"2021-08-09",
            "name":"Apellis Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"APLS",
            "eps_est":"-1.700",
            "revenue":"623000.000",
            "updated":1628543590,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.570",
            "importance":1,
            "period_year":2021,
            "revenue_est":"810000.000",
            "eps_surprise":"-1.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"-187000.0000",
            "eps_surprise_percent":"-0.6000",
            "revenue_surprise_percent":"-0.2309"
         },
         "prev_quarter_earnings":{
            "id":"5eaa7780981f9a0001574025",
            "eps":"-2.320",
            "date":"2021-04-28",
            "name":"Apellis Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"APLS",
            "eps_est":"-1.620",
            "revenue":"0.000",
            "updated":1619645486,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-2.290",
            "importance":1,
            "period_year":2021,
            "revenue_est":"2270000.000",
            "eps_surprise":"-0.7000",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"-2270000.0000",
            "eps_surprise_percent":"-0.4321",
            "revenue_surprise_percent":"-1.0000"
         },
         "cash_equivalents_and_short_term_investments":599010000,
         "operating_cash_flow":-128688000,
         "monthly_cash_burn":-42896000,
         "est_live_cash":523227066,
         "est_months_cash":12.197572407683699,
         "total_liabilities":841405000,
         "net_cash":-318177934,
         "enterpriseValue":5139572206,
         "total_debt_to_equity":7.9400000000000004,
         "float":60293900,
         "insiderholdingspct":4.7999999999999998
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":7868,
      "name":"SerpinPC (ApcinteX)",
      "craft_entry_id":111824,
      "indication":"Hemophilia A",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-second-quarter-2021-financial",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2a top-line data due 3Q 2021.",
      "estimated_primary_completion_date":"April 2022",
      "updated_at":"2021-08-16 07:37:25",
      "stage":{
         "id":5,
         "label":"Phase 2a",
         "value":"phase2a"
      },
      "companies":{
         "id":940,
         "ticker":"CNTA",
         "name":"Centessa Pharmaceuticals plc",
         "exchange":null,
         "price":21.07,
         "change":0.070000000000000007,
         "percent_change":0.33000000000000002,
         "number_of_shares":89899419,
         "market_cap":1894180758,
         "short_ratio":null,
         "volume":21317,
         "average_daily_volume":197599,
         "relative_volume":0.11,
         "price_to_book":null,
         "open":21.300000000000001,
         "previous_close":21,
         "created_at":"2021-05-28T01:11:17.000000Z",
         "updated_at":"2021-08-20T23:55:05.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Hemophilia",
         "Hemophilia A"
      ],
      "cashflow":{
         "id":802,
         "ticker":"CNTA",
         "earnings":{
            "id":"60d2ecedcaedc70001d266b7",
            "eps":"-0.650",
            "date":"2021-08-16",
            "name":"Centessa Pharmaceuticals",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CNTA",
            "eps_est":"-0.730",
            "revenue":"0.000",
            "updated":1629190075,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0800",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.1096",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":null,
         "cash_equivalents_and_short_term_investments":613759000,
         "operating_cash_flow":null,
         "monthly_cash_burn":null,
         "est_live_cash":613759000,
         "est_months_cash":null,
         "total_liabilities":58115000,
         "net_cash":555644000,
         "enterpriseValue":1843706758,
         "total_debt_to_equity":0.01,
         "float":89000772,
         "insiderholdingspct":1
      },
      "updated_at_formatted":"16/08/2021"
   },
   {
      "id":3266,
      "name":"Tumor Treating Fields (TTFields) - INNOVATE-3",
      "craft_entry_id":2950,
      "indication":"Ovarian cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210729005357/en/",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 interim analysis 3Q 2021 with final data due 2023.",
      "estimated_primary_completion_date":"September 2023",
      "updated_at":"2021-07-29 08:15:06",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":216,
         "ticker":"NVCR",
         "name":"NovoCure Limited",
         "exchange":null,
         "price":132.43000000000001,
         "change":3.5699999999999998,
         "percent_change":2.77,
         "number_of_shares":103647871,
         "market_cap":13726087557,
         "short_ratio":null,
         "volume":270709,
         "average_daily_volume":725808,
         "relative_volume":0.37,
         "price_to_book":34.579999999999998,
         "open":128.78,
         "previous_close":128.86000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Ovarian cancer",
         "Oncology"
      ],
      "cashflow":{
         "id":176,
         "ticker":"NVCR",
         "earnings":{
            "id":"5f2270f844c96f00014e77c1",
            "eps":"-0.140",
            "date":"2021-07-29",
            "name":"NovoCure",
            "time":"06:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"NVCR",
            "eps_est":"0.010",
            "revenue":"133517000.000",
            "updated":1627554290,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"0.020",
            "importance":1,
            "period_year":2021,
            "revenue_est":"141890000.000",
            "eps_surprise":"-0.1500",
            "revenue_type":"GAAP",
            "revenue_prior":"115925000.000",
            "date_confirmed":1,
            "revenue_surprise":"-8373000.0000",
            "eps_surprise_percent":"-15.0000",
            "revenue_surprise_percent":"-0.0590"
         },
         "prev_quarter_earnings":{
            "id":"5eaa77bc981f9a00015741a3",
            "eps":"-0.040",
            "date":"2021-04-29",
            "name":"NovoCure",
            "time":"06:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"NVCR",
            "eps_est":"0.020",
            "revenue":"134695000.000",
            "updated":1619691325,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"0.040",
            "importance":1,
            "period_year":2021,
            "revenue_est":"139360000.000",
            "eps_surprise":"-0.0600",
            "revenue_type":"GAAP",
            "revenue_prior":"101828000.000",
            "date_confirmed":1,
            "revenue_surprise":"-4665000.0000",
            "eps_surprise_percent":"-3.0000",
            "revenue_surprise_percent":"-0.0335"
         },
         "cash_equivalents_and_short_term_investments":899031000,
         "operating_cash_flow":26172000,
         "monthly_cash_burn":8724000,
         "est_live_cash":914443400,
         "est_months_cash":104.81928014672168,
         "total_liabilities":699790000,
         "net_cash":214653400,
         "enterpriseValue":13399562556,
         "total_debt_to_equity":1.4399999999999999,
         "float":102348400,
         "insiderholdingspct":7.7000000000000002
      },
      "updated_at_formatted":"29/07/2021"
   },
   {
      "id":6594,
      "name":"Pacritinib (PRE-VENT)",
      "craft_entry_id":46380,
      "indication":"COVID-19",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/cti-biopharma-reports-second-quarter-2021-financial-results-301349723.html",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 interim data due 3Q 2021.",
      "estimated_primary_completion_date":"July 31, 2021",
      "updated_at":"2021-08-05 18:39:33",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":105,
         "ticker":"CTIC",
         "name":"CTI BioPharma Corp.",
         "exchange":null,
         "price":2.6000000000000001,
         "change":0.050000000000000003,
         "percent_change":1.96,
         "number_of_shares":93309923,
         "market_cap":242605800,
         "short_ratio":null,
         "volume":1652251,
         "average_daily_volume":576105,
         "relative_volume":2.8700000000000001,
         "price_to_book":3.9399999999999999,
         "open":2.54,
         "previous_close":2.5499999999999998,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Coronavirus",
         "COVID-19"
      ],
      "cashflow":{
         "id":88,
         "ticker":"CTIC",
         "earnings":{
            "id":"5f2cfc0fa3eee500019e8e95",
            "eps":"-0.210",
            "date":"2021-08-05",
            "name":"CTI BioPharma",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CTIC",
            "eps_est":"-0.210",
            "revenue":"0.000",
            "updated":1628199863,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.190",
            "importance":1,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0000",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0000",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eb50390f857860001768c46",
            "eps":"-0.230",
            "date":"2021-06-01",
            "name":"CTI BioPharma",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"CTIC",
            "eps_est":"-0.220",
            "revenue":"0.000",
            "updated":1622578614,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.200",
            "importance":1,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.0455",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":71881000,
         "operating_cash_flow":-17593000,
         "monthly_cash_burn":-5864333,
         "est_live_cash":61520678,
         "est_months_cash":10.490652219101474,
         "total_liabilities":15789000,
         "net_cash":45731678,
         "enterpriseValue":174714799,
         "total_debt_to_equity":0.059999999999999998,
         "float":71272835,
         "insiderholdingspct":8
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":5829,
      "name":"AT-007 (ACTION-Galactosemia kids)",
      "craft_entry_id":27263,
      "indication":"Galactosemia",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-reports-second-quarter-2021-financial",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1/2 trial clinical hold has been lifted - February 1, 2021. NDA filing due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-12 07:51:31",
      "stage":{
         "id":10,
         "label":"NDA Filing",
         "value":"ndaFiling"
      },
      "companies":{
         "id":665,
         "ticker":"APLT",
         "name":"Applied Therapeutics Inc.",
         "exchange":null,
         "price":16.16,
         "change":0.51000000000000001,
         "percent_change":3.2599999999999998,
         "number_of_shares":26177836,
         "market_cap":423033830,
         "short_ratio":null,
         "volume":49769,
         "average_daily_volume":88099,
         "relative_volume":0.56000000000000005,
         "price_to_book":3.7599999999999998,
         "open":15.51,
         "previous_close":15.65,
         "created_at":"2019-05-18T23:35:03.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Galactosemia"
      ],
      "cashflow":{
         "id":536,
         "ticker":"APLT",
         "earnings":{
            "id":"5f33937db7c159000133e705",
            "eps":"-0.990",
            "date":"2021-08-12",
            "name":"Applied Therapeutics",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"APLT",
            "eps_est":"-1.130",
            "revenue":"0.000",
            "updated":1628846914,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.270",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.1400",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.1239",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eba497ca2467b00013633df",
            "eps":"-1.000",
            "date":"2021-05-11",
            "name":"Applied Therapeutics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"APLT",
            "eps_est":"-1.010",
            "revenue":"0.000",
            "updated":1620733218,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.590",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0099",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":125616000,
         "operating_cash_flow":-25908000,
         "monthly_cash_burn":-8636000,
         "est_live_cash":110359066,
         "est_months_cash":12.778956229735989,
         "total_liabilities":24519000,
         "net_cash":85840066,
         "enterpriseValue":302115829,
         "total_debt_to_equity":0.040000000000000001,
         "float":17716529,
         "insiderholdingspct":3.2999999999999998
      },
      "updated_at_formatted":"12/08/2021"
   },
   {
      "id":7365,
      "name":"COVID-19 vaccine - CORAL",
      "craft_entry_id":84158,
      "indication":"COVID-19 vaccine",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-reports-first-quarter-2021-financial-results-and",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1 initial data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-05-06 09:57:49",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":592,
         "ticker":"GRTS",
         "name":"Gritstone bio Inc.",
         "exchange":null,
         "price":7.5300000000000002,
         "change":0.11,
         "percent_change":1.48,
         "number_of_shares":49447693,
         "market_cap":372341128,
         "short_ratio":null,
         "volume":770589,
         "average_daily_volume":653651,
         "relative_volume":1.1799999999999999,
         "price_to_book":2.0800000000000001,
         "open":7.5700000000000003,
         "previous_close":7.4199999999999999,
         "created_at":"2018-10-02T03:31:09.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Coronavirus",
         "COVID-19",
         "COVID-19 vaccine"
      ],
      "cashflow":{
         "id":467,
         "ticker":"GRTS",
         "earnings":{
            "id":"5f2bb7ca713ee300019dfed9",
            "eps":"-0.330",
            "date":"2021-08-05",
            "name":"Gritstone Oncology",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"GRTS",
            "eps_est":"-0.580",
            "revenue":"2843000.000",
            "updated":1628208653,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.690",
            "importance":0,
            "period_year":2021,
            "revenue_est":"2240000.000",
            "eps_surprise":"0.2500",
            "revenue_type":"GAAP",
            "revenue_prior":"488000.000",
            "date_confirmed":1,
            "revenue_surprise":"603000.0000",
            "eps_surprise_percent":"0.4310",
            "revenue_surprise_percent":"0.2692"
         },
         "prev_quarter_earnings":{
            "id":"5eb503a2f857860001768c7c",
            "eps":"0.100",
            "date":"2021-05-06",
            "name":"Gritstone Bio",
            "time":"09:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"GRTS",
            "eps_est":"-0.580",
            "revenue":"39693000.000",
            "updated":1620370199,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.710",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.6800",
            "revenue_type":"GAAP",
            "revenue_prior":"1262000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"1.1724",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":171182000,
         "operating_cash_flow":-22682000,
         "monthly_cash_burn":-7560666,
         "est_live_cash":157824823,
         "est_months_cash":20.874460398065462,
         "total_liabilities":45399000,
         "net_cash":112425823,
         "enterpriseValue":223506128,
         "total_debt_to_equity":0.12,
         "float":40257957,
         "insiderholdingspct":1.5
      },
      "updated_at_formatted":"06/05/2021"
   },
   {
      "id":6095,
      "name":"Roxadustat (WHITNEY)",
      "craft_entry_id":32290,
      "indication":"Chemotherapy-induced anemia (CIA)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-reports-second-quarter-2021-financial-results",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2 data due 3Q 2021.",
      "estimated_primary_completion_date":"March 26, 2021",
      "updated_at":"2021-08-09 19:26:41",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":142,
         "ticker":"FGEN",
         "name":"FibroGen Inc",
         "exchange":null,
         "price":12.109999999999999,
         "change":0.64000000000000001,
         "percent_change":5.5800000000000001,
         "number_of_shares":92621941,
         "market_cap":1121651706,
         "short_ratio":null,
         "volume":2053562,
         "average_daily_volume":1515642,
         "relative_volume":1.3500000000000001,
         "price_to_book":4.3099999999999996,
         "open":12.02,
         "previous_close":11.470000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Anemia"
      ],
      "cashflow":{
         "id":115,
         "ticker":"FGEN",
         "earnings":{
            "id":"5f2bb60a713ee300019dfe95",
            "eps":"-1.450",
            "date":"2021-08-09",
            "name":"FibroGen",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"FGEN",
            "eps_est":"-0.450",
            "revenue":"24364000.000",
            "updated":1628586902,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.950",
            "importance":0,
            "period_year":2021,
            "revenue_est":"71380000.000",
            "eps_surprise":"-1.0000",
            "revenue_type":"GAAP",
            "revenue_prior":"42888000.000",
            "date_confirmed":1,
            "revenue_surprise":"-47016000.0000",
            "eps_surprise_percent":"-2.2222",
            "revenue_surprise_percent":"-0.6587"
         },
         "prev_quarter_earnings":{
            "id":"5eb3b217885f2800019b34e2",
            "eps":"-0.780",
            "date":"2021-05-10",
            "name":"FibroGen",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"FGEN",
            "eps_est":"-0.870",
            "revenue":"38429000.000",
            "updated":1620678690,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.890",
            "importance":0,
            "period_year":2021,
            "revenue_est":"41790000.000",
            "eps_surprise":"0.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"24401000.000",
            "date_confirmed":1,
            "revenue_surprise":"-3361000.0000",
            "eps_surprise_percent":"0.1034",
            "revenue_surprise_percent":"-0.0804"
         },
         "cash_equivalents_and_short_term_investments":507212000,
         "operating_cash_flow":-26543000,
         "monthly_cash_burn":-8847666,
         "est_live_cash":491581123,
         "est_months_cash":55.560542520479409,
         "total_liabilities":528767000,
         "net_cash":-37185877,
         "enterpriseValue":719382705,
         "total_debt_to_equity":0.40000000000000002,
         "float":81614674,
         "insiderholdingspct":4.9000000000000004
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":6607,
      "name":"EMPAVELI (pegcetacoplan) - DERBY",
      "craft_entry_id":46559,
      "indication":"Geographic atrophy (GA)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-reports-second-quarter-2021-financial",
      "catalyst_date_text":"September 2021",
      "note":"Phase 3 data due September 2021.",
      "estimated_primary_completion_date":"July 30, 2021",
      "updated_at":"2021-08-09 20:08:55",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":465,
         "ticker":"APLS",
         "name":"Apellis Pharmaceuticals Inc.",
         "exchange":null,
         "price":61.25,
         "change":0.97999999999999998,
         "percent_change":1.6299999999999999,
         "number_of_shares":87003285,
         "market_cap":5328951206,
         "short_ratio":null,
         "volume":1035065,
         "average_daily_volume":859922,
         "relative_volume":1.2,
         "price_to_book":-37.579999999999998,
         "open":59.409999999999997,
         "previous_close":60.270000000000003,
         "created_at":"2018-01-24T06:32:57.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Geographic atrophy (GA)"
      ],
      "cashflow":{
         "id":375,
         "ticker":"APLS",
         "earnings":{
            "id":"5f251314bfce6200014a693d",
            "eps":"-2.720",
            "date":"2021-08-09",
            "name":"Apellis Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"APLS",
            "eps_est":"-1.700",
            "revenue":"623000.000",
            "updated":1628543590,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.570",
            "importance":1,
            "period_year":2021,
            "revenue_est":"810000.000",
            "eps_surprise":"-1.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"-187000.0000",
            "eps_surprise_percent":"-0.6000",
            "revenue_surprise_percent":"-0.2309"
         },
         "prev_quarter_earnings":{
            "id":"5eaa7780981f9a0001574025",
            "eps":"-2.320",
            "date":"2021-04-28",
            "name":"Apellis Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"APLS",
            "eps_est":"-1.620",
            "revenue":"0.000",
            "updated":1619645486,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-2.290",
            "importance":1,
            "period_year":2021,
            "revenue_est":"2270000.000",
            "eps_surprise":"-0.7000",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"-2270000.0000",
            "eps_surprise_percent":"-0.4321",
            "revenue_surprise_percent":"-1.0000"
         },
         "cash_equivalents_and_short_term_investments":599010000,
         "operating_cash_flow":-128688000,
         "monthly_cash_burn":-42896000,
         "est_live_cash":523227066,
         "est_months_cash":12.197572407683699,
         "total_liabilities":841405000,
         "net_cash":-318177934,
         "enterpriseValue":5139572206,
         "total_debt_to_equity":7.9400000000000004,
         "float":60293900,
         "insiderholdingspct":4.7999999999999998
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":7887,
      "name":"LPCN 1154",
      "craft_entry_id":114897,
      "indication":"Postpartum Depression",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-second-quarter-ended-june-30-2021-301348161.html",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2 trial planned. Dosing to commence 4Q 2021. PK data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-05 09:15:12",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":189,
         "ticker":"LPCN",
         "name":"Lipocine Inc.",
         "exchange":null,
         "price":1.3900000000000001,
         "change":0,
         "percent_change":null,
         "number_of_shares":88290650,
         "market_cap":122724003,
         "short_ratio":null,
         "volume":802107,
         "average_daily_volume":918275,
         "relative_volume":0.87,
         "price_to_book":3.48,
         "open":1.3700000000000001,
         "previous_close":1.3900000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Depression",
         "Postpartum depression (PPD)"
      ],
      "cashflow":{
         "id":152,
         "ticker":"LPCN",
         "earnings":{
            "id":"5f2cfc29a3eee500019e8ef9",
            "eps":"-0.030",
            "date":"2021-08-05",
            "name":"Lipocine",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"LPCN",
            "eps_est":"-0.050",
            "revenue":"0.000",
            "updated":1628172684,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.130",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.4000",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eb503b1f857860001768cb6",
            "eps":"-0.040",
            "date":"2021-05-06",
            "name":"Lipocine",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"LPCN",
            "eps_est":"-0.050",
            "revenue":"0.000",
            "updated":1620370554,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.140",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.2000",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":46639772,
         "operating_cash_flow":-2363282,
         "monthly_cash_burn":-787760,
         "est_live_cash":45248062,
         "est_months_cash":57.438892556108456,
         "total_liabilities":11433720,
         "net_cash":33814342,
         "enterpriseValue":80041858,
         "total_debt_to_equity":0.11,
         "float":86149561,
         "insiderholdingspct":3.5
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":8144,
      "name":"DMT410",
      "craft_entry_id":126156,
      "indication":"Aesthetic conditions",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.sec.gov/Archives/edgar/data/0001853816/000119312521238151/d137089ds1a.htm",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2 data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-12 22:01:22",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":995,
         "ticker":"DRMA",
         "name":"Dermata Therapeutics Inc.",
         "exchange":null,
         "price":4.6100000000000003,
         "change":-0.33999999999999997,
         "percent_change":-6.8700000000000001,
         "number_of_shares":8328629,
         "market_cap":38394980,
         "short_ratio":null,
         "volume":70159,
         "average_daily_volume":0,
         "relative_volume":0,
         "price_to_book":57.619999999999997,
         "open":4.71,
         "previous_close":4.9500000000000002,
         "created_at":"2021-08-13T01:47:16.000000Z",
         "updated_at":"2021-08-20T23:55:05.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         
      ],
      "cashflow":{
         "id":852,
         "ticker":"DRMA",
         "earnings":null,
         "prev_quarter_earnings":null,
         "cash_equivalents_and_short_term_investments":1330415,
         "operating_cash_flow":-776220,
         "monthly_cash_burn":-258740,
         "est_live_cash":88463,
         "est_months_cash":0.3418992038339646,
         "total_liabilities":939182,
         "net_cash":-850719,
         "enterpriseValue":37246576,
         "total_debt_to_equity":0.25,
         "float":1768271,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"12/08/2021"
   },
   {
      "id":5586,
      "name":"Diazoxide Choline Controlled-Release (DCCR) - DESTINY PWS",
      "craft_entry_id":24469,
      "indication":"Prader-Willi syndrome (PWS)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.globenewswire.com/news-release/2021/07/28/2270692/0/en/Soleno-Therapeutics-Provides-Corporate-Update-and-Reports-Second-Quarter-2021-Financial-Results.html",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 trial did not meet its primary endpoint - June 8, 2020. Further trial required. Data to be submitted to FDA 3Q 2021. ",
      "estimated_primary_completion_date":"May 1, 2020",
      "updated_at":"2021-07-28 16:56:15",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":610,
         "ticker":"SLNO",
         "name":"Soleno Therapeutics Inc.",
         "exchange":null,
         "price":0.81999999999999995,
         "change":0.02,
         "percent_change":2.7800000000000002,
         "number_of_shares":79759225,
         "market_cap":65721601,
         "short_ratio":null,
         "volume":177603,
         "average_daily_volume":835542,
         "relative_volume":0.20999999999999999,
         "price_to_book":2.4199999999999999,
         "open":0.82999999999999996,
         "previous_close":0.80000000000000004,
         "created_at":"2018-11-16T03:16:47.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Prader-Willi Syndrome (PWS)"
      ],
      "cashflow":{
         "id":485,
         "ticker":"SLNO",
         "earnings":{
            "id":"5f3242389c32ef000199d5da",
            "eps":"-0.140",
            "date":"2021-07-28",
            "name":"Soleno Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"SLNO",
            "eps_est":"",
            "revenue":"0.000",
            "updated":1627512897,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.160",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ebb9b430f28ed0001709823",
            "eps":"-0.110",
            "date":"2021-05-05",
            "name":"Soleno Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"SLNO",
            "eps_est":"-0.080",
            "revenue":"0.000",
            "updated":1620284386,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.130",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.3750",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":33596000,
         "operating_cash_flow":-8013000,
         "monthly_cash_burn":-2671000,
         "est_live_cash":28877233,
         "est_months_cash":10.811393859977537,
         "total_liabilities":21341000,
         "net_cash":7536233,
         "enterpriseValue":32677601,
         "total_debt_to_equity":0.02,
         "float":52002724,
         "insiderholdingspct":2.8999999999999999
      },
      "updated_at_formatted":"28/07/2021"
   },
   {
      "id":3048,
      "name":"Ampreloxetine",
      "craft_entry_id":3635,
      "indication":"nOH",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/theravance-biopharma-inc-reports-second-quarter-2021-financial-results-and-provides-business-update-301347426.html",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 data due 3Q 2021.",
      "estimated_primary_completion_date":"August 2021",
      "updated_at":"2021-08-03 16:36:44",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":289,
         "ticker":"TBPH",
         "name":"Theravance Biopharma Inc.",
         "exchange":null,
         "price":14.050000000000001,
         "change":0.56000000000000005,
         "percent_change":4.1500000000000004,
         "number_of_shares":73470151,
         "market_cap":1032255622,
         "short_ratio":null,
         "volume":773329,
         "average_daily_volume":432890,
         "relative_volume":1.79,
         "price_to_book":-3.4399999999999999,
         "open":13.369999999999999,
         "previous_close":13.49,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Neurogenic Orthostatic Hypotension (nOH)"
      ],
      "cashflow":{
         "id":227,
         "ticker":"TBPH",
         "earnings":{
            "id":"5f2bc603713ee300019e00e7",
            "eps":"-0.800",
            "date":"2021-08-03",
            "name":"Theravance Biopharma",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"TBPH",
            "eps_est":"-1.010",
            "revenue":"12914000.000",
            "updated":1628022099,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.000",
            "importance":0,
            "period_year":2021,
            "revenue_est":"15410000.000",
            "eps_surprise":"0.2100",
            "revenue_type":"GAAP",
            "revenue_prior":"15008000.000",
            "date_confirmed":1,
            "revenue_surprise":"-2496000.0000",
            "eps_surprise_percent":"0.2079",
            "revenue_surprise_percent":"-0.1620"
         },
         "prev_quarter_earnings":{
            "id":"5eb260dd7f47df0001e14e20",
            "eps":"-1.240",
            "date":"2021-05-04",
            "name":"Theravance Biopharma",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"TBPH",
            "eps_est":"-1.050",
            "revenue":"14257000.000",
            "updated":1620161157,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.140",
            "importance":0,
            "period_year":2021,
            "revenue_est":"17270000.000",
            "eps_surprise":"-0.1900",
            "revenue_type":"GAAP",
            "revenue_prior":"19862000.000",
            "date_confirmed":1,
            "revenue_surprise":"-3013000.0000",
            "eps_surprise_percent":"-0.1810",
            "revenue_surprise_percent":"-0.1745"
         },
         "cash_equivalents_and_short_term_investments":264953000,
         "operating_cash_flow":-50113000,
         "monthly_cash_burn":-16704333,
         "est_live_cash":235442011,
         "est_months_cash":14.094666994485802,
         "total_liabilities":729625000,
         "net_cash":-494182989,
         "enterpriseValue":1435616621,
         "total_debt_to_equity":"",
         "float":41813005,
         "insiderholdingspct":7.5999999999999996
      },
      "updated_at_formatted":"03/08/2021"
   },
   {
      "id":4584,
      "name":"BXCL701 and KEYTRUDA (pembrolizumab)",
      "craft_entry_id":15250,
      "indication":"Neuroendocrine Prostate Cancer (NEPC)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":1,
      "press_link":"https://ir.bioxceltherapeutics.com/press-releases/detail/171/bioxcel-therapeutics-reports-second-quarter-2021-financial",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 2 data due 3Q 2021.",
      "estimated_primary_completion_date":"April 2, 2022",
      "updated_at":"2021-08-10 07:55:38",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":533,
         "ticker":"BTAI",
         "name":"BioXcel Therapeutics Inc.",
         "exchange":null,
         "price":24.27,
         "change":-0.18000000000000005,
         "percent_change":-0.73999999999999999,
         "number_of_shares":27968988,
         "market_cap":678807339,
         "short_ratio":null,
         "volume":309136,
         "average_daily_volume":414803,
         "relative_volume":0.75,
         "price_to_book":2.54,
         "open":24.18,
         "previous_close":24.449999999999999,
         "created_at":"2018-04-05T05:52:53.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Oncology",
         "Prostate cancer"
      ],
      "cashflow":{
         "id":411,
         "ticker":"BTAI",
         "earnings":{
            "id":"5f36368463170b0001c8783d",
            "eps":"-1.110",
            "date":"2021-08-10",
            "name":"BioXcel Therapeutics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"BTAI",
            "eps_est":"-1.080",
            "revenue":"0.000",
            "updated":1628596325,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.060",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.0278",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eba4984a2467b00013633f9",
            "eps":"-1.080",
            "date":"2021-05-10",
            "name":"BioXcel Therapeutics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"BTAI",
            "eps_est":"-0.940",
            "revenue":"0.000",
            "updated":1620645063,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.790",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.1400",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.1489",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":273057000,
         "operating_cash_flow":-22382000,
         "monthly_cash_burn":-7460666,
         "est_live_cash":259876490,
         "est_months_cash":34.832880871493245,
         "total_liabilities":13696000,
         "net_cash":246180490,
         "enterpriseValue":407005338,
         "total_debt_to_equity":0,
         "float":18482964,
         "insiderholdingspct":0.80000000000000004
      },
      "updated_at_formatted":"10/08/2021"
   },
   {
      "id":5608,
      "name":"ASLAN004",
      "craft_entry_id":24893,
      "indication":"Atopic dermatitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"http://aslanpharma.com/app/uploads/2021/08/ASLAN-Pharmaceuticals-2Q2021-Financial-Results.pdf",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1 top-line data due end of 3Q 2021. Phase 2b trial to be initiated 4Q 2021.",
      "estimated_primary_completion_date":"August 30, 2021",
      "updated_at":"2021-08-06 07:42:57",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":550,
         "ticker":"ASLN",
         "name":"ASLAN Pharmaceuticals Limited",
         "exchange":null,
         "price":2.3199999999999998,
         "change":-0.069999999999999951,
         "percent_change":-2.9300000000000002,
         "number_of_shares":69617212,
         "market_cap":161511932,
         "short_ratio":null,
         "volume":967722,
         "average_daily_volume":1062160,
         "relative_volume":0.91000000000000003,
         "price_to_book":2.1499999999999999,
         "open":2.3500000000000001,
         "previous_close":2.3900000000000001,
         "created_at":"2018-05-13T20:53:22.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Atopic dermatitis"
      ],
      "cashflow":{
         "id":427,
         "ticker":"ASLN",
         "earnings":{
            "id":"5f0d580e652c2f0001a90744",
            "eps":"-0.020",
            "date":"2021-08-06",
            "name":"ASLAN Pharmaceuticals",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ASLN",
            "eps_est":"-0.110",
            "revenue":"0.000",
            "updated":1628501149,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.100",
            "importance":3,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.8182",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5e731882fe45f20001a6e8a6",
            "eps":"-0.150",
            "date":"2021-04-22",
            "name":"ASLAN Pharmaceuticals",
            "time":"07:51:00",
            "notes":"",
            "period":"Q4",
            "ticker":"ASLN",
            "eps_est":"-0.110",
            "revenue":"0.000",
            "updated":1619162586,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.180",
            "importance":3,
            "period_year":2020,
            "revenue_est":"",
            "eps_surprise":"-0.0400",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.3636",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":94120158,
         "operating_cash_flow":null,
         "monthly_cash_burn":null,
         "est_live_cash":114120158,
         "est_months_cash":null,
         "total_liabilities":20670070,
         "net_cash":93450088,
         "enterpriseValue":82951183,
         "total_debt_to_equity":0.20999999999999999,
         "float":69617212,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"06/08/2021"
   },
   {
      "id":6893,
      "name":"Pevonedistat (TAK-924)",
      "craft_entry_id":57857,
      "indication":"Higher-risk myelodysplastic syndromes (HR-MDS)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.takeda.com/4a21eb/siteassets/system/investors/report/quarterlyannouncements/fy2021/qr2021_q1_p01_en.pdf",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 3 data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-07-30 03:11:00",
      "stage":{
         "id":9,
         "label":"Phase 3",
         "value":"phase3"
      },
      "companies":{
         "id":751,
         "ticker":"TAK",
         "name":"Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)",
         "exchange":null,
         "price":16.68,
         "change":0.089999999999999997,
         "percent_change":0.54000000000000004,
         "number_of_shares":3145059016,
         "market_cap":52459584387,
         "short_ratio":null,
         "volume":966440,
         "average_daily_volume":1875590,
         "relative_volume":0.52000000000000002,
         "price_to_book":1.1000000000000001,
         "open":16.609999999999999,
         "previous_close":16.59,
         "created_at":"2020-05-04T06:35:24.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Myelodysplastic syndromes (MDS)"
      ],
      "cashflow":{
         "id":616,
         "ticker":"TAK",
         "earnings":{
            "id":"5f23c4c0bcf9e90001c5d047",
            "eps":"1.030",
            "date":"2021-07-30",
            "name":"Takeda Pharmaceutical",
            "time":"15:00:00",
            "notes":"FXC",
            "period":"Q1",
            "ticker":"TAK",
            "eps_est":"",
            "revenue":"8641000000.000",
            "updated":1628087142,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"1.140",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"7458000000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ec4d5cd88a06b0001f81c6d",
            "eps":"0.820",
            "date":"2021-05-11",
            "name":"Takeda Pharmaceutical",
            "time":"15:00:00",
            "notes":"FXC",
            "period":"Q4",
            "ticker":"TAK",
            "eps_est":"",
            "revenue":"7241000000.000",
            "updated":1622023626,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NYSE",
            "eps_prior":"0.010",
            "importance":3,
            "period_year":2020,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"7079000000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":684850000000,
         "operating_cash_flow":166858000000,
         "monthly_cash_burn":55619333333,
         "est_live_cash":783110822221,
         "est_months_cash":14.079831153897805,
         "total_liabilities":7418591000000,
         "net_cash":-6635480177779,
         "enterpriseValue":86297643852,
         "total_debt_to_equity":0.82999999999999996,
         "float":3145059016,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"30/07/2021"
   },
   {
      "id":7151,
      "name":"HPP737",
      "craft_entry_id":72991,
      "indication":"Psoriasis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-2021-second-quarter-financial-results",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1 top-line data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-04 17:40:49",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":310,
         "ticker":"VTVT",
         "name":"vTv Therapeutics Inc.",
         "exchange":null,
         "price":1.71,
         "change":0.029999999999999999,
         "percent_change":1.79,
         "number_of_shares":83287827,
         "market_cap":142422184,
         "short_ratio":null,
         "volume":207198,
         "average_daily_volume":1297436,
         "relative_volume":0.16,
         "price_to_book":-3,
         "open":1.7,
         "previous_close":1.6800000000000002,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Psoriasis"
      ],
      "cashflow":{
         "id":243,
         "ticker":"VTVT",
         "earnings":{
            "id":"5f2909f02902dd0001f8575a",
            "eps":"-0.010",
            "date":"2021-08-04",
            "name":"vTv Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"VTVT",
            "eps_est":"-0.070",
            "revenue":"9000.000",
            "updated":1628152667,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.080",
            "importance":0,
            "period_year":2021,
            "revenue_est":"1000000.000",
            "eps_surprise":"0.0600",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"-991000.0000",
            "eps_surprise_percent":"0.8571",
            "revenue_surprise_percent":"-0.9910"
         },
         "prev_quarter_earnings":{
            "id":"5eb503e0f857860001768d64",
            "eps":"-0.090",
            "date":"2021-05-05",
            "name":"vTv Therapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"VTVT",
            "eps_est":"-0.060",
            "revenue":"987000.000",
            "updated":1620284076,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.110",
            "importance":0,
            "period_year":2021,
            "revenue_est":"987000.000",
            "eps_surprise":"-0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"8000.000",
            "date_confirmed":1,
            "revenue_surprise":"0.0000",
            "eps_surprise_percent":"-0.5000",
            "revenue_surprise_percent":"0.0000"
         },
         "cash_equivalents_and_short_term_investments":10835000,
         "operating_cash_flow":-3998000,
         "monthly_cash_burn":-1332666,
         "est_live_cash":8480623,
         "est_months_cash":6.3636522579551063,
         "total_liabilities":69483000,
         "net_cash":-61002377,
         "enterpriseValue":132343183,
         "total_debt_to_equity":"",
         "float":23541468,
         "insiderholdingspct":0.29999999999999999
      },
      "updated_at_formatted":"04/08/2021"
   },
   {
      "id":7409,
      "name":"Toripalimab",
      "craft_entry_id":86457,
      "indication":"Nasopharyngeal carcinoma (NPC)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.coherus.com/news-releases/news-release-details/coherus-biosciences-reports-second-quarter-2021-financial",
      "catalyst_date_text":"3Q 2021",
      "note":"BLA rolling submission has been initiated - March 3, 2021. To be completed 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-05 20:14:58",
      "stage":{
         "id":12,
         "label":"BLA Filing",
         "value":"blaFiling"
      },
      "companies":{
         "id":89,
         "ticker":"CHRS",
         "name":"Coherus BioSciences Inc.",
         "exchange":null,
         "price":15,
         "change":0.46999999999999997,
         "percent_change":3.23,
         "number_of_shares":76480152,
         "market_cap":1147202280,
         "short_ratio":null,
         "volume":810240,
         "average_daily_volume":627775,
         "relative_volume":1.29,
         "price_to_book":7.3499999999999996,
         "open":14.23,
         "previous_close":14.529999999999999,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Nasopharyngeal carcinoma (NPC)"
      ],
      "cashflow":{
         "id":73,
         "ticker":"CHRS",
         "earnings":{
            "id":"5f2cfc0ba3eee500019e8e7f",
            "eps":"-0.360",
            "date":"2021-08-05",
            "name":"Coherus BioSciences",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CHRS",
            "eps_est":"-0.170",
            "revenue":"87643000.000",
            "updated":1628206345,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"0.810",
            "importance":2,
            "period_year":2021,
            "revenue_est":"89810000.000",
            "eps_surprise":"-0.1900",
            "revenue_type":"GAAP",
            "revenue_prior":"135674000.000",
            "date_confirmed":1,
            "revenue_surprise":"-2167000.0000",
            "eps_surprise_percent":"-1.1176",
            "revenue_surprise_percent":"-0.0241"
         },
         "prev_quarter_earnings":{
            "id":"5eb3b208885f2800019b3434",
            "eps":"0.010",
            "date":"2021-05-06",
            "name":"Coherus BioSciences",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"CHRS",
            "eps_est":"0.060",
            "revenue":"83034000.000",
            "updated":1620335628,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"0.480",
            "importance":2,
            "period_year":2021,
            "revenue_est":"96000000.000",
            "eps_surprise":"-0.0500",
            "revenue_type":"GAAP",
            "revenue_prior":"116180000.000",
            "date_confirmed":1,
            "revenue_surprise":"-12966000.0000",
            "eps_surprise_percent":"-0.8333",
            "revenue_surprise_percent":"-0.1351"
         },
         "cash_equivalents_and_short_term_investments":454421000,
         "operating_cash_flow":-188000,
         "monthly_cash_burn":-62666,
         "est_live_cash":454310290,
         "est_months_cash":7249.7094118022533,
         "total_liabilities":583322000,
         "net_cash":-129011710,
         "enterpriseValue":1110723280,
         "total_debt_to_equity":2.6800000000000002,
         "float":54173405,
         "insiderholdingspct":1.3999999999999999
      },
      "updated_at_formatted":"05/08/2021"
   },
   {
      "id":6898,
      "name":"KB295",
      "craft_entry_id":58492,
      "indication":"Ulcerative colitis (UC)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://investors.kaleido.com/news-releases/news-release-details/kaleido-biosciences-reports-second-quarter-2021-financial",
      "catalyst_date_text":"3Q 2021",
      "note":"Top-line data due 3Q 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-11 07:38:35",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":638,
         "ticker":"KLDO",
         "name":"Kaleido Biosciences Inc.",
         "exchange":null,
         "price":5.8300000000000001,
         "change":-0.069999999999999951,
         "percent_change":-1.1899999999999999,
         "number_of_shares":42577529,
         "market_cap":248226994,
         "short_ratio":null,
         "volume":272749,
         "average_daily_volume":295643,
         "relative_volume":0.92000000000000004,
         "price_to_book":4.9399999999999995,
         "open":5.7800000000000002,
         "previous_close":5.9000000000000004,
         "created_at":"2019-03-02T12:24:33.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Ulcerative Colitis"
      ],
      "cashflow":{
         "id":510,
         "ticker":"KLDO",
         "earnings":{
            "id":"5f2a5a48fa46620001949fc8",
            "eps":"-0.560",
            "date":"2021-08-11",
            "name":"Kaleido Biosciences",
            "time":"07:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"KLDO",
            "eps_est":"-0.570",
            "revenue":"211000.000",
            "updated":1628689125,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.590",
            "importance":0,
            "period_year":2021,
            "revenue_est":"110000.000",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"250000.000",
            "date_confirmed":1,
            "revenue_surprise":"101000.0000",
            "eps_surprise_percent":"0.0175",
            "revenue_surprise_percent":"0.9182"
         },
         "prev_quarter_earnings":{
            "id":"5ebcecaa4b88bb0001fc2f7e",
            "eps":"-0.580",
            "date":"2021-05-04",
            "name":"Kaleido Biosciences",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"KLDO",
            "eps_est":"-0.590",
            "revenue":"297000.000",
            "updated":1620200320,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.640",
            "importance":0,
            "period_year":2021,
            "revenue_est":"60000",
            "eps_surprise":"0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0169",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":71979000,
         "operating_cash_flow":-20083000,
         "monthly_cash_burn":-6694333,
         "est_live_cash":60152345,
         "est_months_cash":8.9855621164946538,
         "total_liabilities":34024000,
         "net_cash":26128345,
         "enterpriseValue":197591994,
         "total_debt_to_equity":0.41999999999999998,
         "float":20994841,
         "insiderholdingspct":4.7000000000000002
      },
      "updated_at_formatted":"11/08/2021"
   },
   {
      "id":5876,
      "name":"STK-001 - (MONARCH)",
      "craft_entry_id":28400,
      "indication":"Dravet syndrome",
      "advisory_committee_date":false,
      "catalyst_date":"2021-09-30",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210810005157/en/",
      "catalyst_date_text":"3Q 2021",
      "note":"Phase 1/2 preliminary safety and pharmacokinetic data due 3Q 2021.",
      "estimated_primary_completion_date":"June 27, 2023",
      "updated_at":"2021-08-10 07:16:54",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":670,
         "ticker":"STOK",
         "name":"Stoke Therapeutics Inc.",
         "exchange":null,
         "price":24.899999999999999,
         "change":1.1699999999999999,
         "percent_change":4.9299999999999997,
         "number_of_shares":36749090,
         "market_cap":915052341,
         "short_ratio":null,
         "volume":104170,
         "average_daily_volume":146413,
         "relative_volume":0.70999999999999996,
         "price_to_book":3.5899999999999999,
         "open":23.52,
         "previous_close":23.73,
         "created_at":"2019-06-19T18:41:00.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Dravet Syndrome"
      ],
      "cashflow":{
         "id":541,
         "ticker":"STOK",
         "earnings":{
            "id":"5f32423b9c32ef000199d5ee",
            "eps":"-0.600",
            "date":"2021-08-10",
            "name":"Stoke Therapeutics",
            "time":"07:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"STOK",
            "eps_est":"-0.470",
            "revenue":"0.000",
            "updated":1628595127,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.390",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.1300",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.2766",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ebf8fc9c4c5830001020651",
            "eps":"-0.460",
            "date":"2021-05-10",
            "name":"Stoke Therapeutics",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"STOK",
            "eps_est":"-0.460",
            "revenue":"0.000",
            "updated":1620720672,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.340",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0000",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0000",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":251226000,
         "operating_cash_flow":-15831000,
         "monthly_cash_burn":-5277000,
         "est_live_cash":241903300,
         "est_months_cash":45.841064999052492,
         "total_liabilities":9381000,
         "net_cash":232522300,
         "enterpriseValue":664418341,
         "total_debt_to_equity":0,
         "float":18959096,
         "insiderholdingspct":1.5
      },
      "updated_at_formatted":"10/08/2021"
   },
   {
      "id":5914,
      "name":"AG019 ActoBiotics",
      "craft_entry_id":28895,
      "indication":"Type 1 diabetes",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-01",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/precigen-reports-second-quarter-and-first-half-2021-financial-results-301351238.html",
      "catalyst_date_text":"",
      "note":"Phase 1b/2a further data due October 1, 2021.",
      "estimated_primary_completion_date":"October 31, 2021",
      "updated_at":"2021-08-09 19:31:47",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":730,
         "ticker":"PGEN",
         "name":"Precigen Inc.",
         "exchange":null,
         "price":5.6200000000000001,
         "change":0.13,
         "percent_change":2.3700000000000001,
         "number_of_shares":206643428,
         "market_cap":1161336065,
         "short_ratio":null,
         "volume":868652,
         "average_daily_volume":1241821,
         "relative_volume":0.69999999999999996,
         "price_to_book":7.2999999999999998,
         "open":5.4400000000000004,
         "previous_close":5.4900000000000002,
         "created_at":"2020-01-02T20:39:08.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Type 1 diabetes"
      ],
      "cashflow":{
         "id":604,
         "ticker":"PGEN",
         "earnings":{
            "id":"5f30f0b8a7bff3000162b301",
            "eps":"-0.100",
            "date":"2021-08-09",
            "name":"Precigen",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"PGEN",
            "eps_est":"-0.120",
            "revenue":"33580000.000",
            "updated":1628540184,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.260",
            "importance":0,
            "period_year":2021,
            "revenue_est":"21070000.000",
            "eps_surprise":"0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"30424000.000",
            "date_confirmed":1,
            "revenue_surprise":"12510000.0000",
            "eps_surprise_percent":"0.1667",
            "revenue_surprise_percent":"0.5937"
         },
         "prev_quarter_earnings":{
            "id":"5eb260c97f47df0001e14d76",
            "eps":"-0.110",
            "date":"2021-05-10",
            "name":"Precigen",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"PGEN",
            "eps_est":"-0.150",
            "revenue":"24511000.000",
            "updated":1620719626,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.190",
            "importance":0,
            "period_year":2021,
            "revenue_est":"21580000.000",
            "eps_surprise":"0.0400",
            "revenue_type":"GAAP",
            "revenue_prior":"29838000.000",
            "date_confirmed":1,
            "revenue_surprise":"2931000.0000",
            "eps_surprise_percent":"0.2667",
            "revenue_surprise_percent":"0.1358"
         },
         "cash_equivalents_and_short_term_investments":115106000,
         "operating_cash_flow":-7776000,
         "monthly_cash_burn":-2592000,
         "est_live_cash":110526800,
         "est_months_cash":42.641512345679011,
         "total_liabilities":243377000,
         "net_cash":-132850200,
         "enterpriseValue":1237266065,
         "total_debt_to_equity":1.2,
         "float":94205701,
         "insiderholdingspct":2.1000000000000001
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":4969,
      "name":"EB613",
      "craft_entry_id":17964,
      "indication":"Osteoporosis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-01",
      "fda_calendar":0,
      "press_link":"https://investors.enterabio.com/news-releases/news-release-details/entera-bio-present-phase-2-eb613-oral-pth-osteoporosis-treatment",
      "catalyst_date_text":"",
      "note":"Phase 2 interim biomarker met primary endpoint - March 11, 2021. Final data released June 23, 2021. Data to be presented October 1-4, 2021 at American Society for Bone and Mineral Research Annual Meeting. Phase 3 trial to be initiated in 2022.",
      "estimated_primary_completion_date":"April 27, 2021",
      "updated_at":"2021-08-02 08:45:06",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":571,
         "ticker":"ENTX",
         "name":"Entera Bio Ltd.",
         "exchange":null,
         "price":4.5899999999999999,
         "change":0.16,
         "percent_change":3.6099999999999999,
         "number_of_shares":18234191,
         "market_cap":83694937,
         "short_ratio":null,
         "volume":119805,
         "average_daily_volume":3982060,
         "relative_volume":0.029999999999999999,
         "price_to_book":13.91,
         "open":4.3700000000000001,
         "previous_close":4.4299999999999997,
         "created_at":"2018-07-04T23:04:46.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Osteoporosis"
      ],
      "cashflow":{
         "id":447,
         "ticker":"ENTX",
         "earnings":{
            "id":"5f3e1f9030cb9400010233e2",
            "eps":"-0.200",
            "date":"2021-08-16",
            "name":"Entera Bio",
            "time":"06:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ENTX",
            "eps_est":"-0.120",
            "revenue":"109000.000",
            "updated":1629110867,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.170",
            "importance":0,
            "period_year":2021,
            "revenue_est":"90000.000",
            "eps_surprise":"-0.0800",
            "revenue_type":"GAAP",
            "revenue_prior":"52000.000",
            "date_confirmed":1,
            "revenue_surprise":"19000.0000",
            "eps_surprise_percent":"-0.6667",
            "revenue_surprise_percent":"0.2111"
         },
         "prev_quarter_earnings":{
            "id":"5ec778938cc42e000106d5b7",
            "eps":"-0.430",
            "date":"2021-05-20",
            "name":"Entera Bio",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ENTX",
            "eps_est":"-0.120",
            "revenue":"157000.000",
            "updated":1621513719,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.160",
            "importance":0,
            "period_year":2021,
            "revenue_est":"90000.000",
            "eps_surprise":"-0.3100",
            "revenue_type":"GAAP",
            "revenue_prior":"42000.000",
            "date_confirmed":1,
            "revenue_surprise":"67000.0000",
            "eps_surprise_percent":"-2.5833",
            "revenue_surprise_percent":"0.7444"
         },
         "cash_equivalents_and_short_term_investments":26926000,
         "operating_cash_flow":-2072000,
         "monthly_cash_burn":-690666,
         "est_live_cash":25705823,
         "est_months_cash":37.218891620551759,
         "total_liabilities":3624000,
         "net_cash":22081823,
         "enterpriseValue":28939303,
         "total_debt_to_equity":0.01,
         "float":6309570,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"02/08/2021"
   },
   {
      "id":6610,
      "name":"ANVS401",
      "craft_entry_id":46606,
      "indication":"Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-01",
      "fda_calendar":0,
      "press_link":"https://www.newsfilecorp.com/release/92796",
      "catalyst_date_text":"Early-Fall 2021",
      "note":"Phase 2a completion of dosing announced August 11, 2021 full data due early Fall 2021. Phase 3 trial to be initiated 1Q 2022. ",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-19 18:33:11",
      "stage":{
         "id":5,
         "label":"Phase 2a",
         "value":"phase2a"
      },
      "companies":{
         "id":735,
         "ticker":"ANVS",
         "name":"Annovis Bio Inc.",
         "exchange":null,
         "price":37.100000000000001,
         "change":2,
         "percent_change":5.7000000000000002,
         "number_of_shares":8100570,
         "market_cap":300531147,
         "short_ratio":null,
         "volume":278285,
         "average_daily_volume":885473,
         "relative_volume":0.31,
         "price_to_book":6.1799999999999997,
         "open":34.880000000000003,
         "previous_close":35.100000000000001,
         "created_at":"2020-01-29T07:43:35.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Parkinson\u2019s disease",
         "Alzheimer\u2019s disease"
      ],
      "cashflow":{
         "id":600,
         "ticker":"ANVS",
         "earnings":{
            "id":"5f251313bfce6200014a693b",
            "eps":"-0.340",
            "date":"2021-07-29",
            "name":"Annovis Bio",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ANVS",
            "eps_est":"",
            "revenue":"0.000",
            "updated":1627894901,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"AMEX",
            "eps_prior":"-0.340",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ed5f900f4291c000186346d",
            "eps":"-0.460",
            "date":"2021-05-06",
            "name":"Annovis Bio",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ANVS",
            "eps_est":"",
            "revenue":"0.000",
            "updated":1621495939,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"AMEX",
            "eps_prior":"-0.100",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":49224198,
         "operating_cash_flow":-3144563,
         "monthly_cash_burn":-1048187,
         "est_live_cash":47372400,
         "est_months_cash":45.194607450769759,
         "total_liabilities":884075,
         "net_cash":46488325,
         "enterpriseValue":301029096,
         "total_debt_to_equity":"",
         "float":5639681,
         "insiderholdingspct":31.800000000000001
      },
      "updated_at_formatted":"19/08/2021"
   },
   {
      "id":3322,
      "name":"TECARTUS (brexucabtagene autoleucel) - (ZUMA-3)",
      "craft_entry_id":2874,
      "indication":"Adult patients with r/r ALL - cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-01",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210604005067/en/",
      "catalyst_date_text":"",
      "note":"PDUFA date with priority review October 1, 2021.",
      "estimated_primary_completion_date":"September 9, 2020",
      "updated_at":"2021-06-04 15:04:52",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":378,
         "ticker":"GILD",
         "name":"Gilead Sciences Inc.",
         "exchange":null,
         "price":72.439999999999998,
         "change":0.77000000000000002,
         "percent_change":1.0700000000000001,
         "number_of_shares":1253809440,
         "market_cap":90825955834,
         "short_ratio":null,
         "volume":5649817,
         "average_daily_volume":6258726,
         "relative_volume":0.90000000000000002,
         "price_to_book":4.6100000000000003,
         "open":71.670000000000002,
         "previous_close":71.670000000000002,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Acute lymphoblastic leukemia (ALL)",
         "Leukemia"
      ],
      "cashflow":{
         "id":302,
         "ticker":"GILD",
         "earnings":{
            "id":"5f22708f44c96f00014e76f3",
            "eps":"1.870",
            "date":"2021-07-29",
            "name":"Gilead Sciences",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"GILD",
            "eps_est":"1.730",
            "revenue":"6217000000.000",
            "updated":1627589504,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"1.110",
            "importance":4,
            "period_year":2021,
            "revenue_est":"6070000000.000",
            "eps_surprise":"0.1400",
            "revenue_type":"GAAP",
            "revenue_prior":"5143000000.000",
            "date_confirmed":1,
            "revenue_surprise":"147000000.0000",
            "eps_surprise_percent":"0.0809",
            "revenue_surprise_percent":"0.0242"
         },
         "prev_quarter_earnings":{
            "id":"5eaa77a0981f9a00015740fd",
            "eps":"2.080",
            "date":"2021-04-29",
            "name":"Gilead Sciences",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"GILD",
            "eps_est":"2.090",
            "revenue":"6423000000.000",
            "updated":1619727938,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"1.680",
            "importance":4,
            "period_year":2021,
            "revenue_est":"6740000000.000",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"5548000000.000",
            "date_confirmed":1,
            "revenue_surprise":"-317000000.0000",
            "eps_surprise_percent":"-0.0048",
            "revenue_surprise_percent":"-0.0470"
         },
         "cash_equivalents_and_short_term_investments":6525000000,
         "operating_cash_flow":2316000000,
         "monthly_cash_burn":772000000,
         "est_live_cash":7888866666,
         "est_months_cash":10.218739204663212,
         "total_liabilities":48274000000,
         "net_cash":-40385133334,
         "enterpriseValue":114475955833,
         "total_debt_to_equity":1.0900000000000001,
         "float":1253507953,
         "insiderholdingspct":0.59999999999999998
      },
      "updated_at_formatted":"04/06/2021"
   },
   {
      "id":7425,
      "name":"Omilancor (BT-11)",
      "craft_entry_id":86948,
      "indication":"Ulcerative Colitis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-03",
      "fda_calendar":0,
      "press_link":"https://ir.landosbiopharma.com/news-releases/news-release-details/landos-biopharmas-phase-2-data-omilancor-ulcerative-colitis",
      "catalyst_date_text":"",
      "note":"Phase 2 data to be presented at the United European Gastroenterology Week (UEGW) meeting October 3-5, 2021. Phase 3 trial planned.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-07-22 07:28:32",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":877,
         "ticker":"LABP",
         "name":"Landos Biopharma Inc.",
         "exchange":null,
         "price":13.710000000000001,
         "change":-0.07999999999999996,
         "percent_change":-0.58000000000000007,
         "number_of_shares":40117598,
         "market_cap":550012269,
         "short_ratio":null,
         "volume":23629,
         "average_daily_volume":45950,
         "relative_volume":0.51000000000000001,
         "price_to_book":5.21,
         "open":13.66,
         "previous_close":13.789999999999999,
         "created_at":"2021-02-03T00:14:15.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Ulcerative Colitis"
      ],
      "cashflow":{
         "id":743,
         "ticker":"LABP",
         "earnings":{
            "id":"60211473879cba000136493e",
            "eps":"0.120",
            "date":"2021-07-29",
            "name":"Landos Biopharma",
            "time":"07:30:00",
            "notes":"",
            "period":"Q2",
            "ticker":"LABP",
            "eps_est":"-0.380",
            "revenue":"18000000.000",
            "updated":1627894416,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.5000",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"1.3158",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"60211474879cba0001364940",
            "eps":"-0.380",
            "date":"2021-05-17",
            "name":"Landos Biopharma",
            "time":"07:15:00",
            "notes":"",
            "period":"Q1",
            "ticker":"LABP",
            "eps_est":"-0.370",
            "revenue":"0.000",
            "updated":1621250456,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.490",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.0270",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":115127000,
         "operating_cash_flow":9400000,
         "monthly_cash_burn":3133333,
         "est_live_cash":120662554,
         "est_months_cash":38.509329841418065,
         "total_liabilities":12679000,
         "net_cash":107983554,
         "enterpriseValue":434885268,
         "total_debt_to_equity":"",
         "float":4639108,
         "insiderholdingspct":0.20000000000000001
      },
      "updated_at_formatted":"22/07/2021"
   },
   {
      "id":3696,
      "name":"Somatrogon (hGH-CTP)",
      "craft_entry_id":2420,
      "indication":"Children - growth hormone deficiency",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-04",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20201008005030/en/",
      "catalyst_date_text":"October 2021",
      "note":"BLA filing acceptance announced January 4, 2021. PDUFA date October 2021.",
      "estimated_primary_completion_date":"August 2019",
      "updated_at":"2021-01-04 18:44:26",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":231,
         "ticker":"OPK",
         "name":"Opko Health Inc.",
         "exchange":null,
         "price":3.6699999999999999,
         "change":0.22,
         "percent_change":6.3799999999999999,
         "number_of_shares":681162619,
         "market_cap":2499866812,
         "short_ratio":null,
         "volume":4214874,
         "average_daily_volume":4276503,
         "relative_volume":0.98999999999999999,
         "price_to_book":1.4299999999999999,
         "open":3.4399999999999999,
         "previous_close":3.4500000000000002,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Growth hormone deficiency"
      ],
      "cashflow":{
         "id":184,
         "ticker":"OPK",
         "earnings":{
            "id":"5f22710144c96f00014e77d3",
            "eps":"-0.010",
            "date":"2021-07-29",
            "name":"OPKO Health",
            "time":"16:05:00",
            "notes":"",
            "period":"Q2",
            "ticker":"OPK",
            "eps_est":"0.020",
            "revenue":"442400000.000",
            "updated":1627640129,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"0.050",
            "importance":0,
            "period_year":2021,
            "revenue_est":"456360000.000",
            "eps_surprise":"-0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"301200000.000",
            "date_confirmed":1,
            "revenue_surprise":"-13960000.0000",
            "eps_surprise_percent":"-1.5000",
            "revenue_surprise_percent":"-0.0306"
         },
         "prev_quarter_earnings":{
            "id":"5edb3f31ca75b400018fbc50",
            "eps":"0.050",
            "date":"2021-04-28",
            "name":"OPKO Health",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"OPK",
            "eps_est":"0.050",
            "revenue":"545200000.000",
            "updated":1619644603,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.090",
            "importance":1,
            "period_year":2021,
            "revenue_est":"498460000.000",
            "eps_surprise":"0.0000",
            "revenue_type":"GAAP",
            "revenue_prior":"211500000.000",
            "date_confirmed":1,
            "revenue_surprise":"46740000.0000",
            "eps_surprise_percent":"0.0000",
            "revenue_surprise_percent":"0.0938"
         },
         "cash_equivalents_and_short_term_investments":65757000,
         "operating_cash_flow":-15453000,
         "monthly_cash_burn":-5151000,
         "est_live_cash":56656900,
         "est_months_cash":10.999204038050864,
         "total_liabilities":679065000,
         "net_cash":-622408100,
         "enterpriseValue":2684588811,
         "total_debt_to_equity":0.14000000000000001,
         "float":410492692,
         "insiderholdingspct":6.2999999999999998
      },
      "updated_at_formatted":"04/01/2021"
   },
   {
      "id":4098,
      "name":"Avacopan (CCX168) - (ADVOCATE)",
      "craft_entry_id":1938,
      "indication":"Associated vasculitis (AAV)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-07",
      "fda_calendar":0,
      "press_link":"https://ir.chemocentryx.com/news-releases/news-release-details/chemocentryx-announces-filing-amendment-nda-submission-and",
      "catalyst_date_text":"",
      "note":"Advisory Committee May 6, 2021 voted 10-8 that the benefit-risk and safety profiles are adequate to support approval and 9-9 that the efficacy data supports approval. PDUFA date extended by three months to October 7, 2021.",
      "estimated_primary_completion_date":"September 7, 2019",
      "updated_at":"2021-07-06 11:02:26",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":82,
         "ticker":"CCXI",
         "name":"ChemoCentryx Inc.",
         "exchange":null,
         "price":14.18,
         "change":0.48999999999999999,
         "percent_change":3.5800000000000001,
         "number_of_shares":69903505,
         "market_cap":991231701,
         "short_ratio":null,
         "volume":901240,
         "average_daily_volume":3050674,
         "relative_volume":0.29999999999999999,
         "price_to_book":3,
         "open":13.710000000000001,
         "previous_close":13.69,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Vasculitis",
         "ANCA-associated vasculitis (AAV)"
      ],
      "cashflow":{
         "id":67,
         "ticker":"CCXI",
         "earnings":{
            "id":"5f30f087a7bff3000162b219",
            "eps":"-0.560",
            "date":"2021-08-09",
            "name":"ChemoCentryx",
            "time":"16:05:00",
            "notes":"",
            "period":"Q2",
            "ticker":"CCXI",
            "eps_est":"-0.540",
            "revenue":"1813000.000",
            "updated":1628543913,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"0.290",
            "importance":1,
            "period_year":2021,
            "revenue_est":"4850000.000",
            "eps_surprise":"-0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"49440000.000",
            "date_confirmed":1,
            "revenue_surprise":"-3037000.0000",
            "eps_surprise_percent":"-0.0370",
            "revenue_surprise_percent":"-0.6262"
         },
         "prev_quarter_earnings":{
            "id":"5eb8f808470dcc00012d9dd5",
            "eps":"-0.430",
            "date":"2021-04-29",
            "name":"ChemoCentryx",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"CCXI",
            "eps_est":"-0.400",
            "revenue":"10353000.000",
            "updated":1619729689,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.350",
            "importance":1,
            "period_year":2021,
            "revenue_est":"7930000.000",
            "eps_surprise":"-0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"6008000.000",
            "date_confirmed":1,
            "revenue_surprise":"2423000.0000",
            "eps_surprise_percent":"-0.0750",
            "revenue_surprise_percent":"0.3055"
         },
         "cash_equivalents_and_short_term_investments":312604000,
         "operating_cash_flow":-17851000,
         "monthly_cash_burn":-5950333,
         "est_live_cash":302091745,
         "est_months_cash":50.768880497948601,
         "total_liabilities":137402000,
         "net_cash":164689745,
         "enterpriseValue":750332700,
         "total_debt_to_equity":0.22,
         "float":47274691,
         "insiderholdingspct":4.5
      },
      "updated_at_formatted":"06/07/2021"
   },
   {
      "id":7179,
      "name":"PRT811",
      "craft_entry_id":73574,
      "indication":"Solid Tumors and Recurrent High-Grade Gliomas",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-07",
      "fda_calendar":0,
      "press_link":"https://www.globenewswire.com/news-release/2021/08/12/2279670/0/en/Prelude-Therapeutics-Announces-Second-Quarter-2021-Financial-Results-and-Operations-Update.html",
      "catalyst_date_text":"",
      "note":"Phase 1 dose expansion to commence mid-2021 with dose escalation data due at the AACR-NCI-EORTC Annual Meeting, October 7-10, 2021.",
      "estimated_primary_completion_date":"October 2021",
      "updated_at":"2021-08-12 07:42:15",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":829,
         "ticker":"PRLD",
         "name":"Prelude Therapeutics Incorporated",
         "exchange":null,
         "price":31,
         "change":2.2200000000000002,
         "percent_change":7.71,
         "number_of_shares":47093531,
         "market_cap":1459899461,
         "short_ratio":null,
         "volume":270683,
         "average_daily_volume":201005,
         "relative_volume":1.3500000000000001,
         "price_to_book":4.3700000000000001,
         "open":28.710000000000001,
         "previous_close":28.780000000000001,
         "created_at":"2020-10-16T22:16:38.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology",
         "Glioma"
      ],
      "cashflow":{
         "id":692,
         "ticker":"PRLD",
         "earnings":{
            "id":"5f75d609a442ba0001d9f21b",
            "eps":"-0.580",
            "date":"2021-08-12",
            "name":"Prelude Therapeutics",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"PRLD",
            "eps_est":"-0.490",
            "revenue":"0.000",
            "updated":1628849016,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-5.500",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.1837",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5f75d60aa442ba0001d9f21d",
            "eps":"-0.470",
            "date":"2021-05-11",
            "name":"Prelude Therapeutics",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"PRLD",
            "eps_est":"-0.460",
            "revenue":"0.000",
            "updated":1620807018,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.0217",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":343119000,
         "operating_cash_flow":-19912000,
         "monthly_cash_burn":-6637333,
         "est_live_cash":331393045,
         "est_months_cash":49.928645285689299,
         "total_liabilities":15220000,
         "net_cash":316173045,
         "enterpriseValue":1117027692,
         "total_debt_to_equity":0.01,
         "float":7203248,
         "insiderholdingspct":4.2000000000000002
      },
      "updated_at_formatted":"12/08/2021"
   },
   {
      "id":5660,
      "name":"Repotrectinib (TPX-0005) - TRIDENT-1",
      "craft_entry_id":25971,
      "indication":"Non-small-cell lung cancer (NSCLC) and solid tumors",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-07",
      "fda_calendar":0,
      "press_link":"https://ir.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-reports-second-quarter-financial-0",
      "catalyst_date_text":"",
      "note":"Phase 2 update at AACR-NCI-EORTC meeting October 7 - 10, 2021.",
      "estimated_primary_completion_date":"March 2021",
      "updated_at":"2021-08-09 19:53:12",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":654,
         "ticker":"TPTX",
         "name":"Turning Point Therapeutics Inc.",
         "exchange":null,
         "price":64.109999999999999,
         "change":1.1599999999999999,
         "percent_change":1.8399999999999999,
         "number_of_shares":49407966,
         "market_cap":3167544700,
         "short_ratio":null,
         "volume":255521,
         "average_daily_volume":462011,
         "relative_volume":0.55000000000000004,
         "price_to_book":2.9699999999999998,
         "open":62.509999999999998,
         "previous_close":62.950000000000003,
         "created_at":"2019-04-17T22:55:14.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology",
         "Non-small cell lung cancer (NSCLC)",
         "Lung cancer"
      ],
      "cashflow":{
         "id":525,
         "ticker":"TPTX",
         "earnings":{
            "id":"5f32423f9c32ef000199d602",
            "eps":"-1.140",
            "date":"2021-08-09",
            "name":"Turning Point",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"TPTX",
            "eps_est":"-1.210",
            "revenue":"5164000.000",
            "updated":1628588264,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.820",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0700",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0579",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eba49cda2467b0001363507",
            "eps":"-0.730",
            "date":"2021-05-05",
            "name":"Turning Point",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"TPTX",
            "eps_est":"-0.610",
            "revenue":"25205000.000",
            "updated":1620253734,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.820",
            "importance":0,
            "period_year":2021,
            "revenue_est":"21870000.000",
            "eps_surprise":"-0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"3335000.0000",
            "eps_surprise_percent":"-0.1967",
            "revenue_surprise_percent":"0.1525"
         },
         "cash_equivalents_and_short_term_investments":1077806000,
         "operating_cash_flow":-42387000,
         "monthly_cash_burn":-14129000,
         "est_live_cash":1052844766,
         "est_months_cash":74.51658050817467,
         "total_liabilities":35413000,
         "net_cash":1017431766,
         "enterpriseValue":2096240700,
         "total_debt_to_equity":0.01,
         "float":41021238,
         "insiderholdingspct":4.7000000000000002
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":5966,
      "name":"TPX-0022 ( SHIELD-1)",
      "craft_entry_id":30145,
      "indication":"Solid tumors",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-07",
      "fda_calendar":0,
      "press_link":"https://ir.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-reports-second-quarter-financial-0",
      "catalyst_date_text":"",
      "note":"Phase 1 update due at AACR-NCI-EORTC conference October 7 - 10, 2021. Phase 2 trial to be initiated 4Q 2021.",
      "estimated_primary_completion_date":"November 2022",
      "updated_at":"2021-08-09 19:48:14",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":484,
         "ticker":"ZLAB",
         "name":"Zai Lab Limited",
         "exchange":null,
         "price":134.16999999999999,
         "change":4.1699999999999999,
         "percent_change":3.21,
         "number_of_shares":75375511,
         "market_cap":10113132311,
         "short_ratio":null,
         "volume":968918,
         "average_daily_volume":536617,
         "relative_volume":1.8100000000000001,
         "price_to_book":31.199999999999999,
         "open":127,
         "previous_close":130,
         "created_at":"2018-01-24T06:32:57.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology"
      ],
      "cashflow":{
         "id":392,
         "ticker":"ZLAB",
         "earnings":{
            "id":"6087b6c95df3990001db17a9",
            "eps":"-1.760",
            "date":"2021-08-09",
            "name":"Zai Lab",
            "time":"16:00:00",
            "notes":"",
            "period":"H1",
            "ticker":"ZLAB",
            "eps_est":"-1.300",
            "revenue":"36935000.000",
            "updated":1628545101,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.370",
            "importance":0,
            "period_year":2021,
            "revenue_est":"28260000.000",
            "eps_surprise":"-0.4600",
            "revenue_type":"GAAP",
            "revenue_prior":"3420000.000",
            "date_confirmed":1,
            "revenue_surprise":"8675000.0000",
            "eps_surprise_percent":"-0.3538",
            "revenue_surprise_percent":"0.3070"
         },
         "prev_quarter_earnings":{
            "id":"609a847af7862d0001457cde",
            "eps":"-2.640",
            "date":"2021-05-10",
            "name":"Zai Lab",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ZLAB",
            "eps_est":"-1.350",
            "revenue":"20103000.000",
            "updated":1620740689,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"32600000.000",
            "eps_surprise":"-1.2900",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"-12497000.0000",
            "eps_surprise_percent":"-0.9556",
            "revenue_surprise_percent":"-0.3833"
         },
         "cash_equivalents_and_short_term_investments":1766573000,
         "operating_cash_flow":-65848000,
         "monthly_cash_burn":-21949333,
         "est_live_cash":1727795845,
         "est_months_cash":78.717464671933314,
         "total_liabilities":223517000,
         "net_cash":1504278845,
         "enterpriseValue":1783381173,
         "total_debt_to_equity":0.01,
         "float":75375511,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":5966,
      "name":"TPX-0022 ( SHIELD-1)",
      "craft_entry_id":30145,
      "indication":"Solid tumors",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-07",
      "fda_calendar":0,
      "press_link":"https://ir.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-reports-second-quarter-financial-0",
      "catalyst_date_text":"",
      "note":"Phase 1 update due at AACR-NCI-EORTC conference October 7 - 10, 2021. Phase 2 trial to be initiated 4Q 2021.",
      "estimated_primary_completion_date":"November 2022",
      "updated_at":"2021-08-09 19:48:14",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":654,
         "ticker":"TPTX",
         "name":"Turning Point Therapeutics Inc.",
         "exchange":null,
         "price":64.109999999999999,
         "change":1.1599999999999999,
         "percent_change":1.8399999999999999,
         "number_of_shares":49407966,
         "market_cap":3167544700,
         "short_ratio":null,
         "volume":255521,
         "average_daily_volume":462011,
         "relative_volume":0.55000000000000004,
         "price_to_book":2.9699999999999998,
         "open":62.509999999999998,
         "previous_close":62.950000000000003,
         "created_at":"2019-04-17T22:55:14.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology"
      ],
      "cashflow":{
         "id":525,
         "ticker":"TPTX",
         "earnings":{
            "id":"5f32423f9c32ef000199d602",
            "eps":"-1.140",
            "date":"2021-08-09",
            "name":"Turning Point",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"TPTX",
            "eps_est":"-1.210",
            "revenue":"5164000.000",
            "updated":1628588264,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.820",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0700",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0579",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eba49cda2467b0001363507",
            "eps":"-0.730",
            "date":"2021-05-05",
            "name":"Turning Point",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"TPTX",
            "eps_est":"-0.610",
            "revenue":"25205000.000",
            "updated":1620253734,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.820",
            "importance":0,
            "period_year":2021,
            "revenue_est":"21870000.000",
            "eps_surprise":"-0.1200",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"3335000.0000",
            "eps_surprise_percent":"-0.1967",
            "revenue_surprise_percent":"0.1525"
         },
         "cash_equivalents_and_short_term_investments":1077806000,
         "operating_cash_flow":-42387000,
         "monthly_cash_burn":-14129000,
         "est_live_cash":1052844766,
         "est_months_cash":74.51658050817467,
         "total_liabilities":35413000,
         "net_cash":1017431766,
         "enterpriseValue":2096240700,
         "total_debt_to_equity":0.01,
         "float":41021238,
         "insiderholdingspct":4.7000000000000002
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":6747,
      "name":"FT-7051",
      "craft_entry_id":51201,
      "indication":"Prostate cancer (CRPC)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-07",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210813005019/en/",
      "catalyst_date_text":"",
      "note":"Phase 1 initial data to be presented at the NCI/AACR/EORTC Virtual International Conference October 7-10, 2021",
      "estimated_primary_completion_date":"April 2022",
      "updated_at":"2021-08-13 07:35:44",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":776,
         "ticker":"FMTX",
         "name":"Forma Therapeutics Holdings Inc.",
         "exchange":null,
         "price":22.699999999999999,
         "change":1.48,
         "percent_change":6.9699999999999998,
         "number_of_shares":49894878,
         "market_cap":1132613731,
         "short_ratio":null,
         "volume":175688,
         "average_daily_volume":339659,
         "relative_volume":0.52000000000000002,
         "price_to_book":1.96,
         "open":21.149999999999999,
         "previous_close":21.219999999999999,
         "created_at":"2020-06-18T14:59:38.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Prostate cancer"
      ],
      "cashflow":{
         "id":640,
         "ticker":"FMTX",
         "earnings":{
            "id":"5f36369863170b0001c87871",
            "eps":"-0.920",
            "date":"2021-08-13",
            "name":"Forma Therapeutics Hldgs",
            "time":"07:05:00",
            "notes":"",
            "period":"Q2",
            "ticker":"FMTX",
            "eps_est":"-0.790",
            "revenue":"0.000",
            "updated":1628853512,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-4.580",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.1300",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.1646",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ef991babc896b00015e08e7",
            "eps":"-0.760",
            "date":"2021-05-14",
            "name":"Forma Therapeutics Hldgs",
            "time":"07:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"FMTX",
            "eps_est":"-0.760",
            "revenue":"0.000",
            "updated":1620991335,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0000",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0000",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":535558000,
         "operating_cash_flow":-32539000,
         "monthly_cash_burn":-10846333,
         "est_live_cash":516396145,
         "est_months_cash":47.610205679652282,
         "total_liabilities":33974000,
         "net_cash":482422145,
         "enterpriseValue":601813730,
         "total_debt_to_equity":0.01,
         "float":32086456,
         "insiderholdingspct":1.1000000000000001
      },
      "updated_at_formatted":"13/08/2021"
   },
   {
      "id":7064,
      "name":"PRT543",
      "craft_entry_id":70365,
      "indication":"Solid tumors",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-07",
      "fda_calendar":0,
      "press_link":"https://www.globenewswire.com/news-release/2021/08/12/2279670/0/en/Prelude-Therapeutics-Announces-Second-Quarter-2021-Financial-Results-and-Operations-Update.html",
      "catalyst_date_text":"",
      "note":"Phase 1 interim data due at the AACR-NCI-EORTC Annual Meeting, October 7-10, 2021.",
      "estimated_primary_completion_date":"April 30, 2022",
      "updated_at":"2021-08-12 07:41:25",
      "stage":{
         "id":2,
         "label":"Phase 1",
         "value":"phase1"
      },
      "companies":{
         "id":829,
         "ticker":"PRLD",
         "name":"Prelude Therapeutics Incorporated",
         "exchange":null,
         "price":31,
         "change":2.2200000000000002,
         "percent_change":7.71,
         "number_of_shares":47093531,
         "market_cap":1459899461,
         "short_ratio":null,
         "volume":270683,
         "average_daily_volume":201005,
         "relative_volume":1.3500000000000001,
         "price_to_book":4.3700000000000001,
         "open":28.710000000000001,
         "previous_close":28.780000000000001,
         "created_at":"2020-10-16T22:16:38.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Solid tumors",
         "Oncology"
      ],
      "cashflow":{
         "id":692,
         "ticker":"PRLD",
         "earnings":{
            "id":"5f75d609a442ba0001d9f21b",
            "eps":"-0.580",
            "date":"2021-08-12",
            "name":"Prelude Therapeutics",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"PRLD",
            "eps_est":"-0.490",
            "revenue":"0.000",
            "updated":1628849016,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-5.500",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.1837",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5f75d60aa442ba0001d9f21d",
            "eps":"-0.470",
            "date":"2021-05-11",
            "name":"Prelude Therapeutics",
            "time":"07:30:00",
            "notes":"",
            "period":"Q1",
            "ticker":"PRLD",
            "eps_est":"-0.460",
            "revenue":"0.000",
            "updated":1620807018,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.0217",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":343119000,
         "operating_cash_flow":-19912000,
         "monthly_cash_burn":-6637333,
         "est_live_cash":331393045,
         "est_months_cash":49.928645285689299,
         "total_liabilities":15220000,
         "net_cash":316173045,
         "enterpriseValue":1117027692,
         "total_debt_to_equity":0.01,
         "float":7203248,
         "insiderholdingspct":4.2000000000000002
      },
      "updated_at_formatted":"12/08/2021"
   },
   {
      "id":7484,
      "name":"Tisotumab Vedotin",
      "craft_entry_id":89111,
      "indication":"Cervical Cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-10",
      "fda_calendar":0,
      "press_link":"https://ml-eu.globenewswire.com/Resource/Download/39417f02-cc51-4b42-a4f2-b9ebc579313b",
      "catalyst_date_text":"",
      "note":"PDUFA date under priority review October 10, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-04-10 04:29:05",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":276,
         "ticker":"SGEN",
         "name":"Seagen Inc.",
         "exchange":null,
         "price":159.30000000000001,
         "change":1.21,
         "percent_change":0.77000000000000002,
         "number_of_shares":181934500,
         "market_cap":28982165850,
         "short_ratio":null,
         "volume":590141,
         "average_daily_volume":693685,
         "relative_volume":0.84999999999999998,
         "price_to_book":8.5500000000000007,
         "open":158.94999999999999,
         "previous_close":158.09,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Cervical cancer"
      ],
      "cashflow":{
         "id":215,
         "ticker":"SGEN",
         "earnings":{
            "id":"5f22713444c96f00014e7825",
            "eps":"-0.470",
            "date":"2021-07-29",
            "name":"Seattle Genetics",
            "time":"16:02:00",
            "notes":"",
            "period":"Q2",
            "ticker":"SGEN",
            "eps_est":"-0.600",
            "revenue":"388478000.000",
            "updated":1627593174,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.120",
            "importance":2,
            "period_year":2021,
            "revenue_est":"355030000.000",
            "eps_surprise":"0.1300",
            "revenue_type":"GAAP",
            "revenue_prior":"277998000.000",
            "date_confirmed":1,
            "revenue_surprise":"33448000.0000",
            "eps_surprise_percent":"0.2167",
            "revenue_surprise_percent":"0.0942"
         },
         "prev_quarter_earnings":{
            "id":"5eaa77ce981f9a00015741ef",
            "eps":"-0.670",
            "date":"2021-04-29",
            "name":"Seattle Genetics",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"SGEN",
            "eps_est":"-0.610",
            "revenue":"331983000.000",
            "updated":1619729513,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.980",
            "importance":2,
            "period_year":2021,
            "revenue_est":"336970000.000",
            "eps_surprise":"-0.0600",
            "revenue_type":"GAAP",
            "revenue_prior":"234514000.000",
            "date_confirmed":1,
            "revenue_surprise":"-4987000.0000",
            "eps_surprise_percent":"-0.0984",
            "revenue_surprise_percent":"-0.0148"
         },
         "cash_equivalents_and_short_term_investments":2451612000,
         "operating_cash_flow":-72444000,
         "monthly_cash_burn":-24148000,
         "est_live_cash":2408950533,
         "est_months_cash":99.757765984760638,
         "total_liabilities":560884000,
         "net_cash":1848066533,
         "enterpriseValue":26592478850,
         "total_debt_to_equity":0.02,
         "float":66371701,
         "insiderholdingspct":1.2
      },
      "updated_at_formatted":"10/04/2021"
   },
   {
      "id":7484,
      "name":"Tisotumab Vedotin",
      "craft_entry_id":89111,
      "indication":"Cervical Cancer",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-10",
      "fda_calendar":0,
      "press_link":"https://ml-eu.globenewswire.com/Resource/Download/39417f02-cc51-4b42-a4f2-b9ebc579313b",
      "catalyst_date_text":"",
      "note":"PDUFA date under priority review October 10, 2021.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-04-10 04:29:05",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":684,
         "ticker":"GMAB",
         "name":"Genmab A/S",
         "exchange":null,
         "price":48.020000000000003,
         "change":1.6200000000000001,
         "percent_change":3.4900000000000002,
         "number_of_shares":653818780,
         "market_cap":31396377816,
         "short_ratio":null,
         "volume":556652,
         "average_daily_volume":520798,
         "relative_volume":1.0700000000000001,
         "price_to_book":9.8399999999999999,
         "open":47.619999999999997,
         "previous_close":46.399999999999999,
         "created_at":"2019-07-18T22:06:46.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Oncology",
         "Cervical cancer"
      ],
      "cashflow":{
         "id":552,
         "ticker":"GMAB",
         "earnings":{
            "id":"5f34e51c1ef0a0000183c2d0",
            "eps":"0.750",
            "date":"2021-08-11",
            "name":"Genmab",
            "time":"11:00:00",
            "notes":"FXC",
            "period":"Q2",
            "ticker":"GMAB",
            "eps_est":"",
            "revenue":"319464000.000",
            "updated":1629271712,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"7.580",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"",
            "revenue_type":"GAAP",
            "revenue_prior":"804568000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5ec4d59e88a06b0001f81bff",
            "eps":"2.690",
            "date":"2021-05-05",
            "name":"Genmab",
            "time":"11:00:00",
            "notes":"FXC",
            "period":"Q1",
            "ticker":"GMAB",
            "eps_est":"0.230",
            "revenue":"256280000.000",
            "updated":1620293298,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"0.600",
            "importance":0,
            "period_year":2021,
            "revenue_est":"207510000.000",
            "eps_surprise":"2.4600",
            "revenue_type":"GAAP",
            "revenue_prior":"131659000.000",
            "date_confirmed":1,
            "revenue_surprise":"48770000.0000",
            "eps_surprise_percent":"10.6957",
            "revenue_surprise_percent":"0.2350"
         },
         "cash_equivalents_and_short_term_investments":17875000000,
         "operating_cash_flow":355000000,
         "monthly_cash_burn":118333333,
         "est_live_cash":18084055554,
         "est_months_cash":152.82300511217747,
         "total_liabilities":2231000000,
         "net_cash":15853055554,
         "enterpriseValue":28510683279,
         "total_debt_to_equity":0.02,
         "float":653818780,
         "insiderholdingspct":""
      },
      "updated_at_formatted":"10/04/2021"
   },
   {
      "id":1946,
      "name":"ATA188",
      "craft_entry_id":13911,
      "indication":"Multiple sclerosis",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-13",
      "fda_calendar":1,
      "press_link":"https://www.businesswire.com/news/home/20210809005755/en/",
      "catalyst_date_text":"",
      "note":"Phase 1 open-label data to be presented at ECTRIMS meeting October 13-15, 2021. Phase 2 interim analysis 1H 2022.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-08-09 17:49:57",
      "stage":{
         "id":4,
         "label":"Phase 1/2",
         "value":"phase1.5"
      },
      "companies":{
         "id":54,
         "ticker":"ATRA",
         "name":"Atara Biotherapeutics Inc.",
         "exchange":null,
         "price":12.630000000000001,
         "change":0.64000000000000001,
         "percent_change":5.3399999999999999,
         "number_of_shares":84757551,
         "market_cap":1070487869,
         "short_ratio":null,
         "volume":691921,
         "average_daily_volume":732332,
         "relative_volume":0.93999999999999995,
         "price_to_book":3.23,
         "open":11.880000000000001,
         "previous_close":11.99,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":true,
      "indication_names":[
         "Multiple Sclerosis (MS)"
      ],
      "cashflow":{
         "id":42,
         "ticker":"ATRA",
         "earnings":{
            "id":"5f2a5944fa46620001949e58",
            "eps":"-0.910",
            "date":"2021-08-09",
            "name":"Atara Biotherapeutics",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"ATRA",
            "eps_est":"-0.890",
            "revenue":"3870000.000",
            "updated":1628544478,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.140",
            "importance":0,
            "period_year":2021,
            "revenue_est":"3840000.000",
            "eps_surprise":"-0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"30000.0000",
            "eps_surprise_percent":"-0.0225",
            "revenue_surprise_percent":"0.0078"
         },
         "prev_quarter_earnings":{
            "id":"5eb260857f47df0001e14b8a",
            "eps":"-0.860",
            "date":"2021-05-04",
            "name":"Atara Biotherapeutics",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"ATRA",
            "eps_est":"-0.920",
            "revenue":"3552000.000",
            "updated":1620165153,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-1.200",
            "importance":0,
            "period_year":2021,
            "revenue_est":"1600000.000",
            "eps_surprise":"0.0600",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"1952000.0000",
            "eps_surprise_percent":"0.0652",
            "revenue_surprise_percent":"1.2200"
         },
         "cash_equivalents_and_short_term_investments":373380000,
         "operating_cash_flow":-61577000,
         "monthly_cash_burn":-20525666,
         "est_live_cash":337117990,
         "est_months_cash":16.424216880465657,
         "total_liabilities":125253000,
         "net_cash":211864990,
         "enterpriseValue":709289869,
         "total_debt_to_equity":0.040000000000000001,
         "float":73456041,
         "insiderholdingspct":3
      },
      "updated_at_formatted":"09/08/2021"
   },
   {
      "id":7700,
      "name":"TYVASO (treprostinil) DPI",
      "craft_entry_id":104752,
      "indication":"Pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD) (WHO Group 3)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-15",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/united-therapeutics-announces-fda-acceptance-of-tyvaso-dpi-new-drug-application-for-priority-review-301313312.html",
      "catalyst_date_text":"",
      "note":"NDA filing acceptance announced June 16, 2021 under priority review. PDUFA date not announced. Estimate October 15, 2021 based on 4-month review.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-06-21 18:13:33",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":199,
         "ticker":"MNKD",
         "name":"MannKind Corporation",
         "exchange":null,
         "price":4.2199999999999998,
         "change":0.25,
         "percent_change":6.2999999999999998,
         "number_of_shares":249660178,
         "market_cap":1053565951,
         "short_ratio":null,
         "volume":2063378,
         "average_daily_volume":3090228,
         "relative_volume":0.67000000000000004,
         "price_to_book":-5.7000000000000002,
         "open":4,
         "previous_close":3.9699999999999998,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Pulmonary arterial hypertension (PAH)",
         "Pulmonary Hypertension"
      ],
      "cashflow":{
         "id":161,
         "ticker":"MNKD",
         "earnings":{
            "id":"5f2a5a6efa4662000194a004",
            "eps":"-0.050",
            "date":"2021-08-11",
            "name":"MannKind",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"MNKD",
            "eps_est":"-0.040",
            "revenue":"23280000.000",
            "updated":1628712902,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"-0.050",
            "importance":1,
            "period_year":2021,
            "revenue_est":"17490000.000",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"15114000.000",
            "date_confirmed":1,
            "revenue_surprise":"5790000.0000",
            "eps_surprise_percent":"-0.2500",
            "revenue_surprise_percent":"0.3310"
         },
         "prev_quarter_earnings":{
            "id":"5eb260bb7f47df0001e14d1a",
            "eps":"-0.050",
            "date":"2021-05-12",
            "name":"MannKind",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"MNKD",
            "eps_est":"-0.040",
            "revenue":"17436000.000",
            "updated":1620853024,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.040",
            "importance":1,
            "period_year":2021,
            "revenue_est":"15660000.000",
            "eps_surprise":"-0.0100",
            "revenue_type":"GAAP",
            "revenue_prior":"16235000.000",
            "date_confirmed":1,
            "revenue_surprise":"1776000.0000",
            "eps_surprise_percent":"-0.2500",
            "revenue_surprise_percent":"0.1134"
         },
         "cash_equivalents_and_short_term_investments":162492000,
         "operating_cash_flow":-21447000,
         "monthly_cash_burn":-7149000,
         "est_live_cash":149862100,
         "est_months_cash":20.962666107147854,
         "total_liabilities":436342000,
         "net_cash":-286479900,
         "enterpriseValue":1176766951,
         "total_debt_to_equity":"",
         "float":245425982,
         "insiderholdingspct":3.6000000000000001
      },
      "updated_at_formatted":"21/06/2021"
   },
   {
      "id":7700,
      "name":"TYVASO (treprostinil) DPI",
      "craft_entry_id":104752,
      "indication":"Pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD) (WHO Group 3)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-15",
      "fda_calendar":0,
      "press_link":"https://www.prnewswire.com/news-releases/united-therapeutics-announces-fda-acceptance-of-tyvaso-dpi-new-drug-application-for-priority-review-301313312.html",
      "catalyst_date_text":"",
      "note":"NDA filing acceptance announced June 16, 2021 under priority review. PDUFA date not announced. Estimate October 15, 2021 based on 4-month review.",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-06-21 18:13:33",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":300,
         "ticker":"UTHR",
         "name":"United Therapeutics Corporation",
         "exchange":null,
         "price":204.22,
         "change":3.1699999999999999,
         "percent_change":1.5800000000000001,
         "number_of_shares":44891523,
         "market_cap":9167746827,
         "short_ratio":null,
         "volume":300771,
         "average_daily_volume":347971,
         "relative_volume":0.85999999999999999,
         "price_to_book":2.52,
         "open":201.37,
         "previous_close":201.05000000000001,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Pulmonary arterial hypertension (PAH)",
         "Pulmonary Hypertension"
      ],
      "cashflow":{
         "id":236,
         "ticker":"UTHR",
         "earnings":{
            "id":"5f211fd6aedc510001ba9e36",
            "eps":"4.090",
            "date":"2021-08-04",
            "name":"United Therapeutics",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"UTHR",
            "eps_est":"3.020",
            "revenue":"446500000.000",
            "updated":1628072270,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"3.680",
            "importance":2,
            "period_year":2021,
            "revenue_est":"378750000.000",
            "eps_surprise":"1.0700",
            "revenue_type":"GAAP",
            "revenue_prior":"362000000.000",
            "date_confirmed":1,
            "revenue_surprise":"67750000.0000",
            "eps_surprise_percent":"0.3543",
            "revenue_surprise_percent":"0.1789"
         },
         "prev_quarter_earnings":{
            "id":"5ea926520561160001c22ed8",
            "eps":"3.490",
            "date":"2021-05-05",
            "name":"United Therapeutics",
            "time":"06:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"UTHR",
            "eps_est":"2.940",
            "revenue":"379100000.000",
            "updated":1620211305,
            "currency":"USD",
            "eps_type":"Adj",
            "exchange":"NASDAQ",
            "eps_prior":"3.610",
            "importance":2,
            "period_year":2021,
            "revenue_est":"368950000.000",
            "eps_surprise":"0.5500",
            "revenue_type":"GAAP",
            "revenue_prior":"356300000.000",
            "date_confirmed":1,
            "revenue_surprise":"10150000.0000",
            "eps_surprise_percent":"0.1871",
            "revenue_surprise_percent":"0.0275"
         },
         "cash_equivalents_and_short_term_investments":1967500000,
         "operating_cash_flow":148200000,
         "monthly_cash_burn":49400000,
         "est_live_cash":2054773333,
         "est_months_cash":41.594601882591093,
         "total_liabilities":1205400000,
         "net_cash":849373333,
         "enterpriseValue":8000246827,
         "total_debt_to_equity":0.22,
         "float":44113197,
         "insiderholdingspct":0.20000000000000001
      },
      "updated_at_formatted":"21/06/2021"
   },
   {
      "id":2211,
      "name":"XEN1101 (X-TOLE)",
      "craft_entry_id":13752,
      "indication":"Adult Focal Epilepsy",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-15",
      "fda_calendar":0,
      "press_link":"https://www.benzinga.com/pressreleases/21/08/g22452981/xenon-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-corporate-update",
      "catalyst_date_text":"Late-September ~ mid-October 2021",
      "note":"Phase 2b completion of enrollment announced July 7, 2021. Top-line data due late-September to mid-October 2021.",
      "estimated_primary_completion_date":"June 2021",
      "updated_at":"2021-08-11 18:25:45",
      "stage":{
         "id":6,
         "label":"Phase 2",
         "value":"phase2"
      },
      "companies":{
         "id":313,
         "ticker":"XENE",
         "name":"Xenon Pharmaceuticals Inc.",
         "exchange":null,
         "price":16.440000000000001,
         "change":0.059999999999999998,
         "percent_change":0.37,
         "number_of_shares":41124184,
         "market_cap":676081585,
         "short_ratio":null,
         "volume":78671,
         "average_daily_volume":207979,
         "relative_volume":0.38,
         "price_to_book":2.71,
         "open":16.350000000000001,
         "previous_close":16.379999999999999,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Epilepsy",
         "Seizures"
      ],
      "cashflow":{
         "id":246,
         "ticker":"XENE",
         "earnings":{
            "id":"5f2bc972713ee300019e0163",
            "eps":"-0.510",
            "date":"2021-08-11",
            "name":"Xenon Pharmaceuticals",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"XENE",
            "eps_est":"-0.480",
            "revenue":"2218000.000",
            "updated":1628714255,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"0.000",
            "importance":0,
            "period_year":2021,
            "revenue_est":"2330000.000",
            "eps_surprise":"-0.0300",
            "revenue_type":"GAAP",
            "revenue_prior":"13384000.000",
            "date_confirmed":1,
            "revenue_surprise":"-112000.0000",
            "eps_surprise_percent":"-0.0625",
            "revenue_surprise_percent":"-0.0481"
         },
         "prev_quarter_earnings":{
            "id":"5ec62758908ed5000184d182",
            "eps":"-0.420",
            "date":"2021-05-11",
            "name":"Xenon Pharmaceuticals",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"XENE",
            "eps_est":"-0.400",
            "revenue":"4358000.000",
            "updated":1620767914,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.220",
            "importance":0,
            "period_year":2021,
            "revenue_est":"5150000.000",
            "eps_surprise":"-0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"7078000.000",
            "date_confirmed":1,
            "revenue_surprise":"-792000.0000",
            "eps_surprise_percent":"-0.0500",
            "revenue_surprise_percent":"-0.1538"
         },
         "cash_equivalents_and_short_term_investments":260523000,
         "operating_cash_flow":-13077000,
         "monthly_cash_burn":-4359000,
         "est_live_cash":252822100,
         "est_months_cash":58.000022941041522,
         "total_liabilities":17728000,
         "net_cash":235094100,
         "enterpriseValue":426795584,
         "total_debt_to_equity":0.01,
         "float":40156539,
         "insiderholdingspct":1.8999999999999999
      },
      "updated_at_formatted":"11/08/2021"
   },
   {
      "id":3528,
      "name":"FT 218",
      "craft_entry_id":2115,
      "indication":"Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-15",
      "fda_calendar":0,
      "press_link":"https://www.globenewswire.com/news-release/2021/03/01/2184208/0/en/Avadel-Pharmaceuticals-Announces-FDA-Acceptance-of-New-Drug-Application-for-FT218-in-Adults-with-Narcolepsy-for-the-Treatment-of-Excessive-Daytime-Sleepiness-and-Cataplexy.html",
      "catalyst_date_text":"",
      "note":"PDUFA date October 15, 2021.",
      "estimated_primary_completion_date":"March 25, 2020",
      "updated_at":"2021-03-01 08:08:17",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":365,
         "ticker":"AVDL",
         "name":"Avadel Pharmaceuticals plc",
         "exchange":null,
         "price":7.79,
         "change":0.16,
         "percent_change":2.1000000000000001,
         "number_of_shares":58596238,
         "market_cap":456464694,
         "short_ratio":null,
         "volume":205107,
         "average_daily_volume":280758,
         "relative_volume":0.72999999999999998,
         "price_to_book":3.8399999999999999,
         "open":7.6200000000000001,
         "previous_close":7.6299999999999999,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Narcolepsy"
      ],
      "cashflow":{
         "id":291,
         "ticker":"AVDL",
         "earnings":{
            "id":"5f30f080a7bff3000162b1f3",
            "eps":"-0.330",
            "date":"2021-08-09",
            "name":"Avadel Pharmaceuticals",
            "time":"08:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"AVDL",
            "eps_est":"-0.310",
            "revenue":"0.000",
            "updated":1628511405,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.120",
            "importance":2,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"-0.0200",
            "revenue_type":"GAAP",
            "revenue_prior":"10091000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"-0.0645",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eb8f802470dcc00012d9daf",
            "eps":"-0.230",
            "date":"2021-05-10",
            "name":"Avadel Pharmaceuticals",
            "time":"08:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"AVDL",
            "eps_est":"-0.320",
            "revenue":"0.000",
            "updated":1620649171,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.020",
            "importance":2,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"12243000.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.2812",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":202843000,
         "operating_cash_flow":-10153000,
         "monthly_cash_burn":-3384333,
         "est_live_cash":196864011,
         "est_months_cash":58.169220050154642,
         "total_liabilities":163711000,
         "net_cash":33153011,
         "enterpriseValue":397483694,
         "total_debt_to_equity":1.21,
         "float":57172010,
         "insiderholdingspct":2.3999999999999999
      },
      "updated_at_formatted":"01/03/2021"
   },
   {
      "id":6249,
      "name":"Varenicline (OC-01)",
      "craft_entry_id":35277,
      "indication":"Dry eye disease",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-17",
      "fda_calendar":0,
      "press_link":"https://investors.oysterpointrx.com/news-releases/news-release-details/oyster-point-pharma-announces-fda-acceptance-filing-new-drug",
      "catalyst_date_text":"",
      "note":"PDUFA date October 17, 2021.",
      "estimated_primary_completion_date":"May 8, 2020",
      "updated_at":"2021-05-06 19:22:37",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":718,
         "ticker":"OYST",
         "name":"Oyster Point Pharma Inc.",
         "exchange":null,
         "price":13.15,
         "change":-0.80000000000000004,
         "percent_change":-5.7300000000000004,
         "number_of_shares":26014621,
         "market_cap":342092266,
         "short_ratio":null,
         "volume":383814,
         "average_daily_volume":87986,
         "relative_volume":4.3600000000000003,
         "price_to_book":2.2599999999999998,
         "open":14.109999999999999,
         "previous_close":13.949999999999999,
         "created_at":"2019-11-01T00:23:39.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Dry eye disease"
      ],
      "cashflow":{
         "id":584,
         "ticker":"OYST",
         "earnings":{
            "id":"5f2a5a9cfa4662000194a054",
            "eps":"-0.850",
            "date":"2021-08-05",
            "name":"Oyster Point Pharma",
            "time":"16:01:00",
            "notes":"",
            "period":"Q2",
            "ticker":"OYST",
            "eps_est":"-0.850",
            "revenue":"0.000",
            "updated":1628204370,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.660",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.0000",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.0000",
            "revenue_surprise_percent":""
         },
         "prev_quarter_earnings":{
            "id":"5eb8f838470dcc00012d9ed3",
            "eps":"-0.730",
            "date":"2021-05-06",
            "name":"Oyster Point Pharma",
            "time":"16:01:00",
            "notes":"",
            "period":"Q1",
            "ticker":"OYST",
            "eps_est":"-0.910",
            "revenue":"0.000",
            "updated":1620342813,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.770",
            "importance":0,
            "period_year":2021,
            "revenue_est":"",
            "eps_surprise":"0.1800",
            "revenue_type":"GAAP",
            "revenue_prior":"0.000",
            "date_confirmed":1,
            "revenue_surprise":"",
            "eps_surprise_percent":"0.1978",
            "revenue_surprise_percent":""
         },
         "cash_equivalents_and_short_term_investments":154805000,
         "operating_cash_flow":-20555000,
         "monthly_cash_burn":-6851666,
         "est_live_cash":142700390,
         "est_months_cash":20.827108326646396,
         "total_liabilities":9719000,
         "net_cash":132981390,
         "enterpriseValue":188080266,
         "total_debt_to_equity":0.01,
         "float":11148373,
         "insiderholdingspct":1.8999999999999999
      },
      "updated_at_formatted":"06/05/2021"
   },
   {
      "id":2283,
      "name":"Narsoplimab",
      "craft_entry_id":11647,
      "indication":"Hematopoietic stem cell-associated TMA (HSCT-TMA)",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-17",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210520005392/en/",
      "catalyst_date_text":"",
      "note":"PDUFA date under priority review extended by three months to October 17, 2021. ",
      "estimated_primary_completion_date":"",
      "updated_at":"2021-05-20 08:52:47",
      "stage":{
         "id":14,
         "label":"PDUFA priority review",
         "value":"pdufaPriorityReview"
      },
      "companies":{
         "id":226,
         "ticker":"OMER",
         "name":"Omeros Corporation",
         "exchange":null,
         "price":14.77,
         "change":1,
         "percent_change":7.2599999999999998,
         "number_of_shares":62495645,
         "market_cap":923060677,
         "short_ratio":null,
         "volume":454903,
         "average_daily_volume":427058,
         "relative_volume":1.0700000000000001,
         "price_to_book":-3.75,
         "open":13.67,
         "previous_close":13.77,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:03.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Thrombotic microangiopathy (TMA)",
         "Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)",
         "Hematopoietic stem cell transplantation (HCST)"
      ],
      "cashflow":{
         "id":180,
         "ticker":"OMER",
         "earnings":{
            "id":"5f32422a9c32ef000199d59c",
            "eps":"-0.460",
            "date":"2021-08-09",
            "name":"Omeros",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"OMER",
            "eps_est":"-0.570",
            "revenue":"28823000.000",
            "updated":1628541614,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.610",
            "importance":0,
            "period_year":2021,
            "revenue_est":"24270000.000",
            "eps_surprise":"0.1100",
            "revenue_type":"GAAP",
            "revenue_prior":"13530000.000",
            "date_confirmed":1,
            "revenue_surprise":"4553000.0000",
            "eps_surprise_percent":"0.1930",
            "revenue_surprise_percent":"0.1876"
         },
         "prev_quarter_earnings":{
            "id":"5eb8f836470dcc00012d9ec7",
            "eps":"-0.570",
            "date":"2021-05-10",
            "name":"Omeros",
            "time":"16:00:00",
            "notes":"",
            "period":"Q1",
            "ticker":"OMER",
            "eps_est":"-0.570",
            "revenue":"21061000.000",
            "updated":1620678972,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-0.530",
            "importance":0,
            "period_year":2021,
            "revenue_est":"18740000.000",
            "eps_surprise":"0.0000",
            "revenue_type":"GAAP",
            "revenue_prior":"23537000.000",
            "date_confirmed":1,
            "revenue_surprise":"2321000.0000",
            "eps_surprise_percent":"0.0000",
            "revenue_surprise_percent":"0.1239"
         },
         "cash_equivalents_and_short_term_investments":73658000,
         "operating_cash_flow":-27592000,
         "monthly_cash_burn":-9197333,
         "est_live_cash":57409378,
         "est_months_cash":6.241959272323836,
         "total_liabilities":391687000,
         "net_cash":-334277622,
         "enterpriseValue":1198266676,
         "total_debt_to_equity":"",
         "float":59915908,
         "insiderholdingspct":4.2000000000000002
      },
      "updated_at_formatted":"20/05/2021"
   },
   {
      "id":3400,
      "name":"BRUKINSA (zanubrutinib)",
      "craft_entry_id":1880,
      "indication":"Waldenstr\u00f6m\u2019s macroglobulinemia",
      "advisory_committee_date":false,
      "catalyst_date":"2021-10-18",
      "fda_calendar":0,
      "press_link":"https://www.businesswire.com/news/home/20210217005324/en/",
      "catalyst_date_text":"",
      "note":"PDUFA date October 18, 2021.",
      "estimated_primary_completion_date":"January 18, 2022",
      "updated_at":"2021-05-07 01:12:39",
      "stage":{
         "id":13,
         "label":"PDUFA",
         "value":"pdufa"
      },
      "companies":{
         "id":340,
         "ticker":"BGNE",
         "name":"BeiGene Ltd.",
         "exchange":null,
         "price":249.59999999999999,
         "change":-25.84,
         "percent_change":-9.3800000000000008,
         "number_of_shares":93159001,
         "market_cap":23252486650,
         "short_ratio":null,
         "volume":1445694,
         "average_daily_volume":315067,
         "relative_volume":4.5899999999999999,
         "price_to_book":6.4500000000000002,
         "open":274.30000000000001,
         "previous_close":275.44,
         "created_at":"2018-01-23T07:37:40.000000Z",
         "updated_at":"2021-08-20T23:55:04.000000Z",
         "pivot":null,
         "portfolio_tickers":[
            
         ]
      },
      "fda":false,
      "indication_names":[
         "Waldenstr\u00f6m\u2019s macroglobulinemia"
      ],
      "cashflow":{
         "id":270,
         "ticker":"BGNE",
         "earnings":{
            "id":"5f2cfc06a3eee500019e8e6b",
            "eps":"-5.230",
            "date":"2021-08-05",
            "name":"BeiGene",
            "time":"16:00:00",
            "notes":"",
            "period":"Q2",
            "ticker":"BGNE",
            "eps_est":"-4.140",
            "revenue":"149992000.000",
            "updated":1628208251,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-4.310",
            "importance":1,
            "period_year":2021,
            "revenue_est":"215430000.000",
            "eps_surprise":"-1.0900",
            "revenue_type":"GAAP",
            "revenue_prior":"65635000.000",
            "date_confirmed":1,
            "revenue_surprise":"-65438000.0000",
            "eps_surprise_percent":"-0.2633",
            "revenue_surprise_percent":"-0.3038"
         },
         "prev_quarter_earnings":{
            "id":"5eba4981a2467b00013633ef",
            "eps":"0.690",
            "date":"2021-05-06",
            "name":"BeiGene",
            "time":"16:05:00",
            "notes":"",
            "period":"Q1",
            "ticker":"BGNE",
            "eps_est":"-4.810",
            "revenue":"605872000.000",
            "updated":1620367871,
            "currency":"USD",
            "eps_type":"GAAP",
            "exchange":"NASDAQ",
            "eps_prior":"-4.700",
            "importance":1,
            "period_year":2021,
            "revenue_est":"91820000.000",
            "eps_surprise":"5.5000",
            "revenue_type":"GAAP",
            "revenue_prior":"52059000.000",
            "date_confirmed":1,
            "revenue_surprise":"514052000.0000",
            "eps_surprise_percent":"1.1435",
            "revenue_surprise_percent":"5.5985"
         },
         "cash_equivalents_and_short_term_investments":4381900000,
         "operating_cash_flow":-420266000,
         "monthly_cash_burn":-140088666,
         "est_live_cash":4134410023,
         "est_months_cash":29.512808859212065,
         "total_liabilities":1917341000,
         "net_cash":2217069023,
         "enterpriseValue":21094720121,
         "total_debt_to_equity":0.19,
         "float":89530472,
         "insiderholdingspct":0.29999999999999999
      },
      "updated_at_formatted":"07/05/2021"
   }
]